



Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW[®] 2020

AGA Institute
4930 Del Ray Avenue
Bethesda, MD 20814

301.654.2055 (National Office)
301.654.3978 (Fax)
www.gastro.org

*** Information contained in this report
is current as of April 22, 2020.**



AGA Oral Presentations

1. . . . IMPROVING LYNCH SYNDROME IDENTIFICATION THROUGH THE... (4*)
2. . . . PLACENTAL-DERIVED STEM CELLS AMELIORATE INTESTINAL DAMAGE... (2*)|(4)
3. . . . INTESTINAL EPITHELIAL RECEPTOR LRRC19 DEPLETION PROTECTS... (2*)
4. . . . CROHN'S DISEASE PATHOBIONT ENTEROBACTERIACEAE GROWTH... (6*)
5. . . . USE OF A TARGETED BACTERIOPHAGE COCKTAIL... (3*)| (BiomX Inc.)
6. . . . PATHOETIOLOGY OF LEVATOR ANI SYNDROME: EVALUATION... (5*)
7. . . . IMPROVING THE UTILITY OF HIGH RESOLUTION... (2*)
8. . . . REDUCTIONS IN ALL-CAUSE MORTALITY ASSOCIATED WITH... (3*)|(This work was supported by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.)
9. . . . NEW INSIGHTS INTO THE ROLE OF... (2*)
10. . . . A RANDOMIZED PILOT STUDY TO COMPARE... (7*)|(4)
11. . . . "FLIP"ING FROM INCONTINENCE TO CONTINENCE WITH... (2*)
12. . . . NORMALIZATION OF NUMBER OF REFLUX... (5*)|(The original study was conducted by Torax, Inc, from which this post hoc analysis was extracted)
13. . . . CLINICAL UTILITY OF NARROW BAND IMAGING... (5*)
15. . . . CLINICAL-PHYSIOLOGIC PHENOTYPES OF LARYNGOPHARYNGEAL REFLUX: EXPLORATORY... (7*)
16. . . . IMPAIRED PROXIMAL ESOPHAGEAL CONTRACTILITY IS INDEPENDENTLY... (5*)
17. . . . TALIN-1 IS A NOVEL REGULATOR OF... (2*)
18. . . . IRON DEFICIENCY PROMOTES HELICOBACTER PYLORI-INDUCED CARCINOGENESIS... (2*)
19. . . . OVEREXPRESSION OF CD44V9/SIALYL-LEWIS X METAPLASIA DURING... (2*)
20. . . . BUTYRATE PRODUCING GASTRIC NON-HELICOBACTER COMMENSAL BACTERIA... (4*)|(2)
21. . . . CIRCULAR RNA PABPN1 INHIBITS AUTOPHAGY IN... (2*)
22. . . . NOXIOUS LUMINAL STIMULI TREATED ESOPHAGEAL MYOFIBROBLASTS... (2*)|(4)
23. . . . QUALITY OF CARE INITIATIVE IMPROVES OUTCOMES... (6*)
24. . . . PSYCHIATRIC COMORBIDITY IN IBD INCREASES HEALTH... (2*)
25. . . . ASSOCIATION OF ADDED DIETARY SUGAR AND... (2*)
26. . . . SOCIAL DETERMINANTS OF OUTCOMES IN IBD... (6*)
27. . . . LONGITUDINAL TRAJECTORY OF FATIGUE IN INFLAMMATORY... (6*)
28. . . . FATIGUE IS THE MOST IMPORTANT DRIVER... (3*)|(This work was supported by a restricted grant by dr. Falk Pharma Benelux B.V.)
29. . . . IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH... (5*)
30. . . . TRACING SPATIAL CLONAL EVOLUTION OF INTESTINAL... (2*)|(6)
31. . . . TROP2 IS UPREGULATED IN THE TRANSITION... (2*)|(4)
32. . . . HELICOBACTER PYLORI-MEDIATED ACTIVATION OF NF- κ B-STAT3 NETWORK... (2*)|(4)
33. . . . IN VIVO ADMINISTRATION OF ANTISENSE MIR130B... (2*)
34. . . . DOWN REGULATION OF IL-33 PREVENTS THE... (2*)|(Korean NTIS)
35. . . . SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC, INDUCES... (3*)|(Seres Therapeutics)
36. . . . ANTIBIOTIC PRETREATMENT PRIOR TO FECAL MICROBIOTA... (6*)
37. . . . FECAL MICROBIOTA TRANSPLANTATION IS HIGHLY EFFECTIVE... (2*)
38. . . . VE303, A RATIONALLY DESIGNED BACTERIAL CONSORTIUM... (3*)|(2)| (CARB-X)
39. . . . EFFECT OF MICROBIAL ECOSYSTEM THERAPEUTICS (MET-2)... (3*)|(NuBioyta)
40. . . . THE SUSTAINED INCREASE IN TGF β PRODUCTION... (2*)
41. . . . PREDICTING GASTROINTESTINAL (GI) HEMORRHAGE USING A... (5*)
43. . . . BUILDING AN AI SYSTEM ON HIGH-RESOLUTION... (2*)
44. . . . PROSPECTIVE COMPARISON STUDY OF EUS-FNA ONSITE... (4*)
45. . . . TOWARDS COMPUTER-AIDED DIAGNOSIS (CAD) FOR COLONOSCOPY... (2*)
111. . . . PREVALENCE AND PREDICTORS OF ADVANCED NEOPLASIA... (6*)
112. . . . THE SULFUR MICROBIAL DIET AND RISK... (2*)|(6)
113. . . . COMPARING ADENOMA DETECTION RATE AND STANDARDIZED... (5*)
114. . . . OPPORTUNISTIC INFECTIONS ARE MORE PREVALENT IN... (5*)
115. . . . DISRUPTION OR DISCONNECTION OF THE PANCREATIC... (5*)
116. . . . ALTERED DISTRIBUTION OF THE INTESTINAL NA-BILE... (2*)
117. . . . ENTERAL NUTRITION THERAPY IS ASSOCIATED WITH... (5*)
118. . . . GENE EDITING OF SWINE MYOSIN VB... (2*)
119. . . . THE SULFUR MICROBIAL DIET AND RISK... (2*)|(6)
120. . . . DIETARY INTERVENTION INHIBITS COLONIC INFLAMMATION BY... (2*)|(6)
121. . . . ULCERATIVE COLITIS PATIENTS ACHIEVE MORE ROBUST... (6*)
122. . . . ESTIMATING THE ENVIRONMENTAL IMPACT OF DISPOSABLE... (5*)
123. . . . PATIENT AND PHYSICIAN PERSPECTIVES ON THE... (3*)|(Celgene Corporation)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

124. . . . CANADIAN ASSOCIATION OF GASTROENTEROLOGY CLINICAL PRACTICE... (7*)
125. . . . SUNSHINE ACT: SHEDDING LIGHT ON DISCLOSURES... (5*)
126. . . . IMPACT OF AN ONLINE NIH PROMIS-BASED... (7*)
127. . . . THE VOLUME-OUTCOME EFFECT CALLS FOR CENTRALIZATION... (4*)
128. . . . MAJOR GASTROINTESTINAL BLEEDING RISK WITH DIRECT... (5*)
129. . . . MORTALITY AFTER CHOLECYSTECTOMY IN A NATIONWIDE... (2*)
130. . . . A MURINE MODEL OF OBSTRUCTIVE SLEEP... (2*)|(7)
131. . . . NORMAL WEIGHT TYPE 2 DIABETES IS... (6*)
132. . . . GUT DYSBIOSIS INDUCED BY CIRCADIAN RHYTHM... (2*)
133. . . . INFLUENCE OF EARLY LIFE FACTORS ON... (6*)|(The International Organization for the Study of Inflammatory Bowel Disease (IOIBD), The Crohn's and Colitis Foundation, and the Kenneth Rainin Foundation.)
134. . . . ALTERATIONS OF INTESTINAL MICROBIOTA BY HIGH-FAT... (2*)
135. . . . THE GEM PROJECT: DIETARY PATTERNS ARE... (6*)|(2)
136. . . . NORMAL FUNCTIONAL LUMINAL IMAGING PROBE PANOMETRY... (2*)
137. . . . IMPAIRED ESOPHAGOGASTRIC JUNCTION OPENING ON REAL-TIME... (5*)
138. . . . ACHALASIA SUBTYPES CAN BE IDENTIFIED WITH... (2*)
139. . . . PREVALENCE OF MAJOR AND MINOR MOTOR... (5*)
140. . . . MULTIPLE RAPID SWALLOWS AND RAPID DRINK... (2*)
141. . . . CLASSIFICATION OF ESOPHAGEAL SWALLOWS BY A... (5*)
142. . . . A NOVEL ROLE FOR DOUBLE-STRANDED RNA... (2*)|(7)
143. . . . COLITIS-INDUCED GLYCOLYSIS DRIVES YAP-DEPENDENT REPROGRAMMING OF... (2*)
144. . . . NRF2 REGULATES A NOVEL PROLIFERATIVE CHECKPOINT... (2*)
145. . . . CONSTITUTIVE BINDING OF β PAK-INTERACTING EXCHANGE FACTOR... (2*)
146. . . . TRANSCRIPTION OF MITOCHONDRIA-TRANSCRIBED GENES DIFFERENTIATES NORMAL... (2*)|(4)
148. . . . PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY UNDERGOING... (5*)
149. . . . ARTIFICIAL INTELLIGENCE AUTOMATES EVALUATION OF BASELINE... (5*)
150. . . . NATIONAL TRENDS IN MEDICARE PRESCRIPTIONS OF... (5*)
151. . . . ANTI-REFLUX SURGERY REDUCES MORTALITY IN LUNG... (5*)
152. . . . IS CHRONIC USE OF RANITIDINE... (5*)
153. . . . EXPOSURE OF BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA... (2*)
154. . . . ROLE OF TRANSIENT RECEPTOR POTENTIAL VANILLOID... (2*)
155. . . . PRODUCTS OF MATURE ADIPOCYTES IN VISCERAL... (4*)
156. . . . THE MICROBIOME OF BARRETT'S ESOPHAGUS WITH... (2*)|(4)
157. . . . THE ACTIVATION OF MACROPHAGES PLAYS A... (4*)
198. . . . LOW DIETARY FIBER-INDUCED MUCOSAL EROSION... (2*)
199. . . . METABOLOMICS ANALYSIS IDENTIFIED NOVEL ORALLY ACTIVE... (2*)
200. . . . CHROMOSOME TOPOLOGY ANALYSIS REVEALS REMOTE SUPER-ENHANCERS... (2*)|(4)
201. . . . A NOVEL SYSTEM FOR COMPARTMENTALIZED ANALYSIS... (4*)|(6)
202. . . . FERMENTABLE VS NON-FERMENTABLE DIETARY FIBERS DIFFERENTIALLY... (6*)|(2)
203. . . . THE EFFICACY AND SAFETY OF A... (5*)
204. . . . INCIDENCE, RISK FACTORS AND OUTCOMES ASSOCIATED... (5*)
205. . . . ASSOCIATION OF FASTING GASTRIC VOLUMES WITH... (5*)
206. . . . NEW ONSET DIABETES: A POTENTIAL BIOMARKER... (5*)
207. . . . QUANTIFICATION OF PANCREATIC FAT ON ABDOMINAL... (5*)
220. . . . SERA ANTI-HUD ANTIBODIES FROM IRRITABLE BOWEL... (1*)
221. . . . ACTIVE VARICELLA ZOSTER IDENTIFIED BY NOVEL... (4*)
222. . . . PREIPHERAL CGRP AS A CONVERGENT... (2*)|(3)|(Teva Biologics)
223. . . . LOSS OF CX3CR1+ - GASTRIC MUSCULARIS... (2*)|(7)
224. . . . A NIGRO-VAGAL PATHWAY CONTROLS COLONIC MOTILITY... (2*)
225. . . . EPIGENETIC UPREGULATION OF ACID-SENSING ION CHANNEL... (2*)
226. . . . FOOD-INDUCED IMMEDIATE RESPONSE IN THE ESOPHAGUS... (5*)
227. . . . BUDESONIDE ORAL SUSPENSION (BOS) IMPROVES ENDOSCOPIC... (3*)|(This study was funded by Shire ViroPharma, Inc., a member of the Takeda group of companies. Medical writing support was provided by Joanna L Donnelly of PharmaGenesis London, London, UK, funded by Shire Human Genetic Therapies Inc., a member of the Takeda)
228. . . . INTERIM RESULTS OF AN OPEN-LABEL EXTENSION... (3*)|(2)|(Allakos, Inc.)
229. . . . RESULTS FROM THE ELEMENT STUDY: PROSPECTIVE... (2*)|(Nutritia)
230. . . . PRIMARY AND PLURIPOTENT STEM CELL DERIVED... (2*)
231. . . . MATERNAL SUCRALOSE INTAKE ALTERS GUT MICROBIOTA... (2*)|(4)
232. . . . ALTERED BILE ACID HOMEOSTASIS AND PATHOLOGIC... (7*)|(2)
233. . . . T CELL P38 α PROMOTES NUTRITIONAL STEATOHEPATITIS... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

234. . . . PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE... (5*)
235. . . . LARGE EFFECTS OF SGLT2 INHIBITORS/GLP1 RECEPTOR... (5*)
236. . . . INFLIXIMAB, ADALIMUMAB AND VEDOLIZUMAB LEVELS ARE... (6*)(4)
237. . . . BASELINE DRUG CLEARANCE OF INFLIXIMAB PREDICTS... (5*)
238. . . . VEDOLIZUMAB CONCENTRATIONS IN COLONIC MUCOSAL TISSUE... (5*)
239. . . . THE EARLY APPEARANCE OF ANTI-DRUG ANTIBODIES... (4*)
240. . . . REAL-WORLD APPLICATION OF AN ADAPTIVE DOSING... (4*)(Prometheus Ran the drug levels)
241. . . . COMBINATION OF SERUM ENDOSCOPIC HEALING INDEX... (3*)(7)(Prometheus Biosciences, San Diego, CA)
266. . . . COMPUTER-AIDED DETECTION OF ADVANCED NEOPLASIA IN... (7*)(4)
267. . . . IMPAIRMENT OF THE EMBRYONIC MACROPHAGE COMPARTMENT... (2*)
268. . . . POLY (ADP-RIBOSE) POLYMERASE 1 (PARP1) PROMOTES... (4*)
269. . . . A NOVEL TNFSF13 VARIANT IN VERY... (4*)
270. . . . NEONATAL INTESTINAL MACROPHAGES PROMOTE VASCULAR TUBE-LIKE... (2*)
271. . . . TARGETED DELETION OF THE CDC42/RAC NUCLEOTIDE... (2*)
272. . . . SHORT-TERM WESTERN DIET DRIVES MICROVILLI ALTERATIONS... (2*)
273. . . . PREVALENCE AND IMPACT OF FUNCTIONAL DYSPEPSIA... (3*)(Ironwood, Shire, Allergan, Takeda, Takeda-israel)
274. . . . 4D CINE-MRI-ASSESSED GASTRIC FUNCTION IS MODULATED... (2*)
275. . . . THE EFFECT OF CANNABIS LEGALIZATION ON... (4*)
276. . . . PROTON PUMP INHIBITORS REDUCE DUODENAL EOSINOPHILIA... (4*)
277. . . . PSYCHOLOGICAL FEATURES OF FUNCTIONAL DYSPEPSIA ARE... (5*)
278. . . . PRIMARY RESULTS OF A PHASE 1... (3*)(Allakos, Inc.)
279. . . . COMBINATION THERAPY DOES NOT IMPROVE CLINICAL... (5*)
280. . . . THIOPURINE USE IN IBD IS ASSOCIATED... (3*)(4)(Janssen R&D)
281. . . . FRAILITY IS ASSOCIATED WITH AN INCREASED... (6*)
282. . . . THE INCIDENCE OF PNEUMONIA AND IMPACT... (3*)(This study was supported by an unrestricted research grant from Pfizer Pharmaceuticals. Pfizer had no role in the study concept and design, acquisition of data and interpretation of results.)
283. . . . EFFECTIVENESS OF RECOMBINANT ZOSTER VACCINE (SHINGRIX)... (5*)
284. . . . EARLY LAPAROSCOPIC ILEOCECAL RESECTION DECREASES NEED... (5*)
315. . . . NON-INVASIVE BREATH TEST SCREENING FOR BARRETT'S... (2*)
316. . . . GLYCEMIC STATUS IN PATIENTS WITH CHRONIC... (7*)
317. . . . CYTOF ANALYSIS OF HUMAN COLON AND... (6*)
318. . . . SINGLE CELL DISSECTION OF THE TRANSCRIPTIONAL... (4*)(6)
337. . . . MAJOR GASTROINTESTINAL BLEEDING IN OLDER PERSONS... (2*)(4)(Bayer AG supplied the aspirin tablets and matching placebos but had no other role in trial conduct or reporting.)
338. . . . FEWER GASTROINTESTINAL BLEEDS WITH TICAGRELOR WHEN... (2*)
339. . . . WARFARIN IS ASSOCIATED WITH HIGHER RATES... (4*)
340. . . . PREDICTING TREND OF UPPER AND LOWER... (5*)
341. . . . ANTITHROMBOTIC CESSATION FOLLOWING HOSPITALIZATION FOR DIVERTICULAR... (5*)
342. . . . THE IMPACT OF NIGHT-TIME EMERGENCY DEPARTMENT... (5*)
343. . . . DOES EARLY EGD IMPROVE MORTALITY IN... (5*)
344. . . . INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL HEALING... (3*)(This study was supported by Janssen)
345. . . . ULTRASONOGRAPHY TIGHT CONTROL AND MONITORING IN... (5*)
346. . . . CREEPING FAT IS ASSOCIATED WITH INTESTINAL... (2*)
347. . . . SERUM METABOLOMIC APPROACH IDENTIFIES SECONDARY BILE... (6*)(4)
348. . . . MULTI-'OMICS PROFILING IN PATIENTS WITH QUIESCENT... (2*)(6)(Supported by the National Institutes of Health, Pfizer and Crohn's & Colitis Foundation)
349. . . . MULTIYEAR COMPARISON OF INFLUENCE OF ANTI-SACCHAROMYCES... (2*)
350. . . . ALTERED GENE EXPRESSION IN THE COLON... (2*)(4)
351. . . . ENTERIC NEURONAL AGGREGATION OF α -SYNUCLEIN DISRUPTS... (2*)
352. . . . INCREASED PREVALENCE OF PARKINSON'S DISEASE IN... (5*)
353. . . . PARKINSON'S DISEASE: AN EFFERENT BRAIN-GUT DISORDER... (5*)
354. . . . INTERFERON ALPHA MEDIATES SCHLAFIN4+-MDSC POLARIZATION DURING... (2*)
355. . . . TUMOR-DERIVED BST2 CREATED IMMUNOSUPPRESSIVE MICROENVIRONMENT OF... (2*)
356. . . . B CELL DEFICIENCY RESTRICTS MUCOUS... (2*)
357. . . . TYPE 2 CYTOKINES PROMOTE METAPLASIA DEVELOPMENT... (2*)(4)
358. . . . INDUCTION OF FGFR4 BY H. PYLORI... (2*)(4)
359. . . . ABSENT IN MELANOMA 2 (AIM2) IS... (6*)(2)
371. . . . USE OF ARTIFICIAL INTELLIGENCE WITH A... (5*)
372. . . . MUCOSAL CAPILLARY PATTERN RECOGNITION WITH REAL-TIME... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

373. . . . DEVELOPING SURVEILLANCE STRATEGY FOR PANCREATIC CANCER... (1*)
374. . . . A SYSTEMATIC EVALUATION OF CELL LINEAGE... (5*)
387. . . . NONSTEROIDAL ANTI-INFLAMMATORY DRUGS REDUCE THE RISK... (2*)
388. . . . ASSOCIATION OF ASPIRIN USE AND GASTROINTESTINAL... (5*)|(2)
389. . . . ASPIRIN REDUCES PGE2 BIOSYNTHESIS TO LEVELS... (2*)|(6)
390. . . . THIOGUANINE INHIBITS COLORECTAL TUMORIGENESIS VIA β -CATENIN... (2*)
391. . . . ASPIRIN USE IS ASSOCIATED WITH REDUCED... (2*)
392. . . . A NOVEL PH-SENSITIVE OPIOID ANALGESIC THAT... (6*)
393. . . . CANNABINOIDS AND OPIOIDS SYNERGISTICALLY INHIBIT MOUSE... (4*)
394. . . . RESOLVIN D2 REVERSES VISCERAL HYPERSENSITIVITY IN... (4*)
395. . . . INCREASE IN FETAL CORTICOSTERONE DURING MATERNAL... (2*)
396. . . . INVOLVEMENT OF PIEZO2 IN COLONIC MECHANICAL... (2*)|(4)
397. . . . MICROBIOME GENOMICS REVEALS NOVEL BACTERIAL STRAINS... (3*)|(Biomica LTD.)
398. . . . THE GEM PROJECT: IDENTIFICATION OF A... (2*)|(6)
399. . . . PROTEOMIC AND TRANSCRIPTOMIC ANALYSIS OF VERY... (6*)
400. . . . GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF... (4*)
401. . . . NORMALIZATION OF FECAL CALPROTECTIN WITHIN 12... (5*)
402. . . . RECTAL CANCER INCIDENCE IS LOW FOLLOWING... (4*)
403. . . . THE IMPACT OF CHOLECYSTECTOMY ON LONG-TERM... (2*)
404. . . . RISK OF POST-COLONOSCOPY IRRITABLE BOWEL SYNDROME... (2*)
405. . . . ROME IV AND ROME III IRRITABLE... (3*)|(4)|(Ironwood, Shire, Allergan, Takeda, Takeda-Israel)
406. . . . BAROSTAT ASSISTED SENSORY ADAPTATION TRAINING FOR... (2*)
408. . . . A BRIEF EDUCATIONAL INTERVENTION FOR IBS... (4*)|(1)
409. . . . RANDOMISED TRIAL OF MULTI-DISCIPLINARY VERSUS STANDARD... (1*)
410. . . . LES MUSCLE OF PATIENTS WITH ACHALASIA... (4*)
411. . . . IDENTIFICATION OF ESOPHAGEAL MICROBIOME SIGNATURES IN... (2*)
412. . . . PHARMACOLOGIC PROVOCATION WITH AMYL NITRITE &... (4*)
413. . . . DISTENSION CONTRACTION PLOTS OF ESOPHAGEAL PERISTALSIS... (2*)
414. . . . UPPER ESOPHAGEAL SPHINCTER ABNORMALITIES ARE ASSOCIATED... (5*)
415. . . . UPPER ESOPHAGEAL SPHINCTER DYSFUNCTION IS AN... (5*)
416. . . . CLONAL ARCHITECTURE OF EPITHELIAL STEM CELL... (2*)
417. . . . ANKRD22 AS A PROMISING THERAPEUTIC TARGET... (2*)
418. . . . PROLYL HYDROXYLASE 2 SILENCING ENHANCES THE... (5*)
419. . . . ZERO-SUM EPIGENETIC PATTERNING DEFINES STEM... (2*)
420. . . . INTEGRATING HPSC-DERIVED 3D ORGANIDS AND MOUSE... (2*)|(6)
421. . . . LRIG3 RESTRICTS THE SIZE OF THE... (4*)|(2)
422. . . . A DORMANT BLOOD MICROBIOME MAY UNDERLIE... (4*)
423. . . . DYNAMICS OF INTESTINAL INFLAMMATION AND MICROBIAL... (5*)
424. . . . THE COMBINATION OF ALTERED MICROBIAL BIOGEOGRAPHY... (2*)|(7)|(PFIZER ASPIRE GRANT)
425. . . . SUBSETS OF HUMAN RESIDENT BACTERIAL SPECIES... (2*)
426. . . . FURTHER EVIDENCE THAT PROTEUS MIRABILIS IS... (6*)
427. . . . F.PRAUSNITZII PROTECT THE MICE FROM DEXTRAN-SULFATE... (2*)
445. . . . LIRAGLUTIDE ESCALATED TO 3 MG REDUCES... (2*)
446. . . . A NOVEL TARGET IN THE TREATMENT... (2*)
447. . . . STROMAL DLK1 PROMOTES EPITHELIAL PROLIFERATION AND... (2*)
448. . . . GATA4 IS REQUIRED TO MAINTAIN GASTRIC... (6*)|(2)
459. . . . IDENTIFICATION AND DEVELOPMENT OF GENE SIGNATURE... (5*)
460. . . . SINGLE CELL RNA SEQUENCING ANALYSIS UNVEILS... (7*)|(2)
461. . . . PROTON PUMP INHIBITOR AND STATIN USE... (5*)
462. . . . AURORA KINASE A PROMOTES CANCER CELL... (2*)|(4)
463. . . . THE POTENTIAL OF PERSONALIZED SURVEILLANCE INTERVALS... (6*)|(2)
464. . . . MULTI-OMIC CHARACTERIZATION OF BARRETT'S ESOPHAGUS REVEALS... (6*)
465. . . . ALTERATION OF KRAS, TP53 AND RB1... (4*)
466. . . . PHYSICAL ACTIVITY IS ASSOCIATED WITH A... (2*)
467. . . . INHIBITION OF HUR ASSOCIATION WITH CX43... (2*)
468. . . . LOSS OF INTESTINAL AXIN 1 PROMOTES... (2*)
469. . . . GUT MICROBIOTA REGULATES ROTENONE INDUCED DISRUPTIONS... (5*)
470. . . . TTC7A DIRECTS APICAL LUMEN FORMATION IN... (2*)
471. . . . PROBIOTIC ENHANCEMENT OF INTESTINAL EPITHELIAL BARRIER... (2*)
472. . . . BACTERIAL METABOLITES SHORT CHAIN FATTY ACIDS... (2*)
473. . . . CORRELATION OF FLUORESCENCE IN SITU HYBRIDIZATION... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

474. . . . CORRELATES OF ULTRASOUND QUALITY FOR HCC... (4*)
475. . . . CROTONYLATION OF 44076 PROMOTES METASTASIS AND... (4*)|(2)
476. . . . PREDICTING DECOMPENSATION, DEATH, OR LIVER TRANSPLANTATION... (4*)
477. . . . THE GLOMERULAR FILTRATION RATE IN LIVER... (5*)
478. . . . THE SAFETY AND EFFICACY OF ANTICOAGULATION... (5*)
479. . . . PRO-INFLAMMATORY DRIVEN REACTIVE OXYGEN SPECIES IS... (2*)
480. . . . METAGENOMIC AND METABOLOMIC ANALYSIS UNVEIL THE... (2*)
481. . . . HUMAN MILK OLIGOSACCHARIDES MODULATE THE INTESTINAL... (3*)|(Proacta Bioscience)
482. . . . PROBIOTIC-EDUCATED TREGS ARE MORE POTENT THAN... (2*)
483. . . . EFFECT OF SALACIA SPECIES EXTRACT ON... (3*)|(FUJIFILM Corporation, Japan)
484. . . . EVIDENCE FOR THE PRESENCE OF HUMAN... (3*)|(Glycom A/S sponsored the trial)
485. . . . FINANCIAL VOLATILITY OF INFLAMMATORY BOWEL DISEASES... (5*)|(Claims Data was provided by Health Care Financing Corporation (Blue Cross Blue Shield of Illinois, Texas, Oklahoma, New Mexico and Montana)
486. . . . IMPROVING ACCESS TO CARE REDUCES NEED... (5*)
487. . . . EARLIER ANTI-TNF INITIATION PROMOTES LOWER SUBSEQUENT ... (6*)
488. . . . PROBABILITY OF VEDOLIZUMAB RESPONSE AS DEFINED... (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)
489. . . . HIGH COST-RELATED MEDICATION NON-ADHERENCE AMONG ADULTS... (4*)
490. . . . ASSOCIATION OF INFLAMMATORY BOWEL DISEASE (IBD)... (5*)
491. . . . VARIATIONS IN HEALTHCARE UTILIZATION PATTERNS AMONG... (5*)
515. . . . A MULTIMODAL INTERDISCIPLINARY QI INTERVENTION IS... (5*)
516. . . . THE VALUE OF MANAGING ACUTE PANCREATITIS... (5*)
517. . . . IMPLEMENTATION OF AN INPATIENT IBD SERVICE... (5*)
518. . . . AN ELECTRONIC MEDICAL RECORDS-BASED INTERVENTION REDUCES... (5*)
519. . . . A QUALITY IMPROVEMENT INITIATIVE RESULTS IN... (2*)
520. . . . PREVALENCE AND RISK FACTORS FOR INAPPROPRIATE... (5*)
521. . . . AN AUTOMATED INPATIENT SPLIT-DOSE BOWEL PREPARATION... (5*)
522. . . . BETTER PREP IS JUST ONE PHONE... (5*)
523. . . . A PROSPECTIVE SYSTEM FOR TRACKING COLONOSCOPY... (4*)
524. . . . INSTILLING A GROWTH MINDSET: A QUALITY... (5*)
525. . . . PILOTING THE ANNIE TEXT MESSAGING PROTOCOL... (5*)
526. . . . AUTOMATED TEXT MESSAGE ALGORITHM REDUCES COLONOSCOPY... (2*)
527. . . . COMPARISON OF LOW VERSUS HIGH VOLUME... (5*)
528. . . . IN-SERVICE EDUCATION AND CHANGES TO THE... (5*)
529. . . . BRIDGES TO EXCELLECE (BTE) QUALITY INDICATORS... (5*)
530. . . . OVERUTILIZATION OF FECAL OCCULT BLOOD TEST... (5*)
531. . . . CHARLSON COMORBIDITY INDEX IS A USEFUL... (5*)
532. . . . EFFORTS TO ERADICATE HELICOBACTER PYLORI IN... (5*)
533. . . . SUSTAINED IMPROVEMENT IN ANTIBIOTIC STEWARDSHIP IN... (5*)
534. . . . DEDICATD CYTOPATHOLOGISTS VS COMMUNITY PATHOLOGIST SIGNIFICANTLY... (5*)
535. . . . IMPROVING VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS... (5*)
536. . . . IMPROVING PROPHYLACTIC ANTIBIOTIC USE IN PATIENTS... (5*)
537. . . . WIDE VARIATION IN ADHERENCE TO ROUTINE... (5*)
538. . . . IMPROVING HELICOBACTER PYLORI TESTING IN PATIENTS... (5*)
539. . . . IMPROVING H. PYLORI TESTING IN INPATIENTS... (5*)
540. . . . IT'S ALL ABOUT THE PREP: IMPROVING... (5*)
541. . . . BIOPSY AND EMPIRIC DILATION PRACTICES IN... (5*)
542. . . . HOSPITAL SYSTEM PREDICTORS OF INCOMPLETE COLONOSCOPY... (5*)
543. . . . IMPROVING ENDOSCOPIC AND DISCHARGE MANAGEMENT OF... (5*)
544. . . . TRACKING COLONOSCOPY QUALITY MEASURES IN GI... (5*)
545. . . . PNEUMOCOCCAL VACCINATION RECOMMENDATION AND COMPLETION RATES... (5*)
546. . . . VETERANS WITH HEPATITIS B, WHO IS... (5*)
547. . . . SELECTION OF AN APROPRIATE HELICOBACTER PYLORI... (5*)
548. . . . EVALUATION OF A NOVEL AUTOMATED CONTINUOUS... (5*)
549. . . . IMPROVING VACCINATION RATES IN VETERANS WITH... (5*)
550. . . . INFLAMMATORY BOWEL DISEASE PATIENTS HOSPITALIZED FOR... (5*)
551. . . . REAL WORLD ADHERENCE TO GUIDELINE RECOMMENDATIONS... (5*)
558. . . . STREPTOCOCCUS THERMOPHILUS INHIBITS COLORECTAL TUMORIGENESIS THROUGH... (2*)
559. . . . ACTIVATION OF TOLL-LIKE RECEPTOR 2 (TLR2)... (2*)
561. . . . A RAPID CRISPR/CAS9 GENOME EDITING SCREEN... (7*)|(4)
562. . . . THE JAK INHIBITOR TOFACITINIB RESCUES INTESTINAL... (2*)|(Aspire-Pfizer 2017 IBD Research Award to DFM.)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

563. . . . INTESTINE-SPECIFIC DELETION OF RNA-BINDING MOTIF PROTEIN... (2*)
564. . . . AN INFLAMMATORY DIET AND RISK OF... (2*)
565. . . . TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF A... (6*)(3)|(Takeda Pharmaceuticals)
566. . . . LARGE META GENOME WIDE ASSOCIATION STUDY... (4*)(2)|(Helmsley Charitable Trust)
567. . . . TL1A OVEREXPRESSION IN CD PATIENTS AND... (2*)
568. . . . FAMILIAL SMALL INTESTINAL (MIDGUT) NEUROENDOCRINE TUMOR... (2*)
569. . . . INVESTIGATION OF THE INTEGRIN SIGNALLING PATHWAY... (4*)
570. . . . PREVALENCE OF LYMPH NODE/ DISTANT METASTASIS... (5*)
571. . . . NOVEL DIGITAL SPATIAL PROFILING OF GASTROENTEROPANCREATIC... (2*)
572. . . . ASSOCIATION BETWEEN SOMATOSTATIN ANALOGUE TREATMENT AND... (5*)
573. . . . EGF-INDUCED NUCLEAR EXPORT OF MENIN STIMULATES... (2*)
574. . . . RECENT TRENDS IN COLORECTAL CANCER SCREENING... (3*)(Exact Sciences)
575. . . . A HIGHLY SENSITIVE AND QUANTITATIVE MULTIMODAL... (3*)(CellMax Life)
576. . . . EARLY COLORECTAL CANCER SCREENING IN AFRICAN... (5*)
577. . . . EFFECT OF ORGANIZED MAILED FECAL IMMUNOCHEMICAL... (2*)(4)
578. . . . DELAY TO DIAGNOSTIC COLONOSCOPY AFTER ABNORMAL... (2*)
579. . . . PREVALENCE AND CHARACTERISTICS OF POST-COLONOSCOPY COLORECTAL... (2*)
580. . . . RACE, ETHNICITY, AND SOCIOECONOMIC STATUS PREDICT... (5*)
581. . . . DECREASED EXPRESSION AND FUNCTION OF INTESTINAL... (2*)
582. . . . TEDUGLUTIDE INHIBITS SODIUM CAPRATE-INDUCED CLATHRIN-MEDIATED LPS... (2*)(3)|(Shire/Takeda Pharmaceuticals)
583. . . . NPC1L1-DEPENDENT TRANSPORT OF 27-ALKYNE CHOLESTEROL TO... (2*)
584. . . . DYNAMIC INTERACTIONS AMONG CFTR, NHERF4 (NF4)... (2*)
585. . . . UNIQUE REGULATION OF CHLORIDE BICARBONATE EXCHANGERS... (2*)
586. . . . ER LUMINAL ERAD AS A NOVEL... (4*)(2)
587. . . . INFLAMMATION CAN BE RE-INDUCED IN ORGANOID... (2*)
588. . . . GII.3 HUMAN NOROVIRUS REQUIRES BILE ACID... (2*)
589. . . . PEDIATRIC CROHN'S DISEASE PATIENT DERIVED ORGANOID... (4*)
590. . . . AN ORGANOID-IMMUNE CELL CO-CULTURE PREDICTIVE MODEL... (2*)(4)
591. . . . HUMAN BIOPSY-DERIVED COLONOIDS ARE USEFUL TO... (3*)(Merck IISP 53472)
592. . . . HUMAN INTESTINAL STEM CELL (ISC)-DERIVED ENTEROIDS/COLONOIDS... (2*)
593. . . . CONFOCAL LASER MICROSCOPY FOR DETECTION OF... (2*)
594. . . . CLINICAL SIGNIFICANCE OF SURVEILLANCE-DETECTED DUCTAL ABNORMALITIES... (2*)(6)
595. . . . SYNCHRONOUS OCCURENCE OF PRENEOPLASTIC LESIONS IN... (5*)
596. . . . SURVEILLANCE BIOPSIES SHOULD BE DONE ON... (5*)
597. . . . OUTCOMES OF ENDOSCOPIC SURVEILLANCE AND FAMILY... (5*)
598. . . . POST-COLONOSCOPY COLORECTAL CANCER IN LYNCH SYNDROME... (5*)
611. . . . EFFICACY OF ENDOSCOPIC REVISION WITH COMBINATION... (5*)
613. . . . ANTIBODIES TO INFlixIMAB ACCELERATE DRUG CLEARANCE... (2*)(6)
614. . . . RECTAL TISSUE DNA METHYLATION IN ULCERATIVE... (2*)
615. . . . PHARMACOKINETICS OF USTEKINUMAB IN CHILDREN AND... (3*)(This study was funded by Janssen Research and Development, LLC.)
616. . . . RESULTS OF THE FIRST PAEDIATRIC RANDOMIZED-CONTROLLED... (4*)(3)|(Rebiotix Inc. supplied the fecal transplant product for this study.)
617. . . . TAXA4META: GENERATING PRECISE 16S TAXONOMIC PROFILES... (2*)
618. . . . THE SMALL INTESTINAL MICROBIOME VARIES WITH... (6*)
619. . . . A LOSS OF FUNCTION SNP IN... (2*)
620. . . . A MOLECULAR NETWORK SURVEY PREDICTS NICKEL... (4*)(3)|(Janssen R & D)
621. . . . THE PREVALENCE OF PSYCHIATRIC COMORBIDITY IS... (5*)
622. . . . CURBING CHRONIC PANCREATITIS READMISSIONS: UTILIZING THE... (5*)
623. . . . EXCLUSION OF ATYPICAL FOOD ALLERGENS DETECTED... (4*)(Rashid Hussain trust Kuala Lumpur, Malaysia)
630. . . . TAK-101 (TIMP-GLIA) PREVENTS GLUTEN CHALLENGE INDUCED... (3*)(The study was sponsored by COUR Pharmaceuticals Development Co., Inc.)
631. . . . THE IMPACT OF SCREENING LOWER ENDOSCOPY... (2*)(4)
633. . . . THE FIRST PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED... (3*)(Mitsubishi-Tanabe Pharma)
634. . . . RESULTS FROM THE BARRETT'S OESOPHAGUS TRIAL... (6*)(2)
635. . . . DIRECT ACTING ANTI-VIRAL PROPHYLAXIS TO PREVENT... (4*)(3)|(Gilead provided DAA for some patients.)
636. . . . UNRAVELLING THE MOLECULAR MECHANISM RESPONSIBLE FOR... (2*)(6)
637. . . . TUMOR NECROSIS FACTOR RECEPTOR 2 REGULATES... (2*)(4)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

638. . . . COLONIC SPROUTY2 EXPRESSION IS DYSREGULATED IN... (2*)(6)|(NIH 1R01DK119694 (Frey); Crohn's and Colitis Foundation CDA (Schumacher)
639. . . . NEUROTENSIN (NT) SIGNALING-ASSOCIATED LONG NON-CODING RNA... (6*)
640. . . . CIRCULAR RNA HIPK3 PROMOTES INTESTINAL EPITHELIAL... (2*)
641. . . . DISRUPTION OF INTESTINAL EPITHELIUM DUE TO... (2*)
642. . . . HIGH-THROUGHPUT SCREENING IDENTIFIED LORATADINE AND GENISTEIN... (2*)(3)|(MERCK)
643. . . . HOST-DIRECTED DRUG CANDIDATES TO COMBAT CLOSTRIDIODES... (2*)(4)
644. . . . IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED... (2*)(4)
645. . . . CLOSTRIDIODES DIFFICILE WHOLE GENOME SEQUENCING DIFFERENTIATES... (5*)
646. . . . COLONIC MUCOSAL COLONIZATION OF CLOSTRIDIODES DIFFICILE... (4*)
647. . . . FECAL MICRORNAS ARE ASSOCIATED WITH TGF-BETA... (2*)
648. . . . BRAIN-DERIVED NEUROTROPHIC FACTOR PLAYS A CRITICAL... (2*)
649. . . . DE NOVO ENTERIC NEUROGENESIS IN POST-EMBRYONIC... (2*)(4)
650. . . . ENTERIC GLIAL ACTIVATION IS A PATHWAY-SPECIFIC... (2*)(4)
652. . . . ENTERIC GLIAL MHC II EXPRESSION MODULATES... (2*)
653. . . . MIR-10B-5P RESCUES AND PREVENTS DIABETIC GASTROPARESIS... (2*)
654. . . . EFFECTS OF SCFA ON HISTONE ACETYLATION... (2*)
655. . . . DIETARY MONOSODIUM GLUTAMATE EXACERBATES VISCERAL HYPERSENSITIVITY... (2*)
656. . . . EPIGENETIC MECHANISMS IN THE AMYGDALA UNDERLYING... (2*)
657. . . . PGE2 PRODUCED BY MAST CELLS IS... (2*)
658. . . . GUT DYSBIOSIS PROMOTES COLONIC M1 MACROPHAGE... (2*)
659. . . . ENDOPLASMIC RETICULUM STRESS DRIVES INTESTINAL HYPERPERMEABILITY... (5*)
684. . . . INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN... (3*)(Pfizer Inc)
697. . . . VIRTUAL REALITY MINDFULNESS THERAPY VS. VIRTUAL... (5*)
698. . . . TRANSLUMBOSACRAL NEUROMODULATION THERAPY (TNT): A NOVEL... (5*)
699. . . . CHANGES IN AGED ENS INDUCES A... (2*)
700. . . . CELL THERAPY USING ADULT NEURAL-PROGENITOR CELLS... (4*)
702. . . . MACHINE LEARNING MODELS IN THE PREDICTION... (4*)
703. . . . IS HELICOBACTER PYLORI CURE A LONG-LIFE... (5*)
705. . . . TAILORED ANTIBIOTIC SUSCEPTIBILITY-GUIDED THERAPY VIA GASTRIC... (5*)
706. . . . TREATMENT OF H PYLORI IS NOT... (2*)
707. . . . COMPREHENSIVE PROFILING OF THE ANTIBIOTIC RESISTANCE... (4*)
708. . . . IMMUNOGLOBULIN A COATING OF INTESTINAL MICROBIOTA... (4*)(EB is supported by the Alexandre Suerman program for MD and PhD candidates of the University Medical Centre Utrecht, Netherlands.)
709. . . . PAIRED IMMUNOGLOBULIN-LIKE RECEPTOR B REGULATES INFLAMMATION... (2*)
711. . . . BLOCKADE OF ALPHA E BETA 7... (2*)(6)
712. . . . METABOLIC MODULATION OF CD4+ T CELLS... (4*)(2)
713. . . . NON-INVASIVE ELECTRICAL SPLENIC NERVE STIMULATION AMELIORATES... (3*)(Galvani Bioelectronics)
714. . . . CONSISTENT ALTERATIONS OF SPECIFIC GUT MICROBIAL... (2*)
715. . . . SACCHAROMYCES BOULARDII CNCM I-745 IMPROVES GUT-BRAIN... (3*)(Biocodex – Gentilly – France)
716. . . . INCREASED RISK OF DEPRESSIVE DISORDER AFTR... (2*)
717. . . . NOVEL ASSOCIATIONS OF BRAIN MORPHOMETRY WITH... (2*)
718. . . . EFFECT OF EXCLUSION DIETS ON SYMPTOM... (5*)
719. . . . HIGH STRESS REACTIVITY IS ASSOCIATED WITH... (2*)(4)
736. . . . MUTANT EPCAM MODEL OF CONGENITAL TUFTING... (2*)
737. . . . MICROPHYSIOLOGICAL ENGINEERING OF INTESTINAL MORPHOGENESIS BY... (2*)(4)
750. . . . DIFFERENCES IN THE RISK OF PERSISTENT... (5*)
751. . . . A FIVE BIOMARKER PANEL OUTPERFORMS EXISTING... (2*)
752. . . . THE INTERPLAY BETWEEN GUT MICROBIOTA AND... (2*)
753. . . . NOTCH INHIBITION PROMOTES PANCREATIC KRT5+ CELLS... (4*)
754. . . . VARIABLE CELL-SPECIFIC SPINK1 EXPRESSION IN THE... (2*)(4)
755. . . . AN INDIVIDUAL-HOUSING BASED SOCIOECONOMIC STATUS MEASURE... (5*)
756. . . . ASSOCIATION BETWEEN NEIGHBORHOOD INCOME AND PERSISTENT... (5*)
757. . . . WHO'S OUT? RESULTS OF A SCREENING... (4*)
758. . . . CHILDHOOD GROWTH IN SCREEN-DETECTED CELIAC DISEASE... (2*)
759. . . . IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED CELIAC DISEASE ... (2*)(7)
760. . . . A NOVEL ORDINAL SEVERITY SCALE ALLOWS... (3*)(This study was funded by Takeda Pharmaceutical Company Ltd. Medical writing support was provided by Steve Banner of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

761. . . . MEGA-ANALYSIS REVEALS NOVEL GENETIC ASSOCIATIONS WITH... (2*)(6)
762. . . . INCREASED RISK OF SMALL BOWEL CANCER... (4*)
763. . . . PREVALENCE AND EFFECT OF GENETIC RISK... (4*)(2)|(Helmsley Charitable Trust)
764. . . . MACHINE LEARNING IDENTIFIES NOVEL BLOOD PROTEOMIC... (2*)(6)
765. . . . RISK OF AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER... (5*)
766. . . . SCATTERED INTESTINAL EPITHELIAL APOPTOSIS INDUCES MOUSE... (2*)
767. . . . ACTIVATION OF FXR SUPPRESSES TNFA AND... (3*)(Metacrine)
768. . . . THE ORIGIN AND FUNCTION OF CANCER-ASSOCIATED... (2*)
769. . . . DIETARY PROTEIN DEFICIENCY RECAPITULATES KEY HISTOLOGIC... (4*)
770. . . . GENERATION OF A GASTRIC ADENOCARCINOMA AND... (2*)
771. . . . LYSOPHOSPHATIDIC ACID TREATMENT IMPROVES BRUSH BORDER... (2*)
814. . . . PLACEBO WITHOUT DECEPTION IS EFFECTIVE IN... (2*)(6)
815. . . . IMPACT OF PARENTAL ILLNESS AND INJURY... (2*)
816. . . . OESOPHAGEAL MUCOSAL INTEGRITY AND INNERVATION IN... (4*)
817. . . . THE HUMAN GUT VIROME IS GEOGRAPHY... (2*)(4)
818. . . . IMBALANCE OF THE INTESTINAL VIROME CAUSED... (2*)(4)
825. . . . ONCOGENIC POTENTIAL OF DYSPLASTIC STEM CELLS... (2*)(4)
826. . . . THE ROLE OF THE HIPPO PATHWAY... (2*)(7)
827. . . . STROMAL CELLS STIMULATE BMI1-DEPENDENT SMALL INTESTINAL... (2*)
828. . . . SLC26A9 PROTECTS GASTRIC EPITHELIAL CELLS AGAINST ... (2*)
829. . . . CONFIRMATION OF CHIEF CELLS AS THE... (2*)(4)
830. . . . TYPE II INNATE LYMPHOID CELLS (ILC2S)... (2*)
831. . . . CB1 MEDIATES THE ENERGY EFFECTS OF... (4*)
832. . . . EFFECT OF MODERATE ALCOHOL CONSUMPTION ON... (2*)
833. . . . DIETS HIGH IN OMEGA AND... (2*)
834. . . . EFFECT OF MATERNAL OBESITY INDUCED BY... (4*)
835. . . . LACTATED RINGER'S SOLUTION VERSUS NORMAL SALINE... (5*)
836. . . . EFFECT OF SYNBIOTICS IN REDUCING THE... (4*)
837. . . . RADIOMIC FEATURES DISTINGUISH PANCREATIC CANCER FROM... (2*)
838. . . . DISORDERING OF ACINAR CELL CHOLESTEROL HOMEOSTASIS... (2*)
840. . . . TOWARDS THE BIOCHEMICAL DIAGNOSIS OF BILE... (2*)(3)|(Sigma-tau Rare Disease Ltd. provided chenodeoxycholic acid (Xenbilox®) without restrictions as an independent grant.)
841. . . . EFFECT OF AMOXICILLIN-CLAVULANATE VERSUS METRONIDAZOLE AND... (2*)
842. . . . VALIDATION OF PERIPHERAL EOSINOPENIA AS A... (5*)
844. . . . MEDICATION USE AND MICROSCOPIC COLITIS: A... (5*)
845. . . . CAN WE RELIABLY REPLACE THE SEHCAT... (3*)
846. . . . ANTIBIOTIC USE AND THE DEVELOPMENT OF... (6*)(2)
847. . . . DIETARY GLUTEN INTAKE AND RISK OF... (2*)(4)
848. . . . ASSOCIATION BETWEEN STATIN USE AND RISK... (4*)(6)
849. . . . CHOLECYSTECTOMY CONTRIBUTES TO FUNCTIONAL ABDOMINAL SYMPTOMS... (2*)
850. . . . ASSOCIATION OF LYMPHOMA WITH AGE AT... (6*)
851. . . . SQUALENE EPOXIDASE (SQLE) PROMOTES CRC VIA... (2*)
852. . . . BILOPHILA WADSWORTHIA SUPPLEMENTATION REDUCES ADENOMA BURDEN... (4*)(2)
853. . . . CIGARETTE SMOKE PROMOTES COLORECTAL CANCER THROUGH... (2*)
854. . . . EPITHELIAL TLR4-SHAPED MICROBIOTA INCREASES SUSCEPTIBILITY TO... (2*)(6)
855. . . . INVASIVE E. COLI SUPPRESS EPITHELIAL AUTOPHAGY... (2*)
856. . . . SPATIAL MICROBIAL SIGNATURES IN COLORECTAL NEOPLASIA... (1*)(4)
857. . . . RATES AND TIMECOURSE OF EXCESS SERIOUS... (5*)
858. . . . HOT OR COLD? PERSISTENCE OF HOT... (5*)
859. . . . COMPUTER-AIDED-DETECTION EMBEDDED COLONOSCOPY VERSUS ROUTINE COLONOSCOPY:... (5*)
860. . . . DIGITAL NAVIGATION IMPROVES NO-SHOW RATES AND... (4*)
861. . . . THE BOWEL CLEANSING NATIONAL INITIATIVE (BCLEAN):... (3*)(This study was supported by Pendopharm, division of Pharmascience Inc.)
862. . . . MULTICOMPONENT INTERVENTION IMPROVES UPTAKE OF SURVEILLANCE... (4*)
863. . . . THE IL-33 RECEPTOR ST2 IS HIGHLY... (4*)(2)
864. . . . BARRIER DYSFUNCTION IN EOSINOPHILIC ESOPHAGITIS IS... (6*)(2)
865. . . . EOSINOPHILIC ESOPHAGITIS MAY FOSTER ESOPHAGEAL BASAL... (2*)
866. . . . CD252 (OX40L)+ ANTIGEN PRESENTING CELLS ARE... (4*)
867. . . . EGID BIOPSIES HAVE FUNCTIONALLY DISTINCT AND... (3*)(Allakos, Inc.)
868. . . . HEPATOCELLULAR CARCINOMA INCIDENCE DECLINES AFTER WIDESPREAD... (2*)
869. . . . TELEMEDICINE HCV TREATMENT IN DEPARTMENT OF... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- 870. . . . RANDOMIZED CONTROLLED TRIAL OF IN-REACH WITH...** (2*)(3)|(This study was conducted with support from CPRIT PP180091 and FOCUS.)
- 871. . . . IMMUNOMODULATION OF AUTOIMMUNE HEPATITIS WITH A...** (5*)
- 872. . . . AUTOIMMUNE HEPATITIS PATIENTS ARE LESS LIKELY...** (5*)
- 873. . . . INCREASED RISK OF POST-TRANSPLANT MORTALITY IN...** (5*)
- 911. . . . LINACLOTIDE SAFETY AND EFFICACY IN CHILDREN...** (3*)(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc. Writing assistance by Complete HealthVizion, funded by Allergan plc and Ironwood Pharmaceuticals, Inc.)
- 913. . . . QUANTITATIVE ANALYSIS OF TUG SIGN: AN...** (1*)
- 914. . . . NOVEL SUBTYPING OF EOSINOPHILIC ESOPHAGITIS BASED...** (5*)
- 928. . . . AN ELECTRONIC HEALTH RECORD-BASED MACHINE LEARNING...** (2*)
- 929. . . . INTERLEUKIN13-MEDIATED DISRUPTION OF MITOCHONDRIAL BIOLOGY CONTRIBUTES...** (2*)(4)
- 930. . . . HELICOBACTER PYLORI PROMOTES THE DIFFERENTIATION OF...** (2*)
- 931. . . . INCIDENCE OF NONCARDIA GASTRIC ADENOCARCINOMA AFTER...** (1*)
- 932. . . . HISTOLOGIC AND SYMPTOMATIC IMPROVEMENT ACROSS MULTIPLE...** (3*)(2)|(Allakos, Inc.)
- 933. . . . INTERLEUKIN-23 RECEPTOR SIGNALING MODULATES THE STABILITY...** (2*)(4)
- 934. . . . STROMAL TNF RECEPTOR 1 (TNFR1) PRESERVES...** (2*)
- 935. . . . PRE-TREATMENT MUCOSAL INFLAMMATORY AND WOUND HEALING...** (6*)
- 936. . . . CADHERIN-11 IS UPREGULATED IN INFLAMMATORY BOWEL...** (3*)(Pliant Therapeutics)
- 937. . . . A POSITIVE FEEDBACK LOOP BETWEEN CREEPING...** (4*)
- 938. . . . ADIPOSE DERIVED MESENCHYMAL STEM CELLS ACELLULAR...** (4*)(3)|(MSC2018003 New Strategy to Improve MSC Based GVHD Therapy, Biological Industries USA (Li, PRINCIPAL INVESTIGATOR)
- 939. . . . TRADIPITANT TREATMENT CAUSED CLINICALLY MEANINGFUL AND...** (3*)(Vanda Pharmaceuticals, Inc)
- 940. . . . GLOBAL KNOCKOUT OF MIR-10B IN MICE...** (2*)
- 941. . . . EPIGENETIC ALTERATIONS IN THE PERIPHERAL CIRCULATION...** (2*)
- 942. . . . SYSTEMIC EPIGENETIC ALTERATIONS ARE ASSOCIATED WITH...** (2*)
- 943. . . . ASSESSMENT OF SMALL BOWEL MOTILITY IN...** (4*)
- 944. . . . MOLECULAR MECHANISM OF CINNAMALDEHYDE AND CURCUMIN...** (2*)
- 945. . . . HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS...** (3*)(AbbVie Inc.)
- 946. . . . DEEP REMISSION AT 1 YEAR IS...** (5*)
- 947. . . . TOP-DOWN INFLIXIMAB SUPERIOR TO STEP-UP IN...** (1*)(3)|(Pfizer)
- 948. . . . A NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) IN...** (3*)(Celltrion, Inc.)
- 949. . . . EFFICACY AND SAFETY OF 2 VEDOLIZUMAB...** (3*)(Takeda)
- 950. . . . THE VISIBLE 2 PHASE 3 STUDY...** (3*)(Takeda)
- 951. . . . DEXAMETHASONE PROPHYLAXIS OF POSTEMBOLIZATION SYNDROME AFTER...** (5*)
- 952. . . . INSUFFICIENT RADIOFREQUENCY ABLATION PROMOTES THE METASTASIS...** (2*)
- 953. . . . IN SITU VACCINE IMMUNOTHERAPY FOR GASTROINTESTINAL...** (5*)
- 954. . . . THE INFLUENCE OF IMMUNE HETEROGENEITY ON...** (2*)
- 955. . . . INHIBITION OF CYCLIN DEPENDENT KINASES OVERCOMES...** (6*)
- 956. . . . GENOMEWIDE TRANSCRIPTOMIC PROFILING IDENTIFIES A NOVEL...** (5*)
- 992. . . . VEGETARIAN DIET REDUCES HUMAN GUT MICROBIAL...** (2*)
- 993. . . . NEURAL NETWORK PREDICTS DROP IN HEMOGLOBIN...** (2*)
- 994. . . . ASSOCIATION OF METEOROLOGICAL PARAMETERS WITH INCIDENCES...** (4*)
- 995. . . . PHASE 3 STUDY EVALUATING THE EFFICACY...** (3*)(Funded by Takeda Development Center Asia Pte Ltd, Singapore.)
- 996. . . . OUTCOMES IN PATIENTS ADMITTED WITH ACUTE...** (5*)
- 997. . . . SUPPRESSION OF LPS-INDUCED IL-6 PRODUCTION IN...** (2*)(6)
- 998. . . . LOCAL AND SYSTEMIC IMMUNE SIGNATURE DIFFERENCES...** (2*)
- 999. . . . FECAL MICROBIOTA TRANSPLANTATION AMELIORATES EXPERIMENTALLY INDUCED...** (2*)
- 1000. . . . TWO TYPES OF HUMAN PANCREATIC ACINAR...** (1*)(2)
- 1007. . . . DIETARY FIBER INTAKE, THE GUT MICROBIOME,...** (2*)(4)
- 1008. . . . A RANDOMIZED CONTROLLED-FEEDING STUDY OF THE...** (2*)
- 1009. . . . ALTERED DIURNAL FEEDING PATTERNS LINKED WITH...** (6*)
- 1010. . . . MATERNAL EMULSIFIER EXPOSURE EXACERBATES THE SUSCEPTIBILITY...** (2*)
- 1011. . . . IMPAIRED THERMOGENESIS IN BROWN ADIPOSE TISSUE...** (2*)
- 1012. . . . DIET AND FEEDING PATTERN AFFECT THE...** (2*)(7)
- 1013. . . . SINGLE CELL (SC) RNA SEQ OF...** (2*)(4)
- 1014. . . . EXPLORING THE CANCER GENOME ATLAS (TCGA)...** (5*)
- 1015. . . . INTEGRATIVE MOLECULAR MARKER ANALYSES OF EARLY-ONSET...** (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

1016. . . . LOSS OF TGFBR2 IN DIFFUSE TYPE... (5*)
1017. . . . GENOMIC LANDSCAPE AND IMMUNE CHARACTERISTICS OF... (2*)
1018. . . . IDENTIFICATION OF THE CANCER-SUPPRESSING CANCER-ASSOCIATED FIBROBLASTS... (5*)
1019. . . . VITAMIN D RECEPTOR PROTECTS INTESTINAL BARRIERS... (2*)|(4)
1020. . . . DEOXYCHOLATE ACID INDUCED-GUT DYSBIOSIS DISRUPTS BILE... (2*)|(National Natural Science Foundation of China (81700456 to M.Q.X) , Medical Health Technology Project of Zhejiang, China (2018KY104 to M.Q.X)
1021. . . . NFAT5 POSITIVELY CONTROLS GLYCOLYSIS IN INTESTINAL... (2*)
1022. . . . LOSS OF OLFACTORY G PROTEIN-COUPLED RECEPTOR... (2*)
1023. . . . VITAMIN D RECEPTOR REGULATES EPITHELIAL-MESENCHYMAL TRANSITION... (2*)
1024. . . . FUSOBACTERIUM NUCLEATUM SECRETES OUTER MEMBRANE VESICLES... (2*)
1025. . . . EFFECTS OF ACUPUNCTURE ON SYMPTOMS, MICROBIOTA,... (2*)
1026. . . . LOW DOSE INTERLEUKIN-2 FOR THE TREATMENT... (6*)|(2)
1027. . . . SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A... (3*)|(Pfizer Inc)
1028. . . . USTEKINUMAB IS ASSOCIATED WITH BETTER EFFECTIVENESS... (1*)
1076. . . . GASTRIC SLEEVE SURGERY WITH DUODENAL SWITCH... (4*)
1077. . . . A PHASE 2, OPEN-LABEL, MULTICENTER, 2X2... (3*)|(AzurRx BioPharma Inc.)
1078. . . . A DISTINCT BRAIN-GUT MICROBIOME PROFILE EXISTS... (2*)|(4)
1079. . . . PLASMA METABOLOMICS REVEAL A TARGETED PANEL... (4*)|(3)| (Investigator-initiated grant from Servier)
1080. . . . UTILITY OF COMBINING ENDOSCOPIC ULTRASOUND WITH... (5*)
1081. . . . SEX DIFFERENCES IN PEDIATRIC ACUTE RECURRENT... (2*)
1082. . . . A PROSPECTIVE ENDOSCOPIC AND HISTOLOGIC STUDY... (2*)|(4)
1083. . . . RECURRENT NEOPLASIA AFTER ENDOSCOPIC TREATMENT FOR... (5*)
1084. . . . INDEPENDENT VALIDATION OF AN ACCURATE METHYLATED... (4*)|(3)| (Assays provided by Exact Sciences.)
1085. . . . INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT... (3*)|(Cernostics Inc.)
1092. . . . EPITHELIAL-DERIVED SELENOPROTEIN P ATTENUATES OXIDATIVE STRESS... (2*)|(6)
1093. . . . SPERMIDINE PROTECTS FROM COLITIS AND COLITIS-ASSOCIATED... (2*)|(4)
1094. . . . INHIBITION OF NF-κB SIGNALING IN DCLK1+... (2*)|(4)
1095. . . . CLAUDIN-1 ENHANCES LIPID DROPLET ACCUMULATION TO... (2*)
1096. . . . CLUSTERIN AGGRAVATES COLITIS AND COLON TUMORIGENESIS... (2*)
1097. . . . ROLE OF MYELOID CELLS IN THE... (4*)|(2)
1098. . . . COLONIC EPITHELIAL CELL-SPECIFIC AFTIPHILIN (AFTPH) REGULATES... (6*)
1099. . . . NEUROTENSIN DEFICIENCY IMPROVES BILE ACID HOMEOSTASIS... (2*)
1100. . . . THE ROLE OF SMOOTH MUSCLE CELL... (2*)
1101. . . . LYSOPHOSPHATIDIC ACID RECEPTOR 5 ENHANCES INTESTINAL... (2*)
1102. . . . ELEVATED HEXOKINASE 1 IMPAIRS INTESTINAL ENTEROCYTE... (2*)
1103. . . . EPITHELIAL IKKβ SIGNALING REGULATES NEUTROPHIL RECRUITMENT... (2*)
1104. . . . COLITIS INDUCES CARDIAC REMODELING BY ELEVATING... (2*)|(7)
1105. . . . COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE... (4*)
1107. . . . METTL14 INHIBITS THE TUMORIGENESIS AND METASTASIS... (2*)
1108. . . . A SINGLE RESIDUE IN MYELOID TRANSLOCATION... (2*)|(4)
1109. . . . REGULATION OF SOX-2 EXPRESSION BY BONE... (2*)|(4)
1120. . . . ASSOCIATION BETWEEN PERSISTENT ORGANIC POLLUTANT ... (4*)
1121. . . . INTESTINAL STEM CELL NICHE IN PATIENTS... (5*)
1122. . . . IMMUNE RECOGNITION OF EPITOPES DERIVED FROM... (4*)
1123. . . . ARYL HYDROCARBON RECEPTOR LIGAND PRODUCTION BY... (2*)|(4)
1124. . . . RISK OF SMALL BOWEL ADENOCARCINOMA AND... (5*)
1125. . . . KUMA062 EFFECTIVELY DIGESTS GLUTEN IN THE... (3*)|(The study was sponsored by PvP Biologics, Inc.)
1126. . . . HEALTHY LIFESTYLE, ENDOSCOPIC SCREENING, AND COLORECTAL... (2*)
1127. . . . SCREENING AND SURVEILLANCE COLONOSCOPY FINDINGS ARE... (2*)
1128. . . . CRC SCREENING REDUCES LONG-TERM ALL-CAUSE AND... (2*)
1129. . . . LONG-TERM RISK OF COLORECTAL CANCER AND... (4*)
1130. . . . LONG TERM FOLLOW-UP OF THE ITALIAN... (4*)
1131. . . . COLORECTAL CANCER MORTALITY IN VETERANS WITH... (4*)|(2)
1132. . . . CONTINUOUS NRF2 ACTIVATION SENSITIZES PANCREATIC CANCER... (5*)
1133. . . . PANCREATIC STELLATE CELL AND CANCER CELL... (7*)
1134. . . . USING LARGE SAMPLE REAL-WORLD DATA TO... (5*)
1135. . . . THE DIAGNOSTIC INCIDENCE OF PANCREATIC CYSTS... (5*)
1136. . . . NADPH OXIDASE 4 INDUCES EPITHELIAL-MESENCHYMAL

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

TRANSITION... (2*)|(National Natural Science Foundation of China,81871947)

1137. . . OPIOID-RELATED EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS... (2*)

1138. . . HIGH-DOSE DAILY OPIOID USE AMONG VETERANS... (2*)

1139. . . HIGH-VOLUME OPIOID PRESCRIBERS ACCOUNT FOR A... (4*)

1140. . . PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE... (5*)

1141. . . TRENDS AND SOCIOECONOMIC HEALTH OUTCOMES OF... (5*)

1142. . . MICROBIAL DEGRADATION OF ILEAL MUCUS PROMOTES... (2*)|(0)|

1143. . . URINE 3-INDOXYL SULFATE, A GUT MICROBIOME-DERIVED... (2*)

1144. . . FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT... (2*)|(3)

1145. . . AN EFFECTIVE METHOD OF ERADICATING HELICOBACTER... (2*)

1147. . . DETECTION OF SEASONAL INFLUENZA RNA IN... (2*)|(3)|(|This

research was supported by AMED (grant number JP18fk0108077), and JSPS KAKENHI (grant number JP18K16183). This research was also supported by grants from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Uehara Memorial Foun)

1148. . . JAK INHIBITORS SUPPRESS COLON CANCER CACHEXIA-ASSOCIATED... (7*)|(4)

1149. . . THE DIETARY-SHAPED GUT MICROBIOME ACCELERATES THE... (4*)

1150. . . HIGH FAT DIET PROMOTES COLORECTAL TUMORIGENESIS... (2*)

1151. . . THE SULFUR MICROBIAL DIET SCORE AND... (2*)|(6)

1152. . . AUTOPHAGY INHIBITS COLORECTAL CARCINOGENESIS INDUCED BY... (4*)|(2)

1153. . . TRANSCRIPTIONAL SIGNATURES OF WESTERN-STYLE DIET IN... (4*)

1154. . . RNF125 CONTROL OF THE HISTONE DEACETYLASE... (2*)

1155. . . CO-TARGETING MAPK SIGNALING AND ASPARAGINE... (2*)

1156. . . ALDH1A3 PROMOTES PANCREATIC CANCER METASTASIS VIA... (2*)

1157. . . CIRCULATING IL-10R2+ MYELOID CELLS IN PERIPHERAL... (5*)

1159. . . CLINICOPATHOLOGICAL FEATURES OF THE FLAT... (2*)

1160. . . REAL-WORLD PEDIATRIC INFLIXIMAB PHARMACOKINETIC MODEL VERIFIES... (2*)|(6)

1161. . . CLINICAL AND HOST BIOLOGICAL FACTORS CAN... (2*)

1162. . . BASELINE ILEAL LUMINAL NARROWING IS ASSOCIATED... (2*)|(6)|(|NIH Funding P30DK078392, CCFa funding)

1163. . . STEP-CD STUDY: USTEKINUMAB USE IN PAEDIATRIC... (5*)

1164. . . EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN... (3*)|(This study was funded by Janssen Research and Development, LLC)

1165. . . CLINICAL HYPNOSIS IN PEDIATRIC CROHN'S DISEASE... (4*)|(6)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)



AGA Poster Presentations

- Sa1000... PUBLICATION TRENDS IN GASTROENTEROLOGY AND HEPATOLOGY... (5*)
- Sa1001... ANGIOTENSIN CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR... (5*)
- Sa1002... PREVALENCE OF ACHALASIA IN THE MEDICARE... (2*)
- Sa1003... ACCURACY OF FIBROSCAN CONTINUOUS ATTENUATION PARAMETER... (4*)
- Sa1004... PREVALENCE OF COMPLICATIONS RELATED TO CHRONIC... (5*)
- Sa1005... PREVALENCE OF GASTROINTESTINAL DISEASE IN AN... (2*)
- Sa1006... TRENDS AND CHARACTERISTICS OF ACUTE CARE... (5*)
- Sa1007... PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE... (5*)
- Sa1008... INCIDENCE OF CLOSTRIDIODES DIFFICILE INFECTION FROM... (4*)
- Sa1009... POOR RATES OF RE-TESTING FOR ERADICATION... (2*)
- Sa1010... HEYDE SYNDROME: EPIDEMIOLOGY OF ANGIODYSPLASIA IN... (5*)
- Sa1011... HYPERBILIRUBINEMIA IN HOSPITALIZED PATIENTS: ETIOLOGY AND... (4*)
- Sa1012... EFFECTS OF SYSTEMIC LUPUS ERYTHEMATOSUS ON... (5*)
- Sa1013... EPIDEMIOLOGY AND PREVALENCE OF PSYCHIATRIC DISEASES... (5*)
- Sa1014... WHAT IF IT'S STILL THERE? ANALYSIS... (5*)
- Sa1015... NATIONAL HEALTH BURDEN OF ASPIRATION PNEUMONIA... (3*)|(Aspisafe Solutions Inc.)
- Sa1016... CLOSTRIDIODES DIFFICILE INFECTION: NOT AN EQUAL... (5*)
- Sa1017... A COMPARISON OF LYMPHOCYTIC COLITIS AND... (5*)
- Sa1018... THE EPIDEMIOLOGY OF ANNULAR PANCREAS IN... (5*)
- Sa1019... CHRONIC MESENTERIC ISCHEMIA, A HORSE INSTEAD... (5*)
- Sa1020... EFFECT OF HELICOBACTER PYLORI ERADICATION ON... (5*)
- Sa1021... CAN FECAL CALPROTECTIN LEVELS BE USED... (5*)
- Sa1022... EPIDEMIOLOGY OF DEPRESSIVE DISORDERS IN PATIENTS... (5*)
- Sa1023... AN INDIAN NATIONAL SURVEY OF THERAPEUTIC... (5*)
- Sa1025... HIGH COMPLEXITY AND CONFLICTING RECOMMENDATIONS ARE... (5*)
- Sa1026... CHARACTERISTICS OF OPIOID PRESCRIPTIONS TO VETERANS... (2*)
- Sa1027... EVALUATION OF SOCIOECONOMIC AND HEALTHCARE DISPARITIES... (5*)
- Sa1028... GENDER DISPARITIES IN PREVALENCE AND CONFLICTS... (5*)
- Sa1029... INVESTIGATION OF REPEAT GASTROINTESTINAL BLEEDING AMONG... (5*)
- Sa1030... THE OVERALL QUALITY OF EVIDENCE SURROUNDING... (5*)
- Sa1031... ENHANCED E-CONSULTS AT A FEDARALLY QUALIFIED... (5*)
- Sa1032... DEVELOPMENT OF A PRELIMINARY QUESTION PROMPT... (5*)
- Sa1033... FECAL GOLD MINE: TWITTER AS A... (2*)
- Sa1034... ALARMING TRENDS IN ERCP ADMISSIONS FOR... (5*)
- Sa1035... IDENTIFYING PATIENTS WITH ACUTE GASTROINTESTINAL BLEEDING... (5*)
- Sa1036... HARD TO SWALLOW RESULTS: ASSESSMENT OF... (5*)
- Sa1037... WHAT TYPES OF QUESTIONS CAN BE... (5*)
- Sa1038... DEVELOPMENT OF QUALITY INDICATORS FOR THE... (5*)
- Sa1039... TIME AND EFFORT SPENT AFTER WORK... (5*)
- Sa1040... PATIENT AND PROCESS-DRIVEN BARRIERS TO GASTROENTEROLOGY... (5*)
- Sa1041... CLINICAL CHARACTERISTICS ASSOCIATED WITH INCREASED INPATIENT... (5*)
- Sa1042... REPORTING OF CONFLICTS OF INTEREST DURING... (5*)
- Sa1043... A SINGLE CENTER STUDY ON THE... (5*)
- Sa1044... ASSOCIATION BETWEEN MEDITERRANEAN DIET ADHERENCE AND... (5*)
- Sa1045... WHAT IS KNOWN AND WHAT IS... (5*)
- Sa1046... ELEMENTS FOR EARLY DETECTION IN PANCREATIC... (5*)
- Sa1047... THE CLINICAL FEATURES OF SESSILE SERRATED... (2*)
- Sa1048... PATIENT FACTORS AFFECT ERGONOMIC STRAIN OF... (7*)
- Sa1049... CANADIAN GASTROENTEROLOGY CAREER PATHWAY EXPERIENCES: A... (5*)
- Sa1050... VALIDATION OF A NOVEL ENDOSCOPIC SUTURING... (5*)
- Sa1051... WHAT IS THE IMPACT OF TRAINEE... (5*)
- Sa1052... SIMULATOR-BASED TRAINING PROGRAMS ACCELERATE ACQUISITION OF... (5*)
- Sa1053... MIND THE GAP: WOMEN REPRESENTATION ON... (5*)
- Sa1054... USEFULNESS OF JHALA ALGORITHM IN ASSESSMENT... (5*)
- Sa1055... SHIFTS IN PERSPECTIVES OF SOCIAL MEDIA... (5*)
- Sa1056... ADDRESSING EDUCATIONAL NEEDS TOWARDS ENHANCED CARE... (3*)|(This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.)
- Sa1057... EVALUATION OF A NUTRITION CURRICULUM DESIGNED... (5*)
- Sa1058... FROM ABSTRACT TO PUBLICATION SUCCESS: A... (5*)
- Sa1059... COLONOSCOPY QUALITY METRICS DURING GASTROENTEROLOGY FELLOWSHIP:... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1060... COMPARING THE CONTRIBUTION OF INTERNATIONAL MEDICAL... (5*)

Sa1061... CHARACTERIZATION OF ENGAGEMENT AND CONTENT ANALYSIS... (5*)

Sa1062... CHANGHAI ADVANCED ENDOSCOPY COURSES FOR ERCP... (5*)

Sa1063... ARE PARENTAL LEAVE POLICES HELPING OUR... (5*)

Sa1064... SURVEYING GASTROENTEROLOGY CONTENT AND METHODS OF... (5*)

Sa1065... TEACHING GASTROENTEROLOGY TO FIRST YEAR MEDICAL... (5*)

Sa1066... ADVANCED ENDOSCOPY TRAINING IN PEDIATRICS: THE... (5*)

Sa1067... IMPLEMENTATION OF A FIRST-YEAR GASTROENTEROLOGY FELLOWS'... (4*)

Sa1068... GI TALK: A COMMUNICATION SKILLS TRAINING... (5*)

Sa1069... GENDER DISPARITIES IN GASTROENTEROLOGY FELLOWS ACROSS... (5*)

Sa1070... IMPACT OF A VIRTUAL REALITY SIMULATION... (5*)

Sa1071... EVALUATING THE IMPACT OF ADVANCED ENDOSCOPY... (5*)

Sa1072... IMPACT OF PARENTHOOD ON GASTROENTEROLOGY TRAINING... (5*)

Sa1073... IMPACT OF TRAINEE PARTICIPATION ON ADENOMA... (5*)

Sa1074... SIGNIFICANT IMPROVEMENT OF PRIMARY CARE DOCTORS'... (3*)|(Xian Janssen Pharmaceutical Ltd)

Sa1075... HONOKIOL, A NOVEL AGENT THAT PROMOTES... (2*)

Sa1076... A NOVEL RAT MODEL OF HEARTBURN... (2*)|(4)

Sa1077... P2X7 RECEPTOR ANTAGONIST RECOVERS MYENTERIC NEURONS... (4*)

Sa1078... CANNABINOID RECEPTOR EXPRESSION AND THE EFFECT... (3*)|(2)|(Arena Pharmaceuticals)

Sa1079... ESTABLISHING AN INTESTINAL EPITHELIAL-NEURONAL CO-CULTURE SYSTEM... (4*)|(2)

Sa1080... THE DEUBIQUITINATING ENZYME USP10 REGULATES NA+/H+... (2*)

Sa1081... UNIQUE MECHANISMS OF REGULATION OF L-TYPE... (2*)

Sa1082... MOLECULAR MECHANISM OF STIMULATION OF NA-K-ATPASE... (2*)

Sa1083... GASTRIC AND PANCREATIC-DERIVED DOPAMINE STIMULATES... (2*)

Sa1084... MUSCARINIC AND NICOTINIC SIGNALING SYNERGISTICALLY REGULATE... (2*)

Sa1085... REGULATION OF ELECTROLYTE AND NUTRIENT TRANSPORTERS... (2*)

Sa1086... AUTOPHAGY REGULATES PUTATIVE ANION TRANSPORTER 1... (2*)

Sa1087... DEFICIENT ACTIVITY OF A GOBLET CELL-SPECIFIC... (2*)|(6)

Sa1088... GLUCOSE-STIMULATED ANION CHANNEL ACTIVITY DECREASED NET... (3*)

Sa1089... SLC26A3 (DRA) IS STIMULATED BY BOTH... (2*)

Sa1090... PROTEIN KINASE A-ALPHA REGULATES PGE2 MEDIATED... (2*)

Sa1091... POLARIZED RESPONSES TO EXTRACELLULAR CYCLIC DINUCLEOTIDES... (2*)

Sa1092... APICAL BK CHANNELS IN INTESTINAL EPITHELIA... (6*)

Sa1093... CONTRIBUTION OF EPITHELIAL HYPERPROLIFERATION TO INCREASED... (6*)

Sa1094... EVIDENCE OF DUODENAL EPITHELIAL BARRIER IMPAIRMENT... (4*)|(2)

Sa1095... PARD6B REGULATES INTESTINAL BARRIER FUNCTION IN... (2*)

Sa1096... SELECTIVE INHIBITION OF COX-1, BUT NOT... (2*)

Sa1097... EXPLORING THE MECHANISMS OF LARAZOTIDE IN... (3*)|(Innovate Biopharmaceuticals Inc., Raleigh, NC, USA)

Sa1098... OLEOYLETHANOLAMIDE AMELIORATES DEXTRAN SULFATE SODIUM-INDUCED COLITIS... (4*)

Sa1099... LACTOBACILLUS RHAMNOSUS GG (LGG) #NAME? ENTERIC... (2*)

Sa1100... INGESTED MICROPLASTICS POSE A POTENTIALLY SERIOUS... (4*)

Sa1102... PROTECTIVE EFFECT OF ALISMATIS RHIZOMA ON... (2*)

Sa1103... ANTI-INFLAMMATORY EFFECT OF TEGOPRAZAN(CJ-12420), A NOVEL... (5*)

Sa1104... RELATIONSHIP BETWEEN ANTIMICROBIAL REG IIIy EXPRESSION... (5*)

Sa1105... EFFECT OF ANTIBIOTICS-INDUCED DYSBIOSIS ON MACROPHAGE... (5*)

Sa1106... THE IMPACT OF BILE SALT SEQUESTRANTS... (3*)

Sa1107... EFFECTS OF QIZHI WEITONG GRANULES ON... (5*)

Sa1108... SERUM AMYLOID A PROMOTES INFLAMMATION-ASSOCIATED DAMAGE,... (2*)|(6)

Sa1109... CRONKHITE-CANADA SYNDROME: A PRELIMINARY STUDY TO... (2*)

Sa1110... ENDOSCOPIC AND HISTOLOGIC INFLAMMATION IN THE... (5*)

Sa1111... DOWN-REGULATION OF OLFM4 CONTRIBUTES TO METASTASIS... (5*)

Sa1112... TARGETED DELETION OF CIRCULAR RNA CDR1AS... (2*)

Sa1113... LYCIUM BARBARUM POLYSACCHARIDES ATTENUATES COLONIC INFLAMMATION... (4*)

Sa1114... MODELING CONTEXT-DEPENDENT BUBR1 KINASE SIGNALING USING... (2*)|(6)

Sa1115... CIRCADIAN MISALIGNMENT BY ENVIRONMENTAL LIGHT:DARK SHIFTING... (5*)

Sa1116... BISMUTH SUBSALICYLATE ALTERS THE EFFECTS OF... (3*)|(P & G grant IISP opportunity)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1117... THE EFFECTS OF SULGLYCOTIDE ON THE...** (3*)|(Samil pharmaceutical company)
- Sa1118... AUTOPHAGY IS REQUIRED FOR THE BENEFICIAL...** (4*)
- Sa1119... TRISTETRAPROLIN EXPRESSION IN THE INTESTINAL EPITHELIUM...** (5*)
- Sa1120... DEPLETION OF DELTA-LIKE LIGAND 4 (DLL4)...** (2*)
- Sa1121... COMPOUND HETEROZYGOTE TRIM22 VARIANTS ARE A...** (6*)
- Sa1122... TARGETED DRUG DELIVERY FOR INFLAMMATORY BOWEL...** (2*)
- Sa1123... REGULATORS OF THE GUANYLATE CYCLASE PATHWAY...** (2*)
- Sa1124... SINGLE CELL TRANSCRIPTOMIC APPROACH TO UNDERSTANDING...** (2*)|(U01DK112194 (Baylor), U01DK073983(JHU), U01DK112193 (Braden Kuo), U01DK073975 (Temple), U01DK074035 (TTU), U01DK074007 (Louisville – Abell), U01DK073974 (Wake Forest – Koch), U01DK074008)
- Sa1125... GENE EXPRESSION (GE) VALUES IN A...** (3*)|(NCT02589665 and this subsidiary analysis were designed, funded and conducted by Eli Lilly and Company.)
- Sa1126... IMMUNE IMPAIRMENTS IN BOWEL OBSTRUCTION: ROLE...** (2*)
- Sa1127... THE KETOGENIC ENZYME, HMGCS2, PROTECTS INTESTINAL...** (2*)
- Sa1128... LUBIPROSTONE INCREASED EXPRESSION OF CLAUDIN-1 AND...** (4*)
- Sa1129... WATER AVOIDANCE STRESS DECREASES INNATE LYMPHOID...** (4*)
- Sa1130... THE EFFECT OF PHOENIXIN-14 ON...** (4*)
- Sa1131... EXOSOMES FROM HUMAN MESENCHYMAL STEM CELLS...** (2*)
- Sa1132... CHARACTERIZATION OF IL10 GENE-DEFICIENT MOUSE INTESTINAL...** (2*)|(4)| (National Natural Science Foundation of China, 81670477, 81600418, 81600412, 81600419 ; Sun Yat-Sen University
- Clinical Research 5010 Program (2014008))
- Sa1133... THE ROLE OF INTERFERON- α AND PLASMACYTOID...** (4*)
- Sa1134... THE GUT-SKIN AXIS IN SAMP1/YITFC MICE...** (2*)
- Sa1135... CYSTATHIONINE- γ -LYASE (CSE) DERIVED HYDROGEN SULFIDE (H2S)...** (2*)
- Sa1136... EFFECT OF TETRAHYDROCANNABINOL ON THE CANONICAL...** (4*)
- Sa1137... AN ADHESIOGENIC ROLE OF THBS4 IN...** (2*)
- Sa1138... MURINE INTRARECTAL INSTILLATION OF PURIFIED RECOMBINANT...** (2*)|(4)
- Sa1139... NEW THERAPEUTIC STRATEGY FOR AMINO ACID:...** (2*)
- Sa1140... MMP-9 DISRUPTION OF INTESTINAL EPITHELIAL TIGHT ...** (6*)|(4)
- Sa1141... CSN6 PROMOTES COLORECTAL CANCER BY SUPPORTING...** (2*)
- Sa1142... THE ROLE FOR LONG NON-CODING RNA...** (4*)
- Sa1144... CONCONDANCE BETWEEN SOMATIC AND GERMLINE MUTATION...** (5*)
- Sa1145... NOVEL LNCRNA HERES REGULATES WNT SIGNALING...** (2*)|(This study was funded by the Ministry of Science and Information and Communication Technologies (ICT) (grant numbers 2017M3A9G8084539, 2017R1A2B4006316, and 2018R1A2B2003782))
- Sa1146... CANCER-RELATED GENETIC VARIANTS OF HELICOBACTER PYLORI...** (2*)|This work was supported by JSPS (Japan Society for the Promotion of Science) KAKENHI Grant Numbers JP16K09295 to Yoshiyuki Watanabe.)
- Sa1147... GENETIC COMPARISON OF YOUNG-ONSET AND LATE-ONSET...** (2*)
- Sa1148... GENERATION AND CHARACTERIZATION OF HUMAN PANCREATIC...** (2*)
- Sa1150... CAN LONG TERM USE OF PROTON...** (5*)
- Sa1151... POST-TRAUMATIC STRESS DISORDER IN NEUROENDOCRINE TUMOR...** (5*)
- Sa1152... TUMOR RESPONSE TO PEPTIDE RECEPTOR RADIONUCLIDE...** (5*)
- Sa1153... RACIAL DIFFERENCES IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR...** (6*)
- Sa1154... ORGANOID-BASED PRECLINICAL MODELS RECAPITULATE RENALASE SIGNALING...** (2*)
- Sa1155... BILE ACIDS AND THE MICROBIOTA PLAY...** (2*)|(6)
- Sa1156... ROLE OF WNT NON-CANONICAL PATHWAY IN...** (4*)
- Sa1157... HSA_CIRC_0021087 INHIBITS GASTRIC CANCER PROGRESSION BY...** (2*)
- Sa1158... GENERATION OF PATIENT-DERIVED PANCREATIC CANCER ORGANOID...** (5*)
- Sa1159... NOTCH2 SIGNALING REGULATES DENDRITIC CELLS TO...** (2*)
- Sa1160... ROLE OF P21 IN CD4+ T...** (4*)
- Sa1161... INFLAMMATORY IMMUNE RESPONSES ASSOCIATED WITH ORAL...** (4*)
- Sa1162... COLORECTAL CANCER PROLIFERATION AND SURVIVAL ARE...** (2*)|(6)
- Sa1163... PATIENTS WITH IBD ARE AT AN...** (5*)
- Sa1164... PREOPERATIVE INTRAVENOUS IRON THERAPY AND SURVIVAL...** (2*)
- Sa1165... THE DNA MISMATCH REPAIR (MMR) PROTEIN...** (2*)|(4)
- Sa1166... SYSTEMIC LUPUS ERYTHEMATOUS AND COLORECTAL CANCER:...** (5*)
- Sa1167... ADRENALINE-DEPENDENT IMMUNOLOGIC REPROGRAMMING IN ENDOTHELIAL CELLS...** (2*)
- Sa1168... RHEUMATOID ARTHRITIS AND COLORECTAL CANCER: THE...** (5*)
- Sa1169... ACHIEVING HISTOLOGIC NORMALIZATION IN LONG-STANDING ULCERATIVE...** (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1170... TRENDS AND PREDICTORS OF ANAL CANCER... (5*)
- Sa1171... UPREGULATED SOX18 MEDIATED BY CCL7/CCR1/ERK/ELK1 PATHWAY... (2*)
- Sa1172... TRIP6-DEPENDENT ACTIVATION OF AKT/HIF1A CASCADE PROMOTES... (2*)
- Sa1173... EVIDENCE THAT ZINC FINGER PROTEIN 277... (2*)
- Sa1174... CYCLOPHILIN B PROMOTES COLON CANCER PROLIFERATION... (2*)
- Sa1175... CARTILAGE OLIGOMERIC MATRIX PROTEIN PROMOTES EPITHELIAL-MESENCHYMAL... (2*)
- Sa1176... NUCLEAR MGP PROMOTES TUMOR PROGRESSION BY... (2*)(4)
- Sa1177... METFORMIN SUPPRESSES CANCER STEM CELLS THROUGH... (5*)
- Sa1178... SECONDARY BILE ACID PROMOTES INTESTINAL TUMOR... (2*)
- Sa1179... YTHDF1 PROMOTES THE TUMORIGENESIS AND METASTASIS... (2*)
- Sa1180... MOLECULAR MECHANISMS UNDERLYING HOMEOPROTEIN NKX6.1 INHIBITING... (5*)
- Sa1181... BCAR3 PARTNERS WITH THE EGF-RECEPTOR TYROSINE... (4*)
- Sa1182... CIRCULAR RNA FOXO3 ATTENUATES DRUG RESISTANCE... (2*)
- Sa1183... INTEGRATED GENETIC AND EPIGENETIC ANALYSIS OF... (5*)
- Sa1184... CIRCULAR RNA CIRC-FOXO3 INHIBITS COLORECTAL CANCER... (2*)
- Sa1185... ABERRANT SOX2 EXPRESSION DIRECTLY UP-REGULATED THE... (4*)
- Sa1186... SELENOPROTEIN P (SELENOP) AS A CONTEXT-DEPENDENT... (2*)(6)
- Sa1187... CLINICAL CORRELATION ANALYSIS OF SLC15A1... (2*)
- Sa1188... NEOPLASIA DETECTION RATE (NDR) IN BARRETT'S... (5*)
- Sa1189... INDEPENDENT VALIDATION OF TISSUECYPHER TO PREDICT... (3*)(Cernostics Inc.)
- Sa1190... NEUTROPHIL-TO-LYMPHOCYTE RATIO PREDICTS PROGRESSION TO HIGH... (5*)
- Sa1191... PREVALENCE AND PREDICTORS OF BARRETT'S ESOPHAGUS... (2*)
- Sa1192... THE INCIDENCE AND PREDICTORS OF DYSPLASIA... (5*)
- Sa1193... DECLINING TRENDS IN THE PREVALENCE OF... (5*)
- Sa1194... ACCURACY OF NATURAL LANGUAGE PROCESSING AND... (4*)
- Sa1195... ASSOCIATION BETWEEN NUMBER OF BARRETT'S ESOPHAGUS... (5*)
- Sa1196... UPTAKE AND ACCEPTANCE OF CYTOSPONGE SCREENING... (5*)(Study supported by funding from the Price Family Foundation)
- Sa1197... RATE AND CORRELATES OF PREVALENT, INTERVAL,... (2*)
- Sa1198... PREVALENCE OF BARRETT'S ESOPHAGUS IN THE... (6*)
- Sa1199... NON-GERD RISK FACTORS FOR BARRETT'S ESOPHAGUS:... (2*)
- Sa1200... REDUCED RISK OF BARRETT'S ESOPHAGUS WITH... (2*)
- Sa1201... ACCURACY OF CONSENSUS GUIDELINES IN DETECTING... (5*)
- Sa1202... TOLERABILITY OF A NON-ENDOSCOPIC DISTAL ESOPHAGUS... (2*)(3)
- Sa1203... PREDICTION OF NEOPLASTIC PROGRESSION IN BARRETT'S... (3*)(Cernostics, Inc)
- Sa1204... COMPARATIVE OUTCOMES OF CRYOTHERAPY ABLATION FOR... (5*)
- Sa1205... LONG-TERM EFFICACY AND SAFETY OF CONTINUOUS... (4*)
- Sa1206... TREATMENT OUTCOMES OF BARRETT'S ESOPHAGUS IN... (5*)
- Sa1207... ASSOCIATION BETWEEN OBSTRUCTIVE SLEEP APNEA SYNDROME... (5*)
- Sa1208... GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT'S ESOPHAGUS,... (5*)
- Sa1209... EFFECTS OF SALIVA SECRETION AND SALIVARY... (4*)
- Sa1210... ST6GAL-I IS UPREGULATED IN BARRETT'S ESOPHAGUS... (2*)(4)
- Sa1211... ESOPHAGEAL REFLUX HYPERSENSITIVITY: IDENTIFICATION OF DIFFERENT... (4*)
- Sa1212... THE G-PROTEIN-COUPLED BILE ACID RECEPTOR TGR5... (3*)(Ironwood Pharmaceuticals)
- Sa1213... THE BILE ACID SEQUESTANT COLESEVELAM AMELIORATES... (3*)(Ironwood Pharmaceuticals)
- Sa1214... SLIDING HIATUS HERNIA: TWO STEP PUMP... (2*)
- Sa1215... USING A NOVEL 4-GAS BREATH TEST... (6*)
- Sa1216... IN PATIENTS WITH HEARTBURN, SUPERFICIAL MUCOSAL... (4*)
- Sa1217... DIURNAL VARIATION OF POSTPRANDIAL GASTROESOPHAGEAL REFLUX(GER)... (5*)
- Sa1218... ACIDIC BILE SALT MEDIATED INDUCTION AND... (4*)
- Sa1219... CENTRAL OBESITY IS A PRIMARY AND... (7*)(Medtronic : Provided Bravo pH probes)
- Sa1220... HELICOBACTER PYLORI INFECTED GERD PATIENTS HAVE... (2*)(4)
- Sa1221... TGR5 COUPLES WITH NCX1 CHANNEL TO... (2*)(National Natural Science Foundation of China (NSFC))
- Sa1222... DEFECTIVE SECONDARY PERISTALSIS DETECTED BY FUNCTIONAL... (5*)
- Sa1223... DIAPHRAGMATIC BREATHING EFFECTIVELY TREATS UPRIGHT GASTROESOPHAGEAL... (4*)
- Sa1224... THE PRESENCE OF OBSTRUCTIVE SLEEP APNEA... (5*)
- Sa1225... IMPACT: OESOPHAGEAL PROTECTION DURING AF ABLATION,... (2*)(3)(Attune Medical (Chicago, IL) acted as a supplementary funder towards the study; which is self-funded via the National Health Service (NHS) of the United Kingdom (UK). The funding was to support the additional endoscopies performed for study purposes.)
- Sa1226... ARE THERE RISK FACTORS FOR DEVELOPING... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1332... GASTRIC CORPUS MUCOSAL HYPERPLASIA AND NEUROENDOCRINE... (4*)

Sa1333... BILE ACIDS PROMOTE GASTRIC INTESTINAL METAPLASIA... (2*)

Sa1334... CLINICOPATHOLOGICAL FEATURES AND TREATMENTS EFFECTS ON... (5*)

Sa1335... NEOPLASIA RISK AND RESECTION COMPLICATIONS... (5*)

Sa1336... HYPERGASTRINEMIA IS ASSOCIATED WITH PROXIMAL AND... (2*)(7)

Sa1337... DIFFERENTIAL EXPRESSION OF CIRCULATING MICRORNAS IN... (4*)(6)

Sa1338... NATURAL HISTORY OF AUTOIMMUNE GASTRITIS: PROSPECTIVE... (5*)

Sa1339... INTEROBSERVER CONSISTENCY ON THE HISTOLOGICAL ASSESSMENT... (5*)

Sa1340... IMPACT OF OBESITY ON RATES AND... (2*)

Sa1341... HELICOBACTER PYLORI INFECTION IS ASSOCIATED WITH... (5*)

Sa1342... GASTRIC CANCER OCCURRENCE DESPITE PRIOR ENDOSCOPY:... (5*)

Sa1343... CLASSIFICATION OF AUTOIMMUNE GASTRITIS BASED ON... (5*)

Sa1344... STAT3 SIGNALING ACTIVATES CDX2 VIA INDUCTION... (5*)

Sa1345... THE GASTRIC PRECANCEROUS CONDITIONS STUDY (GAPS)... (4*)(6)

Sa1346... HYPERGASTRINEMIA DUE TO P-CAB (AN... (5*)

Sa1347... MTHFR C677T GENETIC POLYMORPHISM INVOLVED IN... (2*)

Sa1348... CORRELATION BETWEEN SERUM GASTRIC BIOMARKERS AND... (5*)

Sa1349... A NON-INVASIVE TEST IN THE MANAGEMENT... (5*)

Sa1351... COMPARISON BETWEEN PROACTIVE VERSUS STANDARD PERCUTANEOUS... (5*)

Sa1352... MOLECULAR PHENOTYPING OF INFECTED PANCREATIC NECROSIS... (6*)

Sa1353... MORTALITY IN PATIENTS WITH ACUTE PANCREATITIS... (5*)

Sa1354... THE VALIDATION OF PANCREATITIS ACTIVITY SCORING... (5*)

Sa1355... CAN ARTIFICIAL INTELLIGENCE (AI) PREDICT... (5*)

Sa1356... NEED FOR INTERVENTION IN NECROTIZING PANCREATITIS... (5*)

Sa1357... BILIARY INTERVENTIONS IN PATIENTS WITH STERILE... (5*)

Sa1358... VALUE OF MEASUREMENT OF WHOLE BODY... (5*)

Sa1359... LONGITUDINAL ASSESSMENT OF HBA1C LEVELS IN... (3*)(4)|(AbbVie)

Sa1360... IMMUNE CHECKPOINT-INHIBITOR INDUCED ACUTE PANCREATITIS: A... (5*)

Sa1361... PATIENT-CONTROLLED ANALGESIA LEADS TO INCREASED HOSPITAL... (5*)

Sa1362... INCREASED FLUID RATE HASTENS RECOVERY OF... (5*)

Sa1363... USE OF ACOUSTIC RADIATION FORCE IMPULSE... (5*)

Sa1364... PANCREATIC CANCER IN ACUTE PANCREATITIS: A... (5*)

Sa1365... PRACTICE PATTERNS IN THE NUTRITIONAL SUPPORT... (5*)

Sa1366... PREDICTORS OF EMERGENCY DEPARTMENT OPIATE USE... (5*)

Sa1367... PROGRESSION FROM ACUTE PANCREATITIS WITH SYSTEMIC... (2*)

Sa1368... ASSOCIATION OF INCREASED SERUM TRIGLYCERIDE LEVELS... (5*)

Sa1369... DIAGNOSIS AND TREATMENT OF PANCREATIC DUCT... (5*)

Sa1370... EPIDEMIOLOGY AND RISK OF ANXIETY AND... (5*)

Sa1371... SPLANCHNIC VEIN THROMBOSIS IN ACUTE PANCREATITIS... (5*)

Sa1372... ISCHEMIC PANCREATITIS IS A RARE BUT... (5*)

Sa1373... PREOPERATIVE ERCP HAS NO IMPACT ON... (2*)

Sa1374... SINGLE OPERATOR PANCREATOSCOPY WITH INTRADUCTAL LITHOTRIPSY... (5*)

Sa1375... FOLATE AND VITAMIN B12 DEFICIENCY INCREASES... (2*)

Sa1376... PANCREAS CANCER ASSOCIATED MORTALITY IS LOW... (7*)(2)

Sa1377... LIFETIME SMOKING IN PERSONS WITH CHRONIC... (2*)

Sa1378... CHRONIC PANCREATITIS (CP) HAS A PROFOUND... (2*)

Sa1379... WHAT IS A BENEFIT OF ISLET... (5*)

Sa1380... SEVERE PAIN IN CHRONIC PANCREATITIS IS... (2*)

Sa1381... PREDICTIVE FACTORS OF RELAPSE IN AUTOIMMUNE... (5*)

Sa1382... CLASSIFICATION OF EARLY-ONSET AND LATE-ONSET IDIOPATHIC... (5*)

Sa1383... A COMPARISON OF UROLOGIST VS. GASTROENTEROLOGIST-DIRECTED... (5*)

Sa1384... FRAGMENTED INPATIENT CARE IS PREVALENT AMONG... (5*)

Sa1385... CHRONIC PANCREATITIS IS ASSOCIATED WITH INCREASED... (5*)

Sa1386... ISLET AUTOTRANSPLANTATION IMPROVES GLYCEMIC CONTROL IN... (5*)

Sa1387... NATIONWIDE EPIDEMIOLOGICAL SURVEY OF AUTOIMMUNE PANCREATITIS... (7*)(2)

Sa1388... LOOKING FOR A SUBROGATE BIOMARKER OF... (5*)

Sa1389... THE RISK OF VITAMIN D DEFICIENCY,... (5*)

Sa1390... MANAGEMENT AND SURVEILLANCE OF EXOCRINE PANCREATIC... (5*)

Sa1391... ANTIOXIDANT DECREASES THE FREQUENCY OF PAIN... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1392... NATIONWIDE EPIDEMIOLOGICAL SURVEY OF CHRONIC... (5*)
- Sa1393... LIFESTYLE MODIFICATIONS IN CHRONIC PANCREATITIS ... (5*)
- Sa1394... OPIATE DEPENDENCE IS A SIGNIFICANT RISK... (5*)
- Sa1550... HEAVY ALCOHOL USE AND LIVER DISEASE... (5*)
- Sa1551... TEMPORAL TRENDS OF MORTALITY AND HEALTHCARE... (5*)
- Sa1552... CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-ALCOHOLIC... (5*)
- Sa1553... PROTON PUMP INHIBITOR THERAPY REDUCES FERRITIN... (5*)
- Sa1554... NATIONAL TRENDS AND OUTCOMES OF GENETICALLY... (5*)
- Sa1555... POLYCYTHEMIA AND ANEMIA IN HEREDITARY HEMOCHROMATOSIS:... (5*)
- Sa1556... IMPAIRED INTESTINAL CHYLOMICRON SECRETION DISSOCIATES REVERSAL... (2*)
- Sa1557... PRAGMATIC USE OF NON-INVASIVE DIAGNOSTIC METHODS... (4*)
- Sa1558... THE ROLE OF IAA IN NONALCOHOLIC... (2*)
- Sa1559... ELEVATED LIVER ENZYMES NOT CORRELATED WITH... (5*)
- Sa1560... PROTEIN TRUNCATING SPLICE VARIANT (RS72613567) IN... (4*)
- Sa1561... CANNABIS IS ASSOCIATED WITH REDUCED IN-PATIENT... (5*)
- Sa1562... NON-ALCOHOLIC STEATOHEPATITIS-ASSOCIATED ALTERATION OF INFLAMMATORY LIPID... (3*)
- Sa1563... FIB-4 INDEX CORRELATES WITH MEASURES OF... (4*)
- Sa1564... CHARACTERISTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE... (5*)
- Sa1565... CHILD-TURCOTTE-PUGH CLASS AT TRANSPLANTATION PREDICTS POST-TRANSPLANTATION... (5*)
- Sa1566... LIVER SURFACE NODULARITY AS AN ESTIMATE... (5*)
- Sa1567... MRI INTENSITY PATTERNS IN PATIENTS WITH... (5*)
- Sa1568... EUS-GUIDED SAMPLING AND PROFILING OF PORTAL... (5*)
- Sa1569... TIMELY DIAGNOSIS AND STAGING OF NAFLD... (5*)
- Sa1615... GASTRIC DYSMOTILITY NEGATIVELY IMPACTS BOTH GASTROINTESTINAL... (2*)
- Sa1616... SACRAL NERVE STIMULATION LEADS TO LONG-TERM... (5*)
- Sa1617... OVERLAPPING SYMPTOMS OF GASTROESOPHAGEAL REFLUX AND... (4*)
- Sa1618... A RETROSPECTIVE REVIEW OF LINACLOTIDE TREATMENT... (5*)
- Sa1619... IS CELIAC DISEASE TESTING NECESSARY IN... (5*)
- Sa1620... POLYETHYLENE GLYCOL 3350 CHANGES STOOL CONSISTENCY... (4*)
- Sa1621... EFFECT OF MIRTAZAPINE IN CHILDREN WITH... (5*)
- Sa1622... SLEEP DISTURBANCES IN SCHOOL-AGE CHILDREN WITH... (2*)
- Sa1623... URINARY EXOSOMES ISOLATED FROM PEDIATRIC PATIENTS... (4*)
- Sa1624... PYRIDOSTIGMINE FOR TREATMENT OF CHILDREN WITH... (5*)
- Sa1625... NON-GASTROINTESTINAL PAIN SYMPTOMS IN CHILDREN WITH... (2*)
- Sa1626... HYPNOSIS TO REDUCE DISTRESS IN CHILDREN... (1*)
- Sa1627... THE NOT SO RARE ABSENT RAI... (5*)
- Sa1628... UTILIZATION AND COST FOR PEDIATRIC IRRITABLE... (5*)
- Sa1629... COMPARISON OF THE BRISTOL STOOL FORM... (5*)
- Sa1630... APREPITANT FOR ACUTE TREATMENT OF SEVERE... (5*)
- Sa1631... INTRAPYLORIC BOTULINUM INJECTIONS IMPROVE FEEDING OUTCOMES... (2*)
- Sa1632... COMPARING VULNERABILITIES AND TRIGGERS IN PEDIATRIC... (5*)
- Sa1633... COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN... (1*)
- Sa1634... ALLERGY-RELATED DISEASES DURING CHILDHOOD AND RISK... (6*)|(2)
- Sa1635... CINE-MRI VERSUS COLONIC MANOMETRY IN THE... (5*)
- Sa1636... PEDIATRIC ROME IV CRITERIA HAS SUBSTANTIAL... (5*)
- Sa1637... IBS MOTHERS IN JAPAN WHO HAVE... (2*)
- Sa1638... STANDARDIZING LONG-TERM GASTROINTESTINAL MOTILITY RECORDINGS IN... (5*)
- Sa1639... AZITHROMYCIN IS EQUALLY ABLE TO INDUCE... (4*)
- Sa1640... NONINVASIVE MEASUREMENT OF SMALL BOWEL SLOW... (4*)
- Sa1641... THE EFFECTS OF DIABETES MELLITUS ON... (5*)
- Sa1642... THE EFFECTS OF VENOUS THROMBOEMBOLISM IN... (5*)
- Sa1643... RISK FACTORS AND INCIDENCE OF 90-DAY... (5*)
- Sa1644... TRENDS IN MANAGEMENT OF ACUTE COLONIC... (5*)
- Sa1645... DIVERTICULAR DISEASE WITH AND WITHOUT BLEEDING:... (5*)
- Sa1646... VIRTUAL REALITY AS AN ALTERNATIVE TO... (4*)
- Sa1647... COMPARISON OF SECOND FORWARD VIEW EXAMINATION... (5*)
- Sa1649... HOT AVULSION VS COLD AVULSION IN... (5*)
- Sa1650... INCIDENCE OF INVASIVE COLORECTAL CANCER AFTER... (5*)
- Sa1651... PLASMA BASED CELL-FREE CIRCULATING TUMOR DNA... (3*)|(Guardant Health)
- Sa1652... ARTIFICIAL INTELLIGENCE-AUGMENTED VISUALIZATION WITH REAL TIME... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1653... THE USEFULNESS OF TOTAL INTESTINAL SURVEY... (5*)

Sa1654... GASTROINTESTINAL BLEEDING RISK AFTER POLYPECTOMY IN... (5*)

Sa1655... UNSUPERVISED MACHINE LEARNING MODELS FOR POLYP... (2*)

Sa1656... APPLICABILITY OF COLON CAPSULE ENDOSCOPY AS... (2*)

Sa1657... OVERALL AND ADVANCED ADENOMATOUS AND SESSILE... (5*)

Sa1658... MICROSIMULATION STUDY OF LIFE-YEARS GAINED FROM... (3*)|Exact Sciences)

Sa1659... COLD OR HOT SNARE POLYPECTOMY FOR... (3*)|(Boston Scientific - US)

Sa1660... A NOVEL MULTI-TASKING PLATFORM FOR ENDOSCOPIC... (5*)

Sa1661... EFFECT OF DISTAL ATTACHMENT MUCOSAL EXPOSURE... (4*)

Sa1662... ACCURACY OF ARTIFICIAL INTELLIGENCE ON HISTOLOGICAL... (4*)

Sa1664... MINIATURIZED MULTI-VIEW IMAGING DEVICE TO IMPROVE... (2*)

Sa1665... IMPACT OF ENGAGEMENT WITH DIGITAL NAVIGATION... (5*)

Sa1666... RATES AND PREDICTORS OF POST COLONOSCOPY... (2*)

Sa1667... CHILEAN COLORECTAL CANCER SCREENING PROGRAM (PRENEC):... (1*)

Sa1668... PRE-MICRORNA-143 AND PRE-MICRORNA -145 TARGETED TO... (2*)|(4)

Sa1669... A SCAVENGER OF ELECTROPHILES REDUCES COLITIS-ASSOCIATED... (2*)|(4)

Sa1670... PREDIAGNOSTIC REGULAR USE OF ASPIRIN AND/OR... (2*)|(4)

Sa1671... RISK FACTOR PROFILING OF COLORECTAL CANCER... (2*)|(7)

Sa1672... REGULAR TADALAFIL USE APPEARS TO LOWER... (5*)

Sa1673... RESTING HEART RATE IS AN INDEPENDENT... (5*)

Sa1674... THE POTENTIAL IMPACT OF THE LOW-SODIUM... (5*)

Sa1675... STATINS REDUCE THE RISK OF ALL... (5*)

Sa1676... EARLY ADVERSE LIFE EVENTS AND POST-TRAUMATIC... (4*)

Sa1677... VOLUMETRIC RECTAL SENSATION TESTING: IS IT... (5*)

Sa1678... PELVIC FLOOR PROLAPSE ASSOCIATED WITH GI-SPECIFIC... (5*)

Sa1679... ANAL AND VAGINAL AREA-PRESSURE BI-LOOPS: TOWARD... (2*)

Sa1680... EFFECTS OF CONCENTRIC PELVIC FLOOR RESISTANCE... (2*)

Sa1681... FECAL INCONTINENCE (FI) STOOL APP IS... (5*)

Sa1682... SIMULATED STOOL TESTING IN OBSTRUCTED DEFECATORS... (2*)

Sa1683... SENSITIVITY AND RECTAL CAPACITY IN PATIENTS... (5*)

Sa1684... PREVALENCE OF DISORDERS OF ANORECTAL FUNCTION... (5*)

Sa1685... BIOFEEDBACK AS A TOOL FOR RESOLUTION... (5*)

Sa1686... FACTORS INFLUENCING EFFICACY OF BIOFEEDBACK THERAPY... (5*)

Sa1687... TRANSLATION OF BIOENGINEERED FUNCTIONALLY INNERVATED HUMAN... (2*)

Sa1688... THE PREDICTORS OF NON-ADHERENCE TO BIOFEEDBACK... (5*)

Sa1689... CLINICAL PRESENTATION AND CHARACTERISTICS OF PELVIC... (5*)

Sa1690... ANAL DISTENSIBILITY IN CONSTIPATED WOMEN ... (2*)

Sa1691... ANALYSIS OF THE SENSITIVITY OF HIGH... (2*)

Sa1692... FATIGABILITY OF EXTERNAL ANAL SPHINCTER MUSCLES... (2*)

Sa1693... IN CONSTIPATED YOUNG MEN ACQUIRED VOIDING... (5*)

Sa1694... ANORECTAL MANOMETRY AS A DIAGNOSTIC TEST... (7*)

Sa1695... ANORECTAL MANOMETRY IN UPRIGHT POSITION WITH... (4*)

Sa1696... PATIENTS WITH REFRACTORY CHRONIC CONSTIPATION OFTEN... (5*)

Sa1697... CHANGES IN ANORECTAL FUNCTION IN PATIENTS... (5*)

Sa1698... EXTERNAL ANAL SPHINCTER STRENGTH TRAINING EXERCISE... (2*)

Sa1699... GEOMETRIC CHARACTERISTICS OF THE ANAL CANAL... (2*)

Sa1700... DYNAMIC ECHODEFECOGRAPHY FOR ASSESMENT OF FUNCTIONAL... (5*)

Sa1701... EFFECTS OF OPIOID POTENCY AND DURATION... (5*)

Sa1702... DOES AGE INFLUENCE ANORECTAL PHYSIOLOGICAL PARAMETERS?... (5*)

Sa1703... USEFULNESS OF THE LONDON CLASSIFICATION FOR... (5*)

Sa1704... MR DEFECOGRAPHY IN THE ASSESSMENT OF... (4*)|(7)

Sa1705... FAILED BALLOON EXPULSION IS THE ONLY... (5*)

Sa1706... ELDERLY PATIENTS DERIVE MORE CLINICAL BENEFITS... (5*)

Sa1707... EVIDENCE OF ABNORMAL CONTRACTION OF THE... (2*)

Sa1708... SMALL INTESTINAL BACTERIAL OVERGROWTH IN REFRACTORY... (5*)

Sa1709... EVALUATION OF REFRACTORY CONSTIPATION: ONE TEST... (5*)

Sa1710... A NEW ROLE OF THE HTR2B... (2*)

Sa1711... ABNORMAL SLEEP DURATION IS ASSOCIATED WITH... (7*)

Sa1712... SAFETY AND EFFICACY EVALUATION OF PLECANATIDE... (3*)|(Salix Pharmaceuticals)

Sa1715... ELOBIXIBAT, ILEAL BILE ACID TRANSPORTER INHIBITOR,... (3*)

Sa1716... ACID SUPPRESSION THERAPY DOES NOT AFFECT... (3*)|(Salix Pharmaceuticals)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1717... THE EFFECT OF ELOBIXIBAT ON GUT... (5*)

Sa1718... PELVIC FLOOR BIOFEEDBACK IS EFFECTIVE TREATMENT... (5*)

Sa1719... EVALUATION OF MAJOR ADVERSE CARDIAC EVENTS... (3*)|(This study was funded by Shire LLC, a Takeda company. Medical writing support was provided by Laura Knapp of PharmaGenesis London, London, UK with funding from Shire Human Genetic Therapies, Inc., a Takeda company.)

Sa1720... PLECANATIDE FOR PATIENTS WITH CHRONIC IDIOPATHIC... (3*)|(Salix Pharmaceuticals)

Sa1721... DISORDERED DEFECATION ASSOCIATED WITH POOR BOWEL... (5*)

Sa1722... OPIOID RELATED DISORDERS IN PATIENTS WITH... (5*)

Sa1723... COSTLY WASTE: EMERGENCY DEPARTMENT VISITS AND... (5*)

Sa1724... PLECANATIDE FOR PATIENTS WITH CHRONIC IDIOPATHIC... (3*)|(Salix Pharmaceuticals)

Sa1725... CONCENTRATION OF SEROTONIN AND ITS METABOLITES... (4*)

Sa1726... ATTRITION OF METHYLNALTREXONE TREATMENT-EMERGENT ADVERSE EVENTS... (3*)|(This analysis was funded by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, Inc., New York, NY, USA.)

Sa1727... CUMULATIVE LAXATION RESPONSE WITH METHYLNALTREXONE: IMPLICATIONS... (3*)|(Source of financial support for this project: This study was funded by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor® from Progenics Pharmaceuticals, I)

Sa1728... HOW USEFUL IS CONSTIPATION STOOL APP... (5*)

Sa1729... EFFICACY OF PRUCALOPRIDE IN PATIENTS WITH...

(3*)|(This analysis was funded by Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies. Medical writing support was provided by Laura Knapp of PharmaGenesis London, London, UK with funding from Shire Human Genetic Therapies, Inc., a me)

Sa1730... CLINICAL CHARACTERISTICS AND ANORECTAL PHYSIOLOGY IN... (5*)

Sa1731... EXPANDING CRITERIA FOR DIAGNOSING SLOW TRANSIT... (5*)

Sa1732... PATTERN OF METHANE LEVELS WITH LACTULOSE... (5*)

Sa1733... RIGHT-SIDEDS COLONIC DIVERICULA ARE NEGATIVELY ASSOCIATED... (5*)

Sa1734... CONSTIPATIN IS ASSOCIATED WITH INCREASED ODDS... (5*)

Sa1735... SAFETY AND EFFICACY OF A NEW... (2*)

Sa1736... PSEUDOMELANOSIS COLI CAUSES DISTURBED COLONIC MOTILITY... (4*)

Sa1737... FAILURE OF PRESCRIBING BOWEL REGIMENS TO... (5*)

Sa1738... LACTULOSE INCREASES SMALL BOWEL BUT NOT... (4*)

Sa1739... DIFFERENCES IN EFFICACY AND SAFETY OF... (5*)

Sa1740... FACTORS ASSOCIATED WITH THE IMPORTANCE OF... (5*)

Sa1741... A REAL-WORLD COMPARISON OF THE EFFECTIVENESS... (3*)|(Takeda Pharmaceuticals Company Ltd.)

Sa1742... THIOGUANINE AND LOW DOSE THIOPURINES AND... (1*)

Sa1743... ACCEPTABILITY OF TREATMENT REGIMEN IN INFLAMMATORY... (5*)

Sa1744... IMPACT OF LINE OF THERAPY, THERAPEUTIC... (5*)

Sa1745... IMPACT OF A PATIENT SUPPORT PROGRAM... (3*)|(Financial support for this study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. All authors contributed to the development of the publication and maintained control over the final conten)

Abstract Funding Source Key

* = Primary Source

Sa1746... VEDOLIZUMAB DOSE ESCALATION IN PATIENTS WITH... (3*)|(This study was sponsored by Takeda Pharmaceuticals International)

Sa1747... A MULTICENTER, OPEN-LABEL, CONTROLLED, RANDOMIZED STUDY... (3*)|(Ferring Pharmaceuticals)

Sa1748... CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE... (3*)|(Takeda Pharmaceuticals Company Ltd)

Sa1749... PATIENTS WITH CROHN'S DISEASE TREATED WITH... (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)

Sa1750... WOULD K50* BY ANY OTHER NAME... (6*)

Sa1751... COMPARATIVE EFFECTIVENESS OF HIGH-DOSE INFLIXIMAB VS... (5*)

Sa1752... POSTOPERATIVE CROHN'S DISEASE RECURRENCE BASED ON... (5*)

Sa1753... STEROID-SPARING THERAPY USE AND PREVENTION OF... (2*)|(6)

Sa1754... THE EFFECT OF IMMUNOMODULATORS AND OTHER... (5*)

Sa1755... EFFECTIVENESS AND SAFETY OF ABP501, AN... (5*)

Sa1756... PRIMARY BIOLOGIC-COMBINATION THERAPY IS SUPERIOR COMPARED... (5*)

Sa1757... THE IBD URGENT CARE TOOLKIT: WHICH... (6*)

Sa1758... TARGETED HOUSESTAFF INTERVENTION REDUCES INAPPROPRIATE OPIOID... (5*)

Sa1759... IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE CARE... (6*)

Sa1760... INCREASING PREVALENCE OF VENOUS THROMBOEMBOLISM IN... (5*)

Sa1761... AN INTERDISCIPLINARY CARE PROGRAM FOR RECENTLY... (4*)|(2)

Sa1763... IBD MEDICATION COVERAGE DENIALS AND FORCED... (6*)|(3)|((CCF and Takeda)

Sa1764... PERCEPTION OF REMISSION AND PREFERENCE FOR... (3*)|(This study was funded by Shire, a

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

member of the Takeda group of companies. Medical writing support was provided by Maxine Cox of PharmaGenesis London, London, UK, with funding from Shire International GmbH, a member of the Takeda group of companies.)

Sa1765... PERCEPTION OF REMISSION AND PREFERENCE FOR... (3*)|This study was funded by Shire, a member of the Takeda group of companies. Medical writing support was provided by Maxine Cox of PharmaGenesis London, London, UK, with funding from Shire International GmbH, a member of the Takeda group of companies.)

Sa1766... EFFECT OF INDIANA OPIOID PRESCRIPTION LEGISLATION... (4*)

Sa1767... PROVIDER COLLABORATION AND INFLUENCE MAY IMPACT... (5*)

Sa1768... A MAJORITY OF YOUNG PATIENTS WITH... (5*)

Sa1769... ASSESSING PATIENT DECISION MAKING ON BIOLOGIC... (3*)|(Pfizer Pharmaceuticals)

Sa1770... PREDICTORS OF MYCHART@ MESSAGING USE IN... (5*)

Sa1772... VENOUS THROMBOEMBOLISM PROPHYLAXIS USE IN IBD... (5*)

Sa1773... POST-OPERATIVE PROPHYLAXIS WITH ANTI-TNF IN PATIENTS... (5*)

Sa1774... ARE WE ADDRESSING THE TOP TEN... (5*)

Sa1775... FELLOW INVOLVEMENT DOES NOT CHANGE THE... (5*)

Sa1776... TRENDS IN MEDICAL MANAGEMENT OF CROHN'S... (5*)

Sa1777... URGENT MEDICAL ACCESS FOR PATIENTS WITH... (5*)

Sa1778... RISK FACTORS FOR NON-ADHERENCE TO SELF-INJECTABLE... (5*)

Sa1779... WHAT HEALTH CARE EXPERIENCE DID PATIENTS... (5*)

Sa1780... A VACCINATION STUDY AT A GROUP... (5*)

Sa1781... MONITORING OF PREVENTIVE CARE IN PATIENTS... (3*)|(Pfizer Grant)

Sa1782... HIGHER INDUCTION PROPOFOL DOSING DECREASES INDUCTION... (5*)

Sa1783... FASTER SEDATION TIMES FOR INFLAMMATORY BOWEL... (5*)

Sa1784... SCREENING FOR MELANOMA AND NON-MELANOMA SKIN... (5*)

Sa1785... OPIOID USE IN IBD PATIENTS: INCREASED... (5*)

Sa1786... INFLAMMATORY BOWEL DISEASE PATIENTS' PERSPECTIVES OF... (3*)|(Roche/Genentech)

Sa1787... CROHN'S DISEASE: PREDICTORS OF HOSPITAL DISPOSITION... (5*)

Sa1788... LOW LEVELS OF VITAMIN D AND... (5*)

Sa1789... THE IMPACT OF INFLAMMATORY BOWEL DISEASE... (1*)

Sa1790... A RANDOMIZED CONTROLLED TRIAL OF THE... (6*)

Sa1791... USE OF A POINT-OF-CARE SCREENING TOOL... (5*)

Sa1792... PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE OUTCOMES... (3*)|(Takeda)

Sa1793... EFFICACY AND SAFETY OF IRON CARBOXYMALTOSE... (3*)|(VIFOR)

Sa1794... MODERATE ENDURANCE- AND MUSCLE TRAINING IS... (6*)|(THIS STUDY WAS SUPPORTED BY THE GERMAN CROHN AND COLITIS FOUNDATION (DCCV E.V.))

Sa1795... DISEASE-SPECIFIC AVOIDANCE IS ASSOCIATED WITH FATIGUE... (5*)

Sa1796... ADJUNCT PHARMACOTHERAPY USE FOR POUCH-RELATED SYMPTOMS... (5*)

Sa1797... REAL WORLD USE OF THE IBD... (5*)

Sa1798... ANOREXIA NERVOSA IS ASSOCIATED WITH WORSE... (5*)

Sa1799... AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER IN AN... (5*)

Abstract Funding Source Key

* = Primary Source

Sa1800... EFFECT OF PATIENT-REPORTED OUTCOMES, PROMIS MEASURES... (2*)

Sa1801... INFLAMMATORY BOWEL DISEASE PATIENTS WITH ACTIVE... (3*)|(Takeda Pharmaceuticals U.S.A., Inc.)

Sa1802... NATIONAL TRENDS IN ANXIETY AND DEPRESSION... (5*)

Sa1803... NATIONAL TRENDS IN ANXIETY AND DEPRESSION... (5*)

Sa1804... GOALS AND CONCERNS REPORTED BY PATIENTS... (7*)

Sa1805... BRAIN DERIVED NEUROTROPHIC FACTOR IS ELEVATED... (2*)

Sa1806... USING A HUMAN-CENTERED DESIGN APPROACH FOR... (3*)|(Takeda)

Sa1807... USTEKINUMAB MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENT IN... (3*)|(This study was funded by Janssen Research & Development, LLC)

Sa1808... C-REACTIVE PROTEIN IS ASSOCIATED WITH DEPRESSION... (5*)

Sa1809... ROUTINE PSYCHOLOGICAL SCREENING IN INFLAMMATORY BOWEL... (5*)

Sa1810... APPLICABILITY OF THE VISCERAL SENSITIVITY INDEX... (4*)

Sa1811... PREVALENCE AND RISK FACTORS FOR SLEEP... (5*)

Sa1812... EATING DISORDERS IN AN OUTPATIENT ACADEMIC... (5*)

Sa1813... THE IMPACT OF INFLAMMATORY BOWEL DISEASE... (5*)

Sa1814... PERCEIVED HEALTH AND ACTIVITY LIMITATIONS IN... (5*)

Sa1815... PATIENT ATTITUDES REGARDING CONTINUATION AND DE-ESCALATION... (5*)

Sa1816... EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED... (3*)|(Takeda)

Sa1817... REAL WORLD PREVALENCE OF BOWEL MOVEMENT... (3*)|The study was funded by Eli Lilly and Company)

Sa1818... FINDINGS FROM A LARGE SAFETY NET... (5*)

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Sa1819... DEVELOPMENT OF AN INFLAMMATORY BOWEL DISEASE... (2*)

Sa1820... THE URGENCY NUMERIC RATING SCALE (NRS)... (5*)

Sa1821... THE FOOD-RELATED QUALITY OF LIFE... (2*)(4)

Sa1822... WORK LIMITATION AMONG ADULTS WITH INFLAMMATORY... (5*)

Sa1823... DO ESTROGEN CONTRACEPTIVES WORSEN DISEASE SEVERITY... (2*)

Sa1824... A PROSPECTIVE COHORT STUDY OF ADHERENCE... (2*)

Sa1825... ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM... (3*)(Takeda)

Sa1826... CHRONIC OPIOID USE IN INFLAMMATORY BOWEL... (5*)

Sa1827... PREGNANCY OUTCOMES IN WOMEN WITH PSORIASIS... (3*)(This study was supported by Janssen Research and Development, LLC and Janssen Biologics B.V.)

Sa1828... INCIDENCE AND PREDICTORS OF FLARE IN... (5*)

Sa1829... CHARACTERISTICS AND LONG-TERM OUTCOMES OF PREGNANCY-ONSET... (5*)

Sa1830... FRAILITY IS INDEPENDENTLY ASSOCIATED WITH INCREASED... (6*)

Sa1831... VEDOLIZUMAB LEVELS IN BREAST MILK: RESULTS... (3*)(Takeda)

Sa1832... DIFFERENCE IN OUTCOMES OF HOSPITALIZATION ACROSS... (5*)

Sa1833... FECAL BIOMARKERS MAY NOT ACCURATELY DETECT... (3*)(4)(TechLab, Inc)

Sa1834... RACE INFLUENCES CLINICAL OUTCOMES OF PATIENTS... (4*)

Sa1835... THE IMPACT OF OBESITY ON OUTCOMES... (5*)

Sa1836... FRAILTY AS A RISK FACTOR FOR... (5*)

Sa1837... INFLAMMATORY BOWEL DISEASE READMISSIONS IN THE... (5*)

Sa1838... SAFETY AND EFFICACY OF CONTRACEPTIVE USE... (5*)

Sa1839... TRENDS IN COMMON LABORATORY MARKERS DURING... (5*)

Sa1840... PATIENTS WITH INFLAMMATORY BOWEL DISEASE DISCONTINUE... (5*)

Sa1841... USTEKINUMAB IS SAFE IN ELDERLY CROHN'S... (5*)

Sa1842... COMPARISON OF MODES OF DELIVERY AND... (1*)

Sa1843... TRENDS AND RISK FACTORS OF ELDERLY-ONSET... (5*)

Sa1844... ELEVATED FECAL CALPROTECTIN IN EARLY PREGNANCY... (5*)

Sa1845... THE RISK OF ADVERSE PREGNANCY-RELATED OUTCOMES... (5*)

Sa1847... EXCLUSIVE ENTERAL NUTRITION(EEN) IS EFFECTIVE FOR... (5*)

Sa1848... DIETARY PRACTICES AND BELIEFS OF PATIENTS... (3*)(Takeda: Investigator Initiated Sponsored Research Grant)

Sa1849... DIETARY PRACTICES AND BELIEFS OF BRITISH... (3*)(Takeda: Investigator Initiated Sponsored Research Grant)

Sa1850... COLITIS PATIENTS WITH PSC MAY... (4*)

Sa1851... LOW PREVALENCE OF NONALCOHOLIC FATTY LIVER... (4*)

Sa1852... VEDOLIZUMAB DRUG LEVELS IN MATERNAL AND... (1*)

Sa1853... DISPARITIES IN IBD-RELATED INPATIENT COMPLICATIONS BETWEEN... (2*)(Oriana Damas supported by NIDDK: 1K23DK117054-01A1)

Sa1854... WOMEN WITH IMMUNE MEDIATED INFLAMMATORY DISEASES... (5*)

Sa1855... PREGNANCY COMPLICATIONS IN WOMEN WITH INFLAMMATORY... (5*)

Sa1856... FRAILTY ESTIMATED BY GERIATRIC NUTRITIONAL RISK... (2*)

Sa1857... EARLY DISCONTINUATION OF ADALIMUMAB THERAPY IN... (5*)

Sa1858... DISPARITIES IN SOCIOECONOMIC STATUS AND HOUSEHOLD... (2*)

Sa1859... SEXUAL FUNCTION AND CONTRACEPTION USE IN... (5*)

Sa1860... DOES RISK OF ADVERSE PREGNANCY-RELATED OUTCOMES... (5*)

Sa1861... SHARED DECISION MAKING IN PREGNANCY IN... (2*)(3)(MSD Grant)

Sa1862... FERTILITY RATE IN WOMEN WITH INFLAMMATORY... (5*)

Sa1863... SNAPSHOT OF INFLAMMATORY BOWEL DISEASE AMONG... (5*)

Sa1864... PROSPECTIVE STUDY OF PHARMACOKINETICS OF INFLIXIMAB... (3*)(Research grant obtained for Mundipharma)

Sa1865... ASSOCIATION BETWEEN VEDOLIZUMAB LEVELS, ANTI-VEDOLIZUMAB LEVELS... (5*)

Sa1866... LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY... (3*)(7)(Biosciences, San Diego, CA)

Sa1867... LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL... (3*)(Supported by an unrestricted educational grant from Takeda)

Sa1868... AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP... (3*)(Takeda)

Sa1869... COMBINATION OF SERUM ENDOSCOPIC HEALING INDEX... (3*)(7)(Prometheus Biosciences, San Diego, CA)

Sa1870... USTEKINUMAB LEVELS DIFFERENTIATE PATIENTS WITH ENDOSCOPICALLY... (3*)(Prometheus Laboratories)

Sa1871... USTEKINUMAB LEVELS MEASURED DURING INDUCTION ARE... (3*)(Testing provided by Prometheus)

Sa1872... IMMUNOGENICITY OF TUMOR NECROSIS FACTOR ANTAGONISTS... (5*)

Sa1873... OBJECTIVE DISEASE ACTIVITY ASSESSMENT AND THERAPEUTIC... (3*)(TARGET PharmaSolutions, Inc. is the sponsor of TARGET-IBD.)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1874... INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S... (5*)**
- Sa1875... THERAPEUTIC THRESHOLDS FOR GOLIMUMAB SERUM CONCENTRATIONS... (3*)|(GO-LEVEL was an investigator initiated study funded by a grant from MSD)**
- Sa1876... LOW FECAL CALPROTECTIN LEVEL PREDICTS HISTOLOGICAL... (5*)**
- Sa1877... EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING... (5*)**
- Sa1878... POST HOC EXAMINATION OF VISIBLE 1... (3*)|(Takeda Pharmaceuticals U.S.A., Inc.)**
- Sa1879... EFFICACY AND SAFETY OF VEDOLIZUMAB REINITIATION... (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)**
- Sa1880... DOSE ESCALATION OF SUBCUTANEOUS VEDOLIZUMAB IN... (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)**
- Sa1881... A COMPARISON OF EARLY RESPONSE PARAMETERS... (3*)|Takeda Pharmaceuticals U.S.A., Inc.)**
- Sa1882... SWITCHING INFLIXIMAB BIOSIMILAR: NO ADVERSE IMPACT... (5*)**
- Sa1883... ADALIMUMAB DRUG LEVELS AT SECONDARY LOSS... (5*)**
- Sa1884... ASSOCIATION OF USTEKINUMAB SERUM CONCENTRATIONS AND... (3*)|(Janssen Canada Inc.)**
- Sa1885... PERIPHERAL BLOOD EOSINOPHILIA PREDICTS EARLIER ANTI-TNF... (2*)**
- Sa1886... EARLY VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL... (3*)|(4)| (Takeda Pharmaceuticals IISR-2017-101926)**
- Sa1887... PROACTIVE DRUG MONITORING IS ASSOCIATED WITH... (4*)|(2)**
- Sa1888... CHRONOTHERAPY OF 6-MERCAPTOPYRIMIDINE (6-MP) METABOLITES IN... (4*)**
- Sa1889... PATIENTS WITH CROHN'S DISEASE AT RISK... (3*)|(UCB, Inc.)**
- Sa1890... DECREASING PATTERNS OF INFLIXIMAB TROUGH LEVELS... (5*)**
- Sa1891... HIGHER INFLIXIMAB AND ADALIMUMAB TROUGH LEVELS... (5*)**
- Sa1892... REVISED THERAPEUTIC DRUG MONITORING VALUES DIRECTLY... (5*)**
- Sa1893... PRIOR IMMUNOGENICITY TO ANTI-TNF BIOLOGICS IS... (5*)**
- Sa1894... IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA)... (4*)**
- Sa1895... VALIDATION OF THE LEMANN INDEX IN... (5*)**
- Sa1896... A SERIES OF GENES AS CANDIDATES... (2*)**
- Sa1897... DEVELOPMENT AND VALIDATION OF DRIED BLOOD... (6*)**
- Sa1898... DEVELOPMENT AND EVALUATION OF I-TRACKER ADALIMUMAB... (3*)|(Theradiag)**
- Sa1899... CLINICAL IMPLICATIONS OF INFLIXIMAB AND ADALIMUMAB... (2*)**
- Sa1900... BIOMARKERS RESPONSE TO ANTI-TNF TREATMENT IN... (5*)**
- Sa1901... B. OVATUS THERAPY UPREGULATES IL-22-MEDIATED SUPPRESSION... (2*)**
- Sa1902... THE NATURAL CLINICAL COURSE AFTER PER-ORAL... (4*)|(Borsa di studio Gerry Scotti 2017)**
- Sa1903... A RATIONALLY SELECTED, ORALLY ADMINISTERED, LIVE... (3*)|(Assembly Biosciences Allergan)**
- Sa1904... EFFICACY OF ANTI-PARASITIC TREATMENT FOR BLASTOCYSTIS... (5*)**
- Sa1905... IN-VIVO SAFETY OF INTERNALLY APPLIED ULTRAVIOLET-A... (6*)**
- Sa1906... HUMAN-DERIVED CLOSTRIDIUM VE202 STRAINS REDUCE ENTEROBACTERIACEAE... (2*)|(6)| (Janssen Research & Development)**
- Sa1907... TIME OF COLLECTION IS CRITICAL TO... (2*)|(7)**
- Sa1908... BERBERINE RESTORES MICROGLIA ACTIVATION INDUCED BY... (2*)**
- Sa1909... THE THERAPEUTIC EFFECT AND RELATED... (2*)**
- Sa1910... GUT ARCHAEOME COMPOSITIONAL AND ECOLOGICAL SHIFTS... (2*)**
- Sa1911... DISTINCT BRAIN-GUT MICROBIOME ALTERATIONS IN FEMALE... (2*)|(4)**
- Sa1912... METHANOGEN ABUNDANCE THRESHOLDS DIFFERENTIATE METHANE AND... (4*)**
- Sa1913... CONSENSUS GUIDELINES FOR THE REGULATION, PRODUCTION... (4*)**
- Sa1914... THE FUNGUS FILOBASIDIUM AS POSSIBLE PREDICTIVE... (2*)**
- Sa1915... POPULATION-LEVEL CONFIGURATIONS OF GUT MYCOBIOME ACROSS... (2*)**
- Sa1916... DEVELOPMENT OF A TARGETED 7 α -DEHYDRATASE... (2*)**
- Sa1917... GUT MICROBIOTA ALONG HUMAN GASTROINTESTINAL TRACTS... (5*)**
- Sa1918... CHANGES OF THE HUMAN GUT MICROBIOTA... (5*)**
- Sa1919... AFFECTING INTESTINAL BIOFILM FORMATION AND COLONIZATION... (7*)|(2)**
- Sa1920... FECAL MICROBIOTA TRANSFER IN PATIENTS WITH... (5*)|(4)**
- Sa1921... FECAL MICROBIOTA TRANSPLANTATION FOR METABOLIC SYNDROME... (5*)**
- Sa1923... IDENTIFICATION OF NEW ASSOCIATIONS BETWEEN PSORIATIC... (6*)|(4)**
- Sa1924... COMPOSITIONAL AND FUNCTIONAL CHANGES OF GUT... (2*)**
- Sa1925... THERE ARE MAJOR DIFFERENCES BETWEEN LUMINAL... (6*)**
- Sa1926... NO DISTINCTION OF FECAL MICROBIOTA BETWEEN... (4*)**
- Sa1927... CHANGES IN FECAL MICROBIOTA, SHORT CHAIN... (7*)|(JGA, JSGE)**
- Sa1928... A 24-WEEK, DOUBLE-BLIND, RANDOMIZED TRIAL OF... (4*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Sa1929... BACTERIAL UREASE MODULATES BOTH MICROBE-MICROBE AND... (2*)|(6)**
- Sa1930... THE EFFECT OF BILE ACIDS AS... (2*)|(This research is financially supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant no. NRF-2017R1D1A1B03034172))**
- Sa1972... POLYOLS ARE A KEY DRIVER OF... (3*)|(Meat and Livestock Australia)**
- Sa1973... ABSENCE OF NEUROTENSIN ATTENUATES INTESTINAL DYSBIOSIS... (2*)**
- Sa1974... WHO USES PROBIOTICS AND WHY? A... (2*)**
- Sa1975... INTERACTION OF SUGAR-SWEETENED BEVERAGE CONSUMPTION AND... (2*)**
- Sa1976... POLYPHENOLS REVERSE THE PATHOLOGIC EFFECTS OF... (4*)|(3)|(3)|(3)|Intestoguard)**
- Sa1977... HIGH MEAT INTAKE IS ASSOCIATED WITH... (2*)**
- Sa1978... ZINC CARNOSINE REDUCES INJURY IN AN... (4*)|(3)|(Xstro solutions)**
- Sa1979... STABILITY OF DIETARY PATTERNS IN INFLAMMATORY... (2*)**
- Sa1980... FOOD INTOLERANCES AMONG PATIENTS WITH INFLAMMATORY... (5*)**
- Sa1981... PILOT STUDY TO DETERMINE FERMENTABILITY AND... (4*)**
- Sa1982... LEVELS OF COMPLIANCE TO LOW FODMAPS... (5*)**
- Sa1983... SELF-REPORTED NON-CELIAC WHEAT SENSITIVITY IN PATIENTS... (2*)**
- Sa1984... CHRONIC VAGAL NERVE STIMULATION USING AN... (2*)**
- Sa1985... PRIOR BARIATRIC SURGERY AND PREGNANCY COMPLICATIONS:... (5*)**
- Sa1986... QUALITY OF LIFE, MENTAL HEALTH AND... (5*)**
- Sa1987... ESOPHAGEAL PHYSIOLOGIC CHANGES AFTER BARIATRIC SURGERY:... (5*)**
- Sa1988... ENDOSCOPIC BARIATRIC THERAPIES IN ADULTS OVER... (5*)**
- Sa1989... ROUX-EN-Y GASTRIC BYPASS IS ASSOCIATED WITH... (2*)**
- Sa1990... PRIMARY OBESITY SURGERY ENDOLUMINAL (POSE) FOR... (5*)**
- Sa1991... ENDOSCOPIC GASTRIC BODY PLICATION FOR THE... (5*)**
- Sa1992... PRIMARY OBESITY SURGERY ENDOLUMINAL 1 AND... (3*)|(USGI (San Clemente, CA))**
- Su1000... SEX, INSURANCE STATUS, AND RACE/ETHNICITY ARE... (5*)**
- Su1001... CLINICAL CHARACTERISTICS AND DISEASE FEATURES FROM... (2*)**
- Su1002... CHOLECYSTECTOMY FOLLOWING CHOLEDOCHOLITHIASIS: THE EFFECT OF... (4*)**
- Su1003... RACIAL DISPARITY IN CHRONIC HEPATITIS C... (5*)**
- Su1004... ESTIMATING THE IMPACT OF ASYLUM-SEEKERS ON... (4*)|(2)**
- Su1005... VARIATION IN THE RISK OF VENOUS... (5*)**
- Su1006... THE EFFECT OF USING INTERPRETER SERVICES... (5*)**
- Su1007... INCREASING INCIDENCE OF GASTRIC CANCER IN... (5*)**
- Su1008... CLINICAL AND PATHOLOGIC CHARACTERISTICS OF EARLY... (5*)**
- Su1009... TREATMENT OF H PYLORI IS NOT... (2*)**
- Su1010... PREVALENCE OF EXTENSIVE AND LIMITED GASTRIC... (5*)**
- Su1011... HEAVY ALCOHOL USE IS ASSOCIATED WITH... (5*)**
- Su1012... TRENDS IN GASTROINTESTINAL CANCER INCIDENCE: AN... (5*)**
- Su1013... BURDEN OF PANCREATIC CANCER: FOUR DECADES... (2*)**
- Su1014... EFFECT OF DIETARY PATTERN ON... (2*)**
- Su1015... INCREASED RISK OF COLORECTAL CANCER IN... (5*)**
- Su1074... BASOPHILS RECRUITMENT IS ONE OF THE... (4*)**
- Su1075... PROBIOTIC-DERIVED POLYPHOSPHATE IMPROVES DAMAGED INTESTINAL EPITHELIA... (4*)**
- Su1076... IN RATS WITH SUPERIOR MESENTERIC ARTERY-OCCLUSION... (4*)**
- Su1077... ANTIULCER BPC 157 EFFECT IN 96%... (4*)**
- Su1078... PENTADECAPEPTIDE BPC 157 THERAPY IN BILE... (4*)**
- Su1079... PENTADECAPEPTIDE BPC 157 COUNTERACTS INTRACRANIAL HYPERTENSION... (4*)**
- Su1080... PENTADECAPEPTIDE BPC 157 THERAPY IN RATS... (4*)**
- Su1081... IN RATS WITH SUPERIOR MESENTERIC VEIN-OCCLUSION... (4*)**
- Su1082... IDENTIFICATION OF TREATMENT RANGE AND APOPTOSIS... (5*)**
- Su1083... ANTIOXIDANT EFFECT OF URIC ACID AMELIORATES... (4*)**
- Su1084... THE ROLE OF THE IBD RISK... (2*)**
- Su1085... IL25 STIMULATES MOVEMENT OF TYPE 2... (4*)**
- Su1086... INHIBITION OF VITAMIN D/VDR PATHWAY DOWNREGULATES... (2*)**
- Su1087... A GUT-TARGETED EICOSAPENTAENOIC ACID DERIVATIVE, SEFA-1024,... (4*)**
- Su1088... PROPROTEIN CONVERTASE FURIN ALLEVIATES COLITIS VIA... (4*)|(2)**
- Su1089... DIFFERENTIATION OF HUMAN INDUCED PLURIPOTENT STEM... (5*)**
- Su1090... ANTI-INFLAMMATORY EFFECTS OF ATRACTYLODIN VIA PPAR-ALPHA... (2*)**
- Su1091... DETECTION AND GENOTYPING OF HELICOBACTER PYLORI... (2*)**
- Su1092... CAUSAL INFERENCE ANALYSIS OF THE TRANSCRIPTOME... (2*)|(This work was supported by National Natural Science Foundation of**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

China 81774152 (to RZ) and 81770571 (to LZ.)

Su1093... ACTIVATION OF EPIDERMAL GROWTH FACTOR RECEPTOR... (2*)

Su1094... THE ER STRESS SENSOR IRE1 β LINKS... (2*)

Su1095... DEGLYCOSYLATED AZITHROMYCIN ENHANCES INTESTINAL SMMOTH MUSCLE... (2*)

Su1096... ROLE OF P21-ACTIVATED KINASE, PAK4, IN... (2*)

Su1097... TL1A-MEDIATED BACTERIAL TRANSCYTOSIS BY A MLCK... (2*)[(Ministry of Science and Technology, Taiwan (MoST 107-2320-B-002-041-MY3))]

Su1098... FAILURE TO INDUCE OXPHOS IMPAIRS EPITHELIAL... (2*)

Su1099... INHIBITION OF JAG1/NOTCH1 SIGNALING EXACERBATES INTESTINAL... (2*)

Su1100... GLUCOSE-INDUCED MESENTERIC ARTERIAL RELAXATION VIA ENDOTHELIUM-DEPENDENT... (4*)

Su1101... DOWNREGULATION OF MITF MEDIATED AUTOPHAGIC FLUX... (4*)

Su1102... EXPLORING THE MOLECULAR SIGNALING PATHWAYS OF... (4*)

Su1103... VITAMIN D/VDR SIGNALING PATHWAY REGULATES COLONIC... (2*)

Su1104... ALPHA-TOCOPHERYLQUINONE ACTIVATES ARYL HYDROCARBON RECEPTOR AND... (4*)[(2)]

Su1105... TRIM 21 PROTECTS FROM ULCERATIVE COLITIS... (4*)

Su1106... KRÜPPEL-LIKE FACTOR 4 MODULATES GOBLET CELL... (2*)

Su1107... CYTOKINE-TRIGGERED STAT5 ACTION PROMOTES METASTASIS THROUGH... (7*)[(Crohn's & Colitis Foundation (CCF))]

Su1108... THE THYROID HORMONE NUCLEAR RECEPTOR Tr α 1... (2*)[(6)]

Su1110... P53-DREAM DIFFERENTIALLY CONTROLS TRANSCRIPTION OF CELL... (2*)

Su1111... CLOCK GENE EXPRESSION LEVELS CAN... (5*)

Su1112... TRANSGENIC EXPRESSION OF MICRORNA-195 DISRUPTS TUFT... (2*)

Su1113... ESTABLISHING HUMAN COLONIC ORGANOIDS FROM TISSUE... (6*)[(4)][(QGel SA, Lausanne, Switzerland)]

Su1114... CILIARY NEUROTROPHIC FACTOR DEFICIENCY IS A... (2*)

Su1115... SINGLE CELL RNA-SEQUENCING REVEALS AGE-ASSOCIATED ALTERATIONS... (4*)

Su1116... HIGH AUTOPHAGIC VESICLE CONTENT IDENTIFIES A... (2*)

Su1117... HUMAN COLONIC ORGANOIDS EXPRESS A SUBSET... (2*)[(4)]

Su1118... THE ROLE OF BUTYRATE ON NHE8-DEFICIENT... (2*)

Su1119... SIRT6 PROTEIN CONTRIBUTES TO INTESTINAL CELL... (2*)

Su1120... CHALLENGING THE INTESTINAL BARRIER FUNCTION IN... (5*)

Su1121... THE EFFECT OF PSYCHOLOGICAL STRESS INDUCED... (5*)[(4)]

Su1122... DEVELOPMENT OF BARRETT'S ESOPHAGUS (BE) AND... (2*)

Su1123... SLFN3 AFFECTS THE MORPHOLOGICAL RESPONSE TO... (2*)

Su1124... SMALL INTESTINE EPITHELIAL ORGANOIDS AS A... (4*)

Su1125... A MODEL TO STUDY ISCHEMIA-REPERFUSION INJURY... (4*)

Su1126... THE ESTABLISHMENT OF GASTRIC FUNDIC AND... (2*)

Su1127... INTEGRATED MAPPING OF CHROMATIN ACCESSIBILITY AND... (2*)[(4)]

Su1128... STROMAL STEM CELL NICHE COMPOSITION AND... (2*)

Su1129... A NEW PHENOMIC ANALYSIS PLATFORM HIGHLIGHTS... (4*)[(2)]

Su1130... LRIG1-BASED LINEAGE TRACING HAS DISTINCT PATTERNS... (2*)[(4)]

Su1132... ORAL MICROBIOME COMPONENTS MIGHT DETERIORATE BARRIER... (4*)

Su1133... AUTOIMMUNE ESOPHAGITIS PATIENT SAMPLES CONTAIN AUTOANTIBODIES... (4*)

Su1134... ESSENTIAL ROLE OF CALCIUM SIGNALING IN... (4*)

Su1135... SODIUM CAPRATE INCREASES BICARBONATE SECRETION VIA... (2*)[(3)][(Shire/Takeda Pharmaceuticals)]

Su1136... THE GASTRIC CARDIA REVISITED: SURPRISING RESULTS... (4*)

Su1137... LYMPHOCYTIC ESOPHAGITIS: IS IT A MEMEDICATION... (5*)

Su1138... ALLYL ISOTHIOCYANATE, AN ACTIVATOR OF TRPA1... (2*)[(4)]

Su1139... ELCTROACUPUNCTURE RESTORES INTESTINAL MUCOSAL BARRIER THROUGH... (2*)[(2018 National Natural Science Foundation of China Key International Cooperative Research Project: "Mechanisms involving the brain-gut-microbiota axis in the treatment of functional dyspepsia in the theory of Balancing Digestive Functions by Regulating)]

Su1140... A RISK-BASED DIAGNOSTIC ALGORITHM OPTIMIZES THE... (5*)

Su1141... HEART RATE VARIABILITY IN PEOPLE WITH... (5*)

Su1142... ARSENIC AS A MEDIATOR OF HEPATIC... (5*)

Su1143... EFFICACY AND SAFETY OF PEMBROLIZUMAB FOR... (5*)

Su1144... ENDOSCOPIC ULTRASOUND GUIDED VERTEPORFIN PHOTODYNAMIC THERAPY... (2*)

Su1145... TUMOR SIZE, TUMOR STAGE, AND SURVIVAL... (2*)[(6)]

Su1146... PANCO: AN OPEN-LABEL, SINGLE-ARM PILOT STUDY... (3*)[(OncoSil Medical Ltd.)]

Su1147... PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PATIENT-DERIVED TUMOR... (4*)[(2)]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1148... DEPRESSION DIAGNOSIS PRECEDING AND FOLLOWING A... (5*)

Su1150... OUTCOMES OF INITIAL PANCREATIC CANCER SURVEILLANCE... (4*)

Su1151... DEEP LEARNING FOR HISTOLOGICAL ANALYSIS OF... (2*)

Su1152... A SIMPLE MODEL TO SCREEN FOR... (5*)

Su1153... NOVEL SMALL MOLECULE INHIBITOR OF ASPARTATE- β -HYDROXYLASE... (2*)

Su1154... WHEN SHOULD WE OPERATE ON PANCREATIC... (2*)|(6)

Su1155... BISPHOSPHONATE USE DOES NOT IMPACT SURVIVAL... (5*)

Su1156... RISK FACTORS AND INCIDENCE OF PANCREATIC... (5*)

Su1157... EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE... (5*)

Su1158... HIGH MORBIDITY AND MORTALITY ASSOCIATED WITH... (5*)

Su1159... FACTORS ASSOCIATED WITH "MISSED CANCERS" IN... (5*)

Su1160... GENETIC RISK OF PANCREATIC CANCER IN... (4*)

Su1161... TRENDS IN 5-YEAR SURVIVAL RATES OF... (5*)

Su1162... COMPOUNDS LN35663290 AND LN35690555 SUPPRESS GROWTH... (2*)

Su1163... THE CLEARANCE OF TUMOR-DERIVED H₂S BY... (5*)

Su1164... EXPLOITING BIM DEPENDENCY OVERCOMES PD-L1-MEDIATED DRUG... (2*)

Su1165... TARGETING NRF2 USING SPECIFIC INHIBITOR IN... (2*)|(4)

Su1166... IDO1 INHIBITION AUGMENTS THE ANTI-TUMOR EFFECTS... (2*)

Su1167... EXPRESSION OF PD-L1 AND CTLA-4 IMMUNOHISTOCHEMICAL... (5*)

Su1168... ENHANCED EXPRESSION OF ASPARAGINE SYNTHETASE UNDER... (5*)

Su1169... RNA BINDING PROTEIN IMP1 MODULATES EXOSOME... (7*)|(2)

Su1170... GAIN-OF-FUNCTION OF ION CHANNEL TRPV1 REMODELS... (2*)

Su1171... NADPH OXIDASES AND REACTIVE OXYGEN SPECIES... (2*)

Su1172... HYDROGEN SULFIDE (H₂S) INHIBITS DENDRITIC CELL... (2*)

Su1173... DELETION OF THE MISMATCH REPAIR PROTEIN... (2*)|(4)

Su1174... CHARACTERIZATION OF IMMUNE MICROENVIRONMENT IN LYNCH... (2*)

Su1175... CLINICAL SIGNIFICANCE OF PROGRAMMED DEATH-LIGAND 1... (5*)

Su1176... CELL TYPE CONTRIBUTIONS OF THE INTERLEUKIN... (2*)|(4)

Su1178... LONG MYOSIN LIGHT CHAIN KINASE DOWNREGULATES... (2*)

Su1179... PANETH CELL-DERIVED WNT3 SUPPORTS INTESTINAL TUMORIGENESIS... (2*)|(4)

Su1180... CXCR4 EXPRESSION ASSOCIATES WITH 5-HYDROXYMETHYLCYTOSINE MODIFICATION... (2*)|(4)

Su1181... THE ROLE OF INFLAMMATION IN REDOX... (2*)|(European Union Funds, Innovative Economy Programme)

Su1182... STOOL INTERLEUKIN-1 β AS A POTENTIAL DIAGNOSTIC... (2*)

Su1183... DIETARY FIBER INTAKE IS NOT ASSOCIATED... (2*)

Su1184... EFFICACY AND SAFETY OF MONOCLONAL ANTIBODIES... (5*)

Su1185... IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS ASSESSMENT AND... (6*)|(3)| (Celgene (Oxford-Celgene Postdoctoral Fellowship))

Su1186... DEOXYCHOLIC ACID ENHANCES INTESTINAL LYMPHOCYTE MIGRATION... (5*)

Su1187... ALMOST EVERYTHING CAUSES DIARRHEA: GASTROINTESTINAL MANIFESTATIONS... (6*)

Su1188... ABDOMINAL CT SHOULD NOT BE USED... (5*)

Su1189... SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN... (5*)

Su1190... IS THERE AN ASSOCIATION BETWEEN SUBSTANCE... (5*)

Su1191... ADULT-ONSET AUTOIMMUNE ENTEROPATHY: A SCOPING REVIEW... (5*)

Su1192... CONCURRENT THERAPY WITH IMMUNE CHECKPOINT INHIBITORS... (2*)|(7)

Su1193... STING ACTIVATION INDUCES REG3 γ EXPRESSION IN... (2*)

Su1194... MODIFICATION OF THE INFLAMMATION-RELATED PHENOTYPE OF... (2*)|(4)

Su1195... DIFFERENTIAL ANTIBIOTIC AND ANTI-FUNGAL TREATMENT REQUIREMENTS... (2*)

Su1196... THE ROLE OF THE SMALL INTESTINAL... (5*)

Su1197... EXPLORING THE MOLECULAR BASIS OF FECAL-MICROBIAL... (4*)|(6)

Su1198... METAGENOMICS AND METABOLOMICS OF THE GASTROINTESTINAL... (2*)|(7)

Su1199... THE IMPACT OF BIOLOGICAL TREATMENT AND... (5*)

Su1200... CLINICAL CHARACTERISTICS AND PRESENTATION OF PATIENTS... (5*)

Su1201... DIFFERENCES IN SMALL INTESTINAL MICROBIOME PATTERNS... (6*)

Su1202... QUANTITATIVE PCR AS A NOVEL APPROACH... (2*)

Su1203... EFFECT OF FECAL MICROBIOTA TRANSPLANTATION ON... (4*)

Su1204... VARIATIONS OF THE MUCOSA ASSOCIATED MICROBIOTA... (2*)

Su1205... GLYPHOSATE EXPOSURE ALTERS THE HOST MICROBIOME... (2*)|(4)

Su1206... ASSOCIATION OF GUT MICROBIOTA WITH GASTROINTESTINAL... (5*)

Su1207... PREVALENCE AND RISK FACTORS OF HELICOBACTER... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1208... FECAL MICROBIOTA RELATED TO THE SEASONAL... (5*)

Su1209... TRANSITION OF GUT MICROBIOTA IN SAME... (4*)

Su1210... RESIDENT MICROBIOTA SELECTIVELY MODULATE INTESTINAL PERMEABILITY... (2*)(4)

Su1211... THE FIRST STUDY TO DETERMINE THE... (6*)

Su1212... THE UTILITY OF REPEATED GI PCR... (5*)

Su1213... GENDER DETERMINES RESPONSE AND RECOVERY OF... (6*)

Su1214... AN ALTERED COMPOSITION OF GUT MICROBIOTA,... (5*)

Su1215... GROWTH INHIBITION OF CLOSTRIDIUM DIFFICILE BY... (5*)

Su1216... REPEAT COLONOSCOPY AND INCREASED NUMBER OF... (5*)

Su1217... ECOLOGICAL AND NETWORK ANALYSES OF THE... (1*)

Su1218... EVALUATION OF GUT MICROBIOTA COMPOSITION IN... (6*)

Su1219... GUT MICROBIAL STRAINS AND METABOLITES IN... (2*)

Su1220... ATTENUATION OF STRESS-INDUCED ACTIVATION OF SUPRASPINAL... (3*)(Ironwood Pharmaceuticals)

Su1221... COMBINATION OF ESTROGENS AND EARLY LIFE... (2*)

Su1222... SEX-DIFFERENCE IN THE GASTROINTESTINAL PHENOTYPE DEPENDS... (2*)

Su1223... MOTILITY DYSFUNCTION AND VISCERAL HYPERSENSITIVITY PERSIST... (2*)

Su1224... VASTOACTIVE INTESTINAL PEPTIDE REGULATES ILEAL GOBLET... (4*)(2)

Su1225... PRESSURE-INDUCED EPITHELIAL ION TRANSPORT OF THE... (2*)(7)

Su1226... IN VIVO GAVAGE OF MONOSODIUM GLUTAMATE... (2*)

Su1227... ROLE OF TRANSIENT RECEPTOR POTENTIAL VANILLOID... (2*)

Su1228... MOR AND DOR SELECTIVE AGONISTS EVOKE... (6*)

Su1229... PANETH CELL LOSS IS ASSOCIATED WITH... (2*)

Su1230... IS EXERCISE THE BEST MEDICINE? EXAMINING... (5*)

Su1231... VALIDATION OF AN IN VITRO HUMAN... (2*)

Su1232... LIPOPOLYSACCHARIDE O-ANTIGEN SPECIFIC TRANSIENT RECEPTOR POTENTIAL... (2*)

Su1233... TOWARDS A VISCERAL HYPERSENSITIVITY-ASSOCIATED MICROBIOME SIGNATURE... (2*)

Su1234... THE INFLUENCE OF SEX AND THE... (2*)

Su1235... ENRICHED ENVIRONMENT HOUSING ALLEVIATES POST-COLITIS PAIN... (4*)

Su1236... TRP53-MEDIATED CELL CYCLE ARREST OF PRECURSORS... (2*)(7)

Su1237... ALTERED STRUCTURE AND FUNCTION OF MITOCHONDRIA... (2*)

Su1238... LACTOBACILLUS RHAMNOSUS GG COLONIZATION IN EARLY... (2*)

Su1239... INCREASED ENTERIC NEURON NUMBER ACCOMPANIES INCREASED... (2*)(4)

Su1240... EXPANSION OF INTESTINAL STEM CELLS THROUGH... (1*)

Su1241... INTESTINAL INFLAMMATION ALTERS THE EXPRESSION OF... (4*)

Su1242... A TWO DIMENSIONAL ENTEROID MODEL TO... (2*)

Su1243... BENCH TO BED-SIDE AND BACK TRANSLATION... (2*)

Su1244... DOSE-DEPENDENT EFFECTS OF SYNBIOTIC SULFORAPHANE ON... (2*)

Su1245... THE ACTIVITY OF LGR5+ CRYPT BASE... (2*)

Su1246... SPECIFIC BACTERIA ISOLATED FROM HUMAN BREAST ... (4*)(2)

Su1247... FXR AGONIST TROPIFEXOR AMELIORATES CHOLESTATIC... (4*)

Su1341... A PROSPECTIVE RANDOMIZED TANDEM GASTROSCOPY STUDY... (5*)

Su1342... A DEEP LEARNING CONVOLUTIONAL NEURAL NETWORK... (4*)

Su1343... THERAPEUTIC EFFECTIVENESS OF SOMATOSTATIN ANALOGUES ON... (4*)

Su1344... ENDOMICROSCOPIC DETECTION OF ATYPICAL FOOD ALLERGY... (5*)

Su1345... TRANSNASAL PROBE FOR MEASURING GUT TRANSPORT... (6*)

Su1346... PHOTOACOUSTIC IMAGING OF FRESH HUMAN SURGICALLY... (5*)

Su1347... ANNUAL ENDOSCOPY IS ENOUGH FOR GASTRIC... (5*)

Su1348... DOPPLER-GUIDED SECOND-LOOK ENDOSCOPY IN PEPTIC ULCER... (4*)

Su1349... FULL-THICKNESS RESECTION DEVICE (FTRD) FOR TREATMENT... (5*)

Su1350... AN INGESTIBLE WIRELESS BIOSENSOR TO DETECT... (3*)

Su1351... THE MAGNETIC FLEXIBLE ENDOSCOPE (MFE): A... (2*)

Su1352... A TRANSNASAL IMAGE-GUIDED APPROACH FOR BRUSH... (6*)

Su1353... MESENTERIC ARTERY CALCIUM SCORING: A POTENTIAL... (5*)

Su1354... MANAGEMENT OF CARCINOID TUMORS OF THE... (5*)

Su1355... DIGITAL KI67 LABELING INDEX FOR GASTROINTESTINAL... (4*)

Su1356... STRETCHABLE ADHESIVE-INTEGRATED ELECTRONICS FOR MULTI-ELECTRODE CUTANEOUS... (4*)

Su1357... INTRAHEPATIC AND INTRAMESENTERIC DYNAMIC CONTRAST MAGNETIC... (1*)

Su1358... INDEX ENDOSCOPY AND INTERVENTION DOES NOT... (5*)

Su1359... A DIAGNOSTIC METHOD FOR GASTRIC CANCER... (5*)

Su1360... THE EFFECT OF PROTON PUMP INHIBITOR... (1*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1362... A POPULATION-BASED STUDY COMPARING THE GASTRIC... (2*)
- Su1363... HELICOBACTER PYLORI ERADICATION THERAPY EFFECTIVELY IMPROVES... (5*)
- Su1364... ERADICATION OF HELICOBACTER PYLORI INFECTION DECREASES... (4*)
- Su1365... ASSOCIATIONS OF OLGA AND OLGIM STAGING... (2*)
- Su1366... CULTURE-GUIDED VS EMPIRICAL HIGH-DOSE PROTON PUMP... (4*)
- Su1367... EXHALED 13C DURING A 13C-UREA BREATH... (4*)|(2)
- Su1368... REAL TIME DETERMINATION OF H PYLORI... (5*)
- Su1369... INCREMENTAL YIELD OF RAPID UREASE TEST... (4*)
- Su1370... THE OPTIMAL CUTOFF VALUE OF SEROLOGIC... (5*)
- Su1371... SEROLOGY AS A DIAGNOSTIC TOOL... (5*)
- Su1372... HELICOBACTER PYLORI ACTIVELY SUPPRESS INNATE IMMUNE... (2*)
- Su1373... REGULATION OF APOPTOTIC AND DNA... (2*)
- Su1374... COEVOLUTIVE ANALYSIS OF HELICOBACTER PYLORI ISOLATED... (4*)
- Su1375... HELICOBACTER PYLORI-INDUCED CANCER-ASSOCIATED FIBROBLASTS INHIBIT TGFβ-DEPENDENT... (4*)
- Su1376... EFFECTIVENESS OF MAASTRICHT V GUIDELINES APPLICATION... (5*)
- Su1377... LEVOFLOXACIN SEQUENTIAL THERAPY VERSUS BISMUTH QUADRUPLE... (2*)|(4)
- Su1378... PHARMACOKINETICS AND EXPOSURE-RESPONSE OF RHB-105, A... (3*)|(RedHill Biopharma, Ltd.)
- Su1379... ANNUAL ERADICATION RATE OF BISMUTH-CONTAINING QUADRUPLE... (5*)
- Su1382... INEFFECTIVENESS OF 14-DAY VONOPRAZAN-BASED DUAL THERAPY... (4*)
- Su1383... CURRENT STATUS OF VONOPRAZAN-CONTAINING ERADICATION TREATMENT... (5*)
- Su1384... ANTIBIOTIC RESISTANCE AND ITS RELATED GENE... (2*)
- Su1385... EFFICACY OF PROBIOTICS COMBINED WITH BISMUTH... (5*)
- Su1386... CULTURE-BASED TAILOR-MAID ANTIBIOTIC REGIMEN IS THE... (5*)
- Su1387... POLYPHENOLIC BIOFRATIONS EXTRACTED FROM AVOCADO (PERSEA... (4*)
- Su1390... GASTRIC INTESTINAL METAPLASIA BEFORE AND AFTER... (1*)|(This work was partly supported by the Sichuan Provincial Science and Technology Department under Grant 2016JY0101;Affiliated Hospital of Southwest Medical University under Grant 15039.)
- Su1391... EFFICACY AND SAFETY OF VONOPRAZAN, SITAFLOXACIN... (5*)
- Su1392... TRIPLE THERAPY IS STILL AN EFFECTIVE... (5*)
- Su1393... EFFICACY OF RIFABUTIN FOR THE RESCUE... (5*)
- Su1394... SELECTION OF CLARITHROMYCIN IN FIRST-LINE HELICOBACTER... (5*)
- Su1395... EFFECTS OF HELICOBACTER PYLORI ERADICATION FOR... (5*)
- Su1396... A HIGH-THROUGHPUT METABOLIC ASSAY AND A... (2*)|(4)
- Su1397... FACTORS PREDICTIVE OF HELICOBACTER PYLORI INFECTION... (5*)
- Su1398... SEVEN-DAY VONOPRAZAN AND LOW-DOSE AMOXICILLIN DUAL... (4*)
- Su1399... PATIENTS WITH PEPTIC ULCER BLEEDING ADMITTED... (5*)
- Su1400... ONE #NAME? INCIDENCE OF NON-VARICEAL UPPER... (5*)
- Su1401... ONE #NAME? INCIDENCE OF NON-VARICEAL UPPER... (5*)
- Su1402... MISOPROSTOL EXPOSURE IS NOT ASSOCIATED WITH... (5*)
- Su1403... CLIPPING OVER-THE-SCOPE IS COST EFFECTIVE FOR... (2*)
- Su1404... COMPARISON OF THE AIMS65, GLASGOW-BLATCHFORD SCORE... (5*)
- Su1405... EXTERNAL VALIDATION OF THE CANUKA SCORING... (5*)
- Su1406... VASCULAR PROTECTIVE DRUGS AND THE OUTCOMES... (4*)
- Su1407... A NOVEL MORTALITY RISK SCORE THAT... (5*)
- Su1408... USE OF DOPPLER ENDOSCOPIC PROBE FOR... (2*)
- Su1409... DIFFERENCES IN THE CLINICAL COURSE OF... (5*)
- Su1410... TRANEXAMIC ACID FOR UPPER GASTROINTESTINAL BLEEDING... (5*)
- Su1411... PORTAL HYPERTENSION AND CKD SIGNIFICANTLY INCREASE... (5*)
- Su1412... TIME TRENDS AND ENDOSCOPIC CHARACTERISTICS OF... (1*)
- Su1413... ASSOCIATION OF GBS SCORE WITH ENDOSCOPIC... (2*)
- Su1414... ASSESSING THE RISK OF PEPTIC ULCER... (5*)
- Su1415... CRITICAL PEPTIC ULCER BLEEDING REQUIRING MASSIVE... (2*)|(Monash University CSL Behring Department of Health and Human Services Victoria National Blood Authority New Zealand Blood Service)
- Su1416... A POPULATION BASED STUDY TO IDENTIFY... (5*)
- Su1417... LESS IS MORE: AN EXAMINATION OF... (5*)
- Su1418... DIAGNOSTIC VALUE OF FOCAL ENHANCED GASTRITIS... (2*)
- Su1419... MALNUTRITION IS ASSOCIATED WITH INCREASED IN-HOSPITAL... (5*)
- Su1421... THE PROGNOSIS DIFFERENCES IN ISCHEMIC HEART... (5*)
- Su1458... ASSESING THE ROLE OF IRRIGATION OF... (4*)
- Su1459... PREDICTORS OF MORTALITY AND MORBIDITY IN... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1460... ASSOCIATION OF FREE FATTY ACID LEVELS... (5*)
- Su1461... ADVERSE HEALTHCARE RESOURCE OUTCOMES IN PATIENTS... (5*)
- Su1462... CHOLECYSTECTOMY VS NO SURGERY IN PATIENTS... (5*)
- Su1463... SARCOPENIA IS ASSOCIATED WITH WORSE OUTCOMES... (5*)
- Su1464... HIGH MORBIDITY AND MORTALITY BURDEN OF... (5*)
- Su1465... DRUG-INDUCED PANCREATITIS IS THE LEADING RISK... (2*)
- Su1466... IMPACT OF HIV STATUS ON OUTCOMES... (5*)
- Su1467... USE OF NSAIDS IS ASSOCIATED WITH... (5*)
- Su1468... A SIMPLE ALGORITHM TO IDENTIFY BILIARY... (5*)
- Su1469... STATIN USE IS ASSOCIATED WITH DECREASED... (5*)
- Su1470... INTRA-ABDOMINAL HYPERTENSION IS A STRONG PREDICTOR... (5*)
- Su1471... LONG TERM CONSEQUENCES OF ACUTE NECROTIZING... (5*)
- Su1472... SAFETY AND SUCCESS OF EARLY (<4... (5*)
- Su1473... PREDICTORS OF DIABETES MELLITUS FOLLOWING DISCHARGE... (5*)
- Su1474... INFLUENCE OF PRE-EXISTING DIABETES MELLITUS ON... (5*)
- Su1475... SEVERITY OF ACUTE PANCREATITIS HOSPITALIZATIONS IN... (5*)
- Su1476... IDENTIFICATION OF A RISK PROFILE FOR... (5*)
- Su1477... TRANSITION OF CLINICAL FEATURES OF ACUTE... (5*)
- Su1478... EARLY (<4 WEEKS) VERSUS STANDARD (≥... (5*)
- Su1479... TREND OF ACUTE PANCREATITIS IN JAPAN... (5*)
- Su1480... CONTROLLING GLYCEMIC HOMEOSTASIS ALLEVIATES ISLET B... (4*)
- Su1481... PANCREAS-DERIVED DOPAMINE INHIBITS INSULIN SECRETION IN... (2*)
- Su1482... THE DURABILITY OF ENDOSCOPIC ULTRASOUND-GUIDED ABLATION... (4*)
- Su1483... THE EFFECT OF ASPIRIN ON RATE... (5*)
- Su1484... VALIDATION OF BASELINE CHARLSON COMORBIDITY INDEX... (5*)
- Su1485... INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH... (5*)
- Su1486... LONG-TERM SURVEILLANCE OF LOW-RISK PRESUMED MUCINOUS... (5*)
- Su1487... MOLECULAR STABILITY, REGRESSION, AND PROGRESSION IN... (3*)|(Interpace Diagnostics)
- Su1488... APPLICATION OF A RISK STRATIFICATION TOOL... (5*)
- Su1489... RISK OF NEOPLASTIC PROGRESSION IN PATIENTS... (5*)
- Su1490... CHARACTERIZATION OF PANCREATIC INTRADUCTAL PAPILLARY NEOPLASM-DERIVED... (5*)
- Su1491... THE EFFECT OF STATINS ON RATE... (5*)
- Su1492... EUS-GUIDED PANCREATIC CYST CHEMOABLATION AS A... (5*)
- Su1493... THE IMPACT OF ENDOSCOPIC ULTRASOUND-GUIDED CONFOCAL... (7*)
- Su1494... A 10-YEAR FOLLOW-UP DESCRIBING THE NATURAL... (5*)
- Su1495... A MULTIDISCIPLINARY PANCREATIC CYST CONFERENCE REDUCES... (5*)
- Su1496... PREOPERATIVE ENDOSCOPIC ULTRASOUND (EUS) OR ENDOSCOPIC... (5*)
- Su1497... PREDICTORS OF ADVANCED NEOPLASIA AND LONG... (5*)
- Su1498... PERCENTAGE OF CYST GROWTH RATE AS... (5*)
- Su1499... PREVALENCE AND RISK FACTORS FOR INTRADUCTAL... (5*)
- Su1500... MOLECULAR ANALYSIS OF EUS-ACQUIRED PANCREATIC CYST... (5*)
- Su1501... THE ROLE OF ENDOSCOPIC ULTRASOUND-GUIDED THROUGH-THE-NEEDLE... (5*)
- Su1502... PREVALENCE OF AND FACTORS INFLUENCING PANCREATIC... (5*)
- Su1503... RANGE OF NORMAL LIVER STIFFNESS AND... (5*)
- Su1504... USE OF NOVEL CYTOPLEX ASSAY TO... (4*)|(2)
- Su1505... HEALTH-RELATED QUALITY OF LIFE, EMOTIONAL, AND... (2*)
- Su1506... TRENDS AND VARIATIONS IN THE MANAGEMENT... (5*)
- Su1507... ESTABLISHING A PEDIATRIC TO ADULT (P2A)... (5*)|(2)
- Su1508... IS ULTRASOUND ENOUGH? EVALUATING IMAGING FOR... (5*)
- Su1672... THE EMERGING ROLE OF FRAILTY AS... (5*)
- Su1673... SEPSIS IS THE LEADING CAUSE OF... (5*)
- Su1674... HANDGRIP STRENGTH DECLINE IN CHRONIC LIVER... (5*)
- Su1675... BARIATRIC SURGERY IN CANDIDATES FOR LIVER... (5*)
- Su1676... VALIDATION OF ENCEPHALAPP STROOP FOR MINIMAL... (2*)|(1)
- Su1677... METHYLENE BLUE INFUSION FOR CRITICALLY ILL... (5*)
- Su1678... IMPACT OF RACE AND ETHNICITY ON... (2*)|(3)|(Investigator initiated grant from Grifols Pharmaceuticals)
- Su1679... RISK FACTORS FOR READMISSION WITH DECOMPENSATED... (5*)
- Su1681... THE HEPATORENAL SYNDROME PATIENT JOURNEY: PORTRAIT... (3*)|(Mallinckrodt)
- Su1682... URGENT ENDOSCOPY IS ASSOCIATED WITH LOWER... (5*)
- Su1683... PREDICTORS OF 30 AND 90 DAY... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1684. . . EFFICACY OF ORAL THROMBOPOIETIN RECEPTOR AGONIST... (3*)(Shionogi Inc.)
- Su1685. . . SMALL INTESTINE VARICES AT A HIGH-VOLUME... (4*)
- Su1686. . . COMPARING OVERALL GI AND NON-GI BLEEDING... (5*)
- Su1687. . . UTILITY OF THE ENCEPHALAPP STROOP TEST... (5*)
- Su1688. . . LOWER GASTROINTESTINAL BLEEDING IN PATIENTS WITH... (5*)
- Su1689. . . MULTIDRUG RESISTANT BACTERIAL INFECTION CHARACTERISTICS AND... (5*)
- Su1712. . . ALTERED MITOCHONDRIAL GENE EXPRESSION IN DUODENAL... (2*)
- Su1713. . . MINIMAL IMPACT OF ACUTE INJECTION AND... (5*)
- Su1714. . . LYSOPHOSPHATIDIC ACID RECEPTOR EXPRESSION IS REDUCED... (2*)(4)
- Su1715. . . AURICULAR VAGAL NERVE STIMULATION IMPROVED DYSMOTILITY... (5*)
- Su1716. . . INTRAVENOUS IMMUNOGLOBULIN IN REFRACTORY GASTROPARESIS PATIENTS... (5*)
- Su1717. . . CHEMOKINE ELEVATION IN PATIENTS WITH THE... (4*)
- Su1718. . . MEDIUM ENERGY GASTRIC ELECTRICAL STIMULATION CAN... (5*)
- Su1719. . . IMPROVED GASTRIC ACCOMMODATION IN WOMEN WITH... (3*)(Censa Pharmaceuticals Inc, Wellesley, MA, USA)
- Su1720. . . CAN TEMPORARY GASTRIC ELECTRICAL STIMULATION HELP... (5*)
- Su1721. . . THE FREQUENCY AND CLINICAL IMPLICATIONS OF... (2*)
- Su1722. . . GASTROINTESTINAL VASCULAR CHANGES IN GENETIC AND... (5*)
- Su1723. . . CARDIAC SAFETY AND CLINICAL EFFICACY OF... (5*)
- Su1724. . . WHOLE GENOME SEQUENCING ANALYSIS OF GASTROPARESIS... (3*)
- Su1725. . . TRENDS AND SOCIOECONOMIC HEALTH OUTCOMES OF... (5*)
- Su1726. . . GASTRIC PER-ORAL ENDOSCOPIC MYOTOMY (G-POEM) FOR... (5*)
- Su1727. . . SUPPLEMENTATION OF 17B-ESTRADIOL NORMALIZES RAPID GASTRIC... (2*)
- Su1728. . . GASTROINTESTINAL SYMPTOMS DURING GASTRIC EMPTYING SCINTIGRAPHY... (5*)
- Su1729. . . PILOTING A PROSPECTIVE PEDIATRIC GASTROPARESIS SYMPTOM... (5*)
- Su1730. . . SEX AND BODY MASS INDEX HAVE... (5*)
- Su1731. . . THE RELATION BETWEEN CHANGES IN GASTRIC... (5*)
- Su1732. . . OVERABUNDANCE OF HISTAMINE PRODUCING ENTEROBACTERIACEAE... (2*)
- Su1733. . . TRENDS AND OUTCOMES OF IDIOPATHIC AND... (5*)
- Su1734. . . MAJORITY OF HOSPITALIZED PATIENTS LABELED AS... (5*)
- Su1735. . . GASTRODUODENAL MANOMETRIC AND GASTRIC EMPTYING SCINTIGRAPHIC... (5*)
- Su1736. . . ALTERATION OF INTESTINAL PERMEABILITY AND EFFECT... (5*)
- Su1737. . . LESSONS LEARNED FROM 8 YEARS... (5*)
- Su1738. . . THE GOLDBLOCKS PRINCIPLE: 24 HOUR AMBULATORY... (4*)
- Su1739. . . SAFETY PHARMACOLOGY EVALUATIONS OF TAK-906, A... (3*)(This study was sponsored by Altos Therapeutics, LLC. Medical writing support was provided by Alex Kisbey of Oxford PharmaGenesis, Oxford, UK and was funded by Takeda Pharmaceutical Company Ltd.)
- Su1740. . . SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF... (3*)(CinRx Pharma)
- Su1741. . . PATHOPHYSIOLOGICAL EVIDENCE PROVIDED BY PYLORIC SMOOTH... (5*)
- Su1742. . . IMPACT OF NUTRITIONAL DEFICIENCIES IN GASTROPARESIS... (5*)
- Su1743. . . PREVALENCE AND SPECTRUM OF GI MOTILITY... (5*)
- Su1744. . . GENDER DIFFERENCES IN REPORTED NEUROLOGIC SIDE... (5*)
- Su1745. . . TREATMENT PATTERNS IN ADULT PATIENTS WITH... (3*)(Takeda Pharmaceuticals)
- Su1746. . . CLINICAL CHARACTERISTICS ASSOCIATED WITH IDIOPATHIC RAPID... (4*)
- Su1747. . . DIFFERENCES IN DEMOGRAPHICS, COMORBIDITIES, AND SYMPTOMATOLOGY... (5*)
- Su1748. . . IMPACT OF CLOSTRIDIUM DIFFICILE INFECTIONS ON... (5*)
- Su1749. . . DOMPERIDONE USE IN GASTROPARESIS: 9-YEAR RETROSPECTIVE... (5*)
- Su1750. . . GASTRIC PER-ORAL ENDOSCOPIC PYLOROMYOTOMY (GPOEM) IS... (5*)
- Su1751. . . CINNAMALDEHYDE AMELIORATES HYPERGLYCEMIA INDUCED ENTERIC NEUROPATHY... (2*)
- Su1752. . . A DOSE-RANGING, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED STUDY... (3*)(Research grant from Takeda)
- Su1753. . . ESTROGEN PROTECTS TYPE 2 DIABETES AND... (2*)
- Su1754. . . PREDICTORS OF LONGITUDINAL CHANGES IN SYMPTOM... (3*)(The parent study supporting the data and analyses included in this abstract were funded by Medtronic (grant MA-501). Medtronic did not participate in study design, data interpretation, writing support, or other preparation assistance for this article.)
- Su1755. . . CONSTIPATION IN PATIENTS WITH SYMPTOMS OF... (2*)
- Su1756. . . MEASURES OF GASTROINTESTINAL VAGAL DYSFUNCTION IN... (4*)(6)
- Su1757. . . PPI THERAPY: DETRIMENTAL OR BENEFICIAL IN... (5*)
- Su1758. . . NAUSEA, VOMITING AND DYSPEPSIA FOLLOWING SOLID... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1759. . . . TRANSCUTANEOUS ELECTRICAL STIMULATION JUMP-STARTS GASTRIC EMPTYING...** (5*)
- Su1760. . . . VISCERAL HYPOSENSITIVITY AND HYPERSENSITIVITY MASK A...** (4*)
- Su1761. . . . SMALL INTESTINAL BACTERIAL OVERGROWTH: IS IT...** (5*)
- Su1762. . . . RELATIONSHIP BETWEEN SYMPTOMS DURING A GASTRIC...** (2*)
- Su1763. . . . DIAGNOSTIC RISK STRATIFICATION IN POST-EGD PATIENTS...** (5*)
- Su1764. . . . TAK-906, A NOVEL DOPAMINE D2/D3 RECEPTOR...** (3*)|(This study was sponsored by Altos Therapeutics, LLC. Formatting and editing support were provided by Oxford PharmaGenesis, Oxford, UK and funded by Takeda Pharmaceutical Company Ltd.)
- Su1765. . . . GASTROPARESIS INCREASES THE RISK FOR LUNG...** (5*)
- Su1766. . . . DIFFERENCES IN CLINICAL PRESENTATION BETWEEN PATIENTS...** (3*)|(Progenity, Inc.)
- Su1767. . . . FACTORS ASSOCIATED WITH BARRETT'S ESOPHAGUS IN...** (5*)
- Su1768. . . . PREVALENCE OF GASTROPARESIS AND FUNCTIONAL DYSPESIA...** (3*)|(This study is funded by Takeda Pharmaceutical Company Limited.)
- Su1769. . . . REAL-WORLD EVIDENCE ON PREVALENCE OF GASTROPARESIS...** (3*)|(The study was funded by Takeda Pharmaceutical Company Limited.)
- Su1770. . . . MEASUREMENT OF THE PYLORIC SPHINCTER USING...** (5*)
- Su1771. . . . IMPACT OF POLYP FEATURES AND COLONOSCOPIST ...** (2*)
- Su1772. . . . MULTI-CANCER DETECTION OF EARLY-STAGE CANCERS WITH...** (3*)|(GRAIL)
- Su1773. . . . MORE FECAL IMMUNOCHEMICAL TESTS ARE NEEDED...** (3*)|(Exact Sciences Corp.)
- Su1774. . . . YOUNG ONSET COLORECTAL ADENOMA: A SYSTEMATIC...** (2*)|(7)
- Su1775. . . . TWO YEARS REAL WORLD CLINICAL...** (5*)
- Su1776. . . . LOW RISK ADENOMAS VERSUS NO ADENOMAS...** (5*)
- Su1777. . . . A MULTICENTERED RETROSPECTIVE STUDY OF CLINICAL...** (5*)
- Su1778. . . . YIELD OF AND RISK FACTORS FOR...** (4*)|(2)
- Su1779. . . . A RANDOMIZED CONTROLLED TRIAL OF AN...** (4*)
- Su1780. . . . THE "PREDICT, RESECT AND DISCARD" STRATEGY...** (5*)
- Su1781. . . . IMPROVEMENT OF ASIA-PACIFIC COLORECTAL SCREENING SCORE...** (2*)|(Supported by the National Natural Science Foundation of China (Grant No. 81770559, 81370500) and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2016-12M-3-001).)
- Su1782. . . . ENDORSEMENT OF WATER EXCHANGE (WE) COLONOSCOPY...** (2*)|(7)
- Su1783. . . . TEST CHARACTERISTICS OF FECAL IMMUNOCHEMICAL TESTS...** (4*)
- Su1784. . . . CHARACTERISTICS AND OUTCOMES AMONG INDIVIDUALS WITH...** (2*)
- Su1785. . . . ADR BY GENDER, RACE AND ETHNICITY...** (5*)|(Health Care Service Corporation, the parent company of Blue Cross Blue Shield of Illinois, Texas, Oklahoma, New Mexico and Montana provided the claims data and performed the statistical analysis)
- Su1786. . . . HIGHER FECAL HB CONCENTRATION PREDICTS RISK...** (5*)
- Su1787. . . . LONG-TERM IMPACT OF A PHYSICIAN...** (5*)
- Su1788. . . . CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH...** (2*)|(4)
- Su1789. . . . OPTIMAL TIMING OF SURVEILLANCE COLONOSCOPY AFTER...** (4*)
- Su1790. . . . THE PREVALENCE OF METACHRONOUS ADVANCED COLORECTAL...** (5*)
- Su1791. . . . MANDATED BOSTON BOWEL PREP SCALE IMPLEMENTATION...** (5*)
- Su1792. . . . IMPROVING FECAL IMMUNOCHEMICAL TESTING RATES FOR...** (5*)
- Su1793. . . . PROXIMAL VERSUS DISTAL COLON ADR: A...** (5*)|(Health Care Financing Corporation which represents Blue Cross Blue Shield of Illinois, Texas, Oklahoma, New Mexico and Montana provided the claims data for this study and contributed the statistical analysis.)
- Su1794. . . . UPTAKE RATE OF COLORECTAL CANCER SCREENING...** (2*)
- Su1795. . . . PREVALENCE AND RISK FACTORS FOR SESSILE...** (6*)
- Su1796. . . . GO BEFORE YOU GO: IMPLEMENTATION OF A SAME DAY...** (5*)
- Su1797. . . . PREVALENCE AND PREDICTORS OF COLORECTAL NEOPLASMS...** (5*)
- Su1798. . . . COLOGUARD POSITIVE SCREENING: REAL WORLD POSITIVE...** (5*)
- Su1799. . . . POLYP SIZE VERSUS NUMBER: WHAT IS...** (5*)
- Su1800. . . . CHARACTERIZING THE ROLE OF GAIN-OF-FUNCTION SYK...** (2*)|(7)
- Su1801. . . . MULTI-RACIAL RISK SCORE INTEGRATION TO PREDICT...** (4*)|(2)
- Su1802. . . . MOLECULAR PREDICTION IN INFLAMMATORY BOWEL DISEASE...** (2*)
- Su1803. . . . THE CLINICAL PHENOTYPE OF COLLAGENOUS COLITIS...** (5*)
- Su1804. . . . GENETIC ANALYSIS OF ULCERATIVE COLITIS IN...** (8*)
- Su1805. . . . THE LONG-TERM CORTICOSTEROID SPARING EFFECT OF...** (6*)
- Su1806. . . . RISK OF ANAL CANCER IN PATIENTS...** (5*)
- Su1807. . . . QUALITY OF LIFE, FECAL CALPROTECTIN AND...** (5*)
- Su1808. . . . PROVIDER RELATIONSHIPS MAY BE AN IMPORTANT...** (5*)
- Su1809. . . . EVALUATING ACCESS TO IBD CARE ACROSS...** (2*)|(4)
- Su1810. . . . OUTCOMES OF IBD MANAGEMENT BASED ON...** (5*)
- Su1811. . . . DIFFERENCES IN CARE AND OUTCOME AMONG...** (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1812. . . IDEAL VIAL SIZE FOR INFLIXIMAB IN... (5*)**
- Su1813. . . COST-EFFECTIVENESS OF VEDOLIZUMAB IV VERSUS ADALIMUMAB... (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)**
- Su1814. . . SEVERE AND REFRACTORY CROHN'S DISEASE: PATTERNS... (5*)**
- Su1815. . . REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS... (3*)|(Takeda Pharmaceuticals U.S.A, Inc.)**
- Su1816. . . COST-EFFECTIVENESS OF 5-ASA THERAPY IN COMBINATION... (5*)**
- Su1817. . . FOCUSING ON THE FUTURE: REDUCING BARRIERS... (2*)|(4)**
- Su1818. . . ANALYSIS OF VENOUS THROMBOEMBOLISM PROPHYLAXIS NON-ADHERENCE... (6*)**
- Su1819. . . THE EFFECTIVENESS OF A STANDARDIZED BIOLOGIC... (5*)**
- Su1820. . . A SYSTEMATIC REVIEW: ARE THE QUALITY... (5*)**
- Su1821. . . SAME-PAGE CARE IS ASSOCIATED WITH IMPROVED... (6*)**
- Su1822. . . POOR PATIENT-REPORTED OUTCOMES WERE OBSERVED IN... (3*)|(This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Bristol-Myers Squibb with financial support provided by Bri)**
- Su1823. . . PATIENT AND PHYSICIAN PERSPECTIVES ON THE... (3*)|(Celgene Corporation)**
- Su1824. . . CONSIDERABLE WORK PRODUCTIVITY LOSS IN PATIENTS... (3*)|(This study was sponsored by Corrona, LLC. Corrona is supported through contracted subscriptions with multiple pharmaceutical companies. The abstract was a collaborative effort between Corrona and Bristol-Myers Squibb with financial support provided by Bri)**
- Su1825. . . QUALITY OF LIFE AND EFFECTIVENESS OF... (3*)|(This study had a ficial support of Takeda Pharma GmbH)**
- Su1826. . . CROHN'S DISEASE EXPERIENCES AMONG A PEDIATRIC... (3*)|(Eli Lilly and Company)**
- Su1827. . . ALIGNMENT OF IBD SYMPTOMS REPORTED BY... (3*)|(Study sponsored by: Janssen Scientific Affairs, LLC, Horsham, PA, USA)**
- Su1828. . . PATIENTS WITH IBD SEEK EXTRA SUPPORTIVE... (5*)**
- Su1829. . . ASSOCIATIONS BETWEEN DIETARY INTAKE, PHYSICAL ACTIVITY... (2*)**
- Su1830. . . PATIENT REPORTED IBD CONTROL SCORES CORRELATES... (5*)**
- Su1831. . . MEASURING VALUE: IDENTIFYING A BALANCED MEASURE... (6*)**
- Su1832. . . USE OF CLINICAL INFLAMMATORY BOWEL DISEASE... (2*)**
- Su1833. . . THE PREVALENCE AND PREDICTORS OF FUTILE... (5*)**
- Su1834. . . ACCURACY OF SELF-REPORTED VACCINATION STATUS IN... (1*)**
- Su1835. . . WHAT IS THE INCIDENCE OF HERPES... (5*)**
- Su1836. . . THE QUALITY AND REPORTING OF INFLAMMATORY... (5*)**
- Su1837. . . OPIOID USE AMONG PATIENTS WITH INFLAMMATORY... (5*)**
- Su1838. . . A COCHRANE REVIEW OF INTERVENTIONS FOR... (2*)|Non-applicable)**
- Su1839. . . INTERVENTIONS FOR MANAGING IRON DEFICIENCY... (2*)**
- Su1840. . . EFFECTIVENESS OF DOSE DE-ESCALATION OF BIOLOGIC... (5*)**
- Su1841. . . INCREASED RISK OF ANTI-DRUG ANTIBODIES TO... (5*)**
- Su1842. . . RISK OF NEW OR RECURRENT CANCERS... (5*)**
- Su1843. . . SUPRA-THERAPEUTIC LEVELS OF INFLIXIMAB DO NOT... (5*)**
- Su1844. . . THE SAFETY OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY... (5*)**
- Su1845. . . SARCOPENIA PREDICTS INFECTION IN PATIENTS WITH... (5*)**
- Su1846. . . ABDOMINAL VISCERAL-TO-SUBCUTANEOUS FAT INDEX IS ASSOCIATED... (5*)**
- Su1847. . . META-ANALYSIS OF THE INCIDENCE OF DERMATOLOGICAL... (5*)**
- Su1848. . . THE SAPPHIRE REGISTRY: SAFETY OF IMMUNOSUPPRESSION... (6*)**
- Su1849. . . RISK OF INCIDENT PARADOXICAL IMMUNE-MEDIATED INFLAMMATORY... (6*)**
- Su1850. . . RISK OF PRIMARY GASTROINTESTINAL LYMPHOMA IN... (5*)**
- Su1851. . . EFFECTS OF VEDOLIZUMAB ON EXTRAINTestinal MANIFESTATIONS... (5*)**
- Su1852. . . CHARACTERISTICS OF SKIN LESIONS ASSOCIATED WITH... (4*)**
- Su1853. . . MALES WITH INFLAMMATORY BOWEL DISEASE TAKING... (4*)**
- Su1854. . . RISK OF HEPATITIS FLARE IN PATIENTS... (5*)**
- Su1855. . . SEROCONVERSION FOR LATENT TUBERCULOSIS IN TRAVELLERS... (4*)**
- Su1856. . . SAFETY OF TOFACITINIB ON POSTOPERATIVE OUTCOMES... (5*)**
- Su1857. . . SEVERITY OF HEPATIC STEATOSIS AND... (7*)|(4)**
- Su1858. . . METABOLIC EFFECTS OF SYSTEMIC CORTICOSTEROID USE... (5*)**
- Su1859. . . HIGHER VEDOLIZUMAB SERUM LEVELS DO NOT... (5*)**
- Su1860. . . MULTICENTER SURVEY ON MESALAMINE INTOLERANCE IN... (5*)**
- Su1861. . . POOLED SAFETY ANALYSES FROM PHASE 3... (3*)|(Gilead Sciences, Galapagos NV)**
- Su1862. . . PREOPERATIVE VEDOLIZUMAB THERAPY IS ASSOCIATED WITH... (5*)**
- Su1863. . . VEDOLIZUMAB IS SAFE IN VETERAN PATIENTS... (5*)**
- Su1864. . . PANETH CELL PHENOTYPE AT ILEAL RESECTION... (4*)**
- Su1865. . . A PRGNOStIC MODEL AND NOMOGRAM PREDICTING... (2*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1867... BIG DATA ANALYTICS DEMONSTRATE A NOVEL,... (2*)
- Su1868... EPIGENETIC PREDICTION OF CROHN'S DISEASE RECURRENCE:... (2*)
- Su1869... FAECAL CALPROTECTIN IS A USEFUL NON-INVASIVE... (4*)
- Su1870... WHEN LESS IS MORE AND MORE... (4*)
- Su1871... VALIDATION OF THE RED FLAGS INDEX... (3*)(7)|(Takeda)
- Su1872... TRENDS IN FAECAL CALPROTECTIN LEVELS... (5*)
- Su1873... HOSPITALIZATIONS FOR ACUTE HERPES AND VARICELLA... (5*)
- Su1874... USEFULNESS OF THE FECAL CALPROTECTIN AS... (4*)
- Su1875... PROSPECTIVE VALIDATION OF FECAL CALPROTECTIN AS... (5*)
- Su1876... 10 YEAR TRENDS OF RADIATION SPARING... (5*)
- Su1877... ENRICHMENT OF POST-TRANSLATIONAL MODIFICATIONS IN INFLAMMATORY... (4*)
- Su1878... ENHANCED MESENTERIC FAT VOLUME - A... (5*)
- Su1879... NOVEL APPROACH TO BIND AND SPECIFICALLY... (2*)
- Su1880... MACHINE LEARNING APPROACHES VALIDATE SEROLOGICAL MARKERS... (4*)
- Su1881... MULTIPLE ENDOPHENOTYPES OF ULCERATIVE COLITIS CORRELATE... (2*)
- Su1882... ENDOSCOPIC ASSESSMENT IN ACUTE SEVERE ULCERATIVE... (5*)
- Su1883... THROMBOCYTOSIS IN ACUTE INFLAMMATORY BOWEL DISEASE-... (5*)
- Su1884... A MUCOSAL MARKER PREDICTING TOFACITINIB INDUCED... (3*)|Research Grant by Pfizer.)
- Su1885... SCREENING FOR STEATOHEPATITIS AND FIBROSIS AMONG... (5*)
- Su1886... OXIDATIVE STRESS CORRELATES WITH DISEASE ACTIVITY... (2*)(European Union Funds, Innovative Economy Programme)
- Su1887... POINT-OF-CARE BOWEL ULTRASOUND FOR DETECTING ILEO-COLONIC... (5*)
- Su1888... INTESTINAL ULTRASOUND THROUGHOUT PREGNANCY IN INFLAMMATORY... (5*)
- Su1889... INTER-OBSERVER AGREEMENT OF AN EXPERT PANEL... (5*)
- Su1890... ULCERATIVE COLITIS PATIENTS WITH QUIESCENT OR... (4*)(6)
- Su1891... THE IMPACT OF HUMAN IMMUNODEFICIENCY VIRUS... (5*)
- Su1892... A SINGLE CENTRE CROSS SECTIONAL COHORT... (1*)
- Su1893... ENHANCED MESENTERIC FAT VOLUME IS ASSOCIATED... (2*)(4)
- Su1894... ILEAL OR COLONIC HISTOLOGIC ACTIVITY DOES... (5*)
- Su1895... PREVALENCE AND CLINICAL SIGNIFICANCE OF ANASTOMOTIC... (5*)
- Su1896... VALIDATION OF DISEASE SEVERITY INDEX FOR... (2*)
- Su1897... TRANSMURAL HEALING WITH VEDOLIZUMAB IN PATIENTS... (3*)(Takeda)
- Su1898... ASSOCIATION BETWEEN SERUM AND TISSUE PROTEIN... (5*)
- Su1899... PATIENT-REPORTED OUTCOMES (PRO-2) AND INTESTINAL ULTRASOUND... (3*)
- Su1901... DIAGNOSTIC ACCURACY OF A SERUM-BASED BIOMARKER... (3*)(Research support from Prometheus Biosciences.)
- Su1902... A SERUM BIOMARKER PANEL CAN ACCURATELY... (5*)(Research support from Prometheus Biosciences.)
- Su1903... THE PREVALENCE AND PROGNOSIS OF DIFFUSE... (5*)
- Su1904... CAN WE PREDICT THE PRESENCE OF... (5*)
- Su1905... CORRELATION BETWEEN MICROBIAL MARKERS AND FECAL... (5*)
- Su1906... A STOOL MARKER-BASED STRATEGY TIMELY AND... (5*)
- Su1907... GLUCOCORTICOID METABOLISM IS ASSOCIATED WITH DISEASE... (4*)
- Su1908... NEUTROPHIL-TO-LYMPHOCYTE RATIO IS ASSOCIATED WITH DISEASE... (4*)
- Su1909... PERIPHERAL BLOOD MONOCYTOSIS IS ASSOCIATED WITH... (5*)
- Su1910... EFFECT OF HISTOLOGICAL ACTIVITY ON CLINICAL... (5*)
- Su1911... CORRELATION BETWEEN HISTOLOGIC AND ENDOSCOPIC SCORING... (5*)
- Su1912... CDEIS SCORE OF 2 IS OPTIMAL... (2*)
- Su1913... MAGNITUDE OF INCREMENTAL BENEFIT OF ACHIEVING... (2*)
- Su1914... NOVEL SERUM SOLUBLE MARKERS OF HISTOLOGICAL... (5*)
- Su1915... CHANGES IN THE INTESTINAL MICROBIOTA OF... (2*)(This work was supported by a grant from the National Research Foundation (NRF) of Korea, funded by the Korea government (MSIP) (number: 2014R1A2A11052136, 2017R1A2B4006767, and 2019R1A2C2010404).)
- Su1916... RAPID HISTO-ENDOSCOPIC MUCOSAL HEALING WITH (HIGH... (3*)(This post-hoc analysis was entirely funded by Dr. Falk Pharma GmbH.)
- Su1917... FAECAL MYELOPEROXIDASE - A POTENTIAL NON-INVASIVE... (1*)(New Zealand Society of Gastroenterology Research Fellowship Grant)
- Su1918... CROHN'S DISEASE SMALL BOWEL STRICTURES: DEVELOPMENT... (4*)
- Su1919... DIFFERENCES IN EXTRA CELLULAR MATRIX REMODELING... (4*)
- Su1920... DETECTION AND CHARACTERIZATION OF EXTRA-INTESTINAL MANIFESTATIONS... (3*)(Acknowledgements: This research was funded by a grant from Abbvie.)
- Su1921... THE ESCALATION OF THERAPY OR INTERVENTION... (5*)
- Su1922... NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Su1923... DIAGNOSTIC ACCURACY OF A HOME-PERFORMED FECAL... (5*)	Su1942... IMPACT OF EXTRA-INTESTINAL MANIFESTATION ON HEALTH... (5*)	Su1961... DECREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE... (5*)
Su1924... CIRCULATING EXTRACELLULAR VESICLES CORRELATE WITH DISEASE... (4*) (2)	Su1943... THE ROLE OF ANTIMICROBIAL MARKERS IN... (3*) (Prometheus Laboratories covered the costs for the serological analyses.)	Su1962... DECREASING PREVALENCE OF CLOSTRIDIODES DIFFICILE INFECTION... (5*)
Su1925... EARLY PREDICTION OF OUTCOME IN ACUTE... (5*)	Su1944... IMPACT OF CIRRHOSIS ON OUTCOMES IN... (5*)	Su1963... THE PREVALENCE OF STROKE IS INCREASED... (5*)
Su1926... FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS... (3*) (Arena Pharmaceuticals, Inc.)	Su1945... IMPACT OF COLONOSCOPY ON OUTCOMES FOR... (5*)	Su1964... IMPACT OF HAVING INFLAMMATORY BOWEL DISEASE... (5*)
Su1927... GASTROINTESTINAL IMAGING IN CHRONIC GRANULOMATOUS DISEASE:... (2*)	Su1946... IMMUNOGLOBULIN DEFICIENCIES IN PATIENTS WITH INFLAMMATORY... (2*)	Su1965... INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNOBIOLOGIC... (5*)
Su1928... EVALUATING ASSOCIATION BETWEEN FECAL CALPROTECTIN AND... (3*) (Genentech, Inc.)	Su1947... ABDOMINAL PAIN IS INDEPENDENTLY ASSOCIATED WITH... (4*)	Su1966... BIOLOGIC INITIATION WITHIN 12 MONTHS OF... (3*) (Eli Lilly and Company)
Su1929... A HYBRID APPROACH OF HANDLING MISSING... (3*) (Takeda)	Su1948... BURDEN OF DISEASE: SUBSTANCE ABUSE IN... (5*)	Su1967... DISEASE BURDEN AND PATIENT-REPORTED OUTCOME MEASURES... (5*)
Su1930... PCR CYCLE TIME AND CLOSTRIDIODES DIFFICILE... (5*)	Su1949... INCIDENCE OF OCCULT COLORECTAL CANCER IN... (4*)	Su1968... LOW BIOSIMILAR USE IN PATIENTS WITH... (5*)
Su1931... PATIENT-REPORTED SYMPTOMS OVER A PERIOD OF... (5*)	Su1950... PHENOTYPE AND NATURAL HISTORY OF INFLAMMATORY... (5*)	Su1969... TRENDS IN IMMUNOMODULATOR AND BIOLOGIC USE... (5*)
Su1932... COMPARISON OF PROSTAGLANDIN E-MAJOR URINARY METABOLITE... (1*)	Su1951... PRE-POUCH ILEITIS IS A RISK FACTOR... (5*)	Su1970... BARIATRIC SURGERY IN INFLAMMATORY BOWEL DISEASE... (5*)
Su1933... FAECAL CALPROTECTIN AS THERAPEUTIC TARGET IN... (5*)	Su1952... SEROLOGICAL AND GENETIC MARKERS ARE ASSOCIATED... (5*)	Su1971... REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB... (5*)
Su1934... A DIRECT COMPARISON OF FECAL CALPROTECTIN,... (5*)	Su1953... THE NATURAL HISTORY OF COLECTOMY AMONG... (4*)	Su1972... INCIDENCE OF POUCHITIS AND ANTIBIOTIC PRESCRIBING... (5*)
Su1935... PERIANAL EXAMINATION AT TIME OF COLONOSCOPY... (5*)	Su1954... COLITIS DUE TO CYTOMEGALOVIRUS ASSOCIATED WITH... (5*)	Su1973... OUTCOMES OF FECAL DIVERSION FOR PERIANAL... (5*)
Su1936... HISTOLOGIC INFLAMMATION DEFINED BY THE ROBERTS... (5*)	Su1955... EAST VERSUS WEST: INDICATIONS, POSTOPERATIVE MANAGEMENT... (5*)	Su1974... FATIGUE IS THE SELF-REPORTED SYMPTOM IN... (2*)
Su1937... PREDICTORS OF PROGNOSIS AND OUTCOMES AFTER... (2*)	Su1956... PERIPHERAL BLOOD EOSINOPHILA IS ASSOCIATED WITH... (5*)	Su1975... CREATION OF A PROSPECTIVE, LONGITUDINAL ADULT... (6*) (3)
Su1938... PATIENT REPORTED OUTCOMES: THE ICHOM STANDARD... (5*)	Su1957... ELDERLY-ONSET INFLAMMATORY BOWEL DISEASE IS ASSOCIATED... (5*)	Su1976... THE PREVALENCE OF INCIDENTAL TERMINAL ILEITIS... (5*)
Su1939... DEMOGRAPHIC DATA AND THERAPY BEFORE PROCTOCOLECTOMY... (4*)	Su1958... CUMULATIVE RISK OF SURGERY IN PATIENTS... (2*)	Su1977... HIGH VOLUMES OF SKELETAL MUSCLE AND... (5*)
Su1940... ACUTE SEVERE ULCERATIVE COLITIS IN PREGNANCY:... (5*)	Su1959... NATURAL HISTORY OF ELDERLY-ONSET INFLAMMATORY BOWEL... (2*)	Su1978... PROTEIN ENERGY MALNUTRITION IS ASSOCIATED WITH... (5*)
Su1941... READMISSION RELATED HEALTH CARE UTILIZATION AND... (5*)	Su1960... THIRTY DAY READMISSIONS AMONG PATIENTS WITH... (5*)	Su1979... NOVEL ASSOCIATIONS OF ADIPOSE TISSUE (AT)... (2*)
		Su1980... THE GEM PROJECT: IMPAIRED GUT BARRIER... (6*) (2)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Su1981. . . TRENDS IN INFLAMMATORY BOWEL DISEASE (IBD)... (3*)**(Bristol-Myers Squibb)
- Su1982. . . AN UPDATE ON CLINICAL OUTCOME AND... (5*)**
- Su1983. . . HIGHER LEVELS OF FECAL CALPROTECTIN PREDICT... (5*)**
- Su1984. . . CLINICAL PRESENTATION AND OUTCOMES OF PRIMARY... (5*)**
- Su1985. . . ENROLLMENT CHARACTERISTICS OF ULCERATIVE COLITIS AND... (5*)**
- Su1986. . . MACHINE LEARNING ALGORITHM CAN HELP PREDICT... (5*)**
- Su1987. . . THE IMPACT OF SOCIAL DETERMINANTS OF... (2*)**(NIDDK: 1K23DK117054-01A1)
- Su1988. . . ENVIRONMENTAL EFFECT OF RESOLVED HUMAN CMV... (2*)**(6)
- Su1989. . . AGE-SPECIFIC HEALTHCARE UTILIZATION TRENDS IN A... (4*)**
- Su1990. . . LNCRNA ZFAS1 INTERACTS WITH POLYADENYLATE-BINDING PROTEIN... (2*)**
- Su1991. . . GENDER-SPECIFIC EFFECT OF DIETARY AND PHYSICAL... (2*)**(4)
- Su1992. . . THE FREQUENCY OF METABOLIC DISORDER IN... (5*)**
- Su1993. . . DIABETES AND PANCREATIC CANCER: A POPULATION-BASED... (5*)**
- Su1994. . . ORAL IRON THERAPY PROMOTES A PROINFLAMMATORY... (4*)**
- Su1995. . . MICROBIOLOGICAL AND IMMUNOLOGICAL INFLAMMATORY IMMUNE RESPONSES... (4*)**
- Su1997. . . DIVERGENT EFFECTS OF ANTIBIOTICS ON DEVELOPMENT... (2*)**
- Su1998. . . FUSOBACTERIUM NUCLEATUM INFECTION IS FACILITATED IN... (2*)**(4)
- Su1999. . . PERIODONTAL DISEASE, TOOTH LOSS AND RISK... (2*)**(7)
- Su2000. . . ABNORMAL EATING PATTERN AND RISK OF... (2*)**(4)
- Su2001. . . EFFECTS OF BILE ACIDS ON METABOLIC... (2*)**(This research is financially supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant no. NRF-2017R1D1A1B03034172))
- Su2003. . . MAPPING OF THE BACTERIAL AND FUNGAL... (4*)**
- Su2004. . . ILEAL MUCOSA-ASSOCIATED MICROBIOME SIGNATURE IN CHILDREN... (5*)**
- Su2005. . . α -GLYCRRHIZIC ACID, A COMPOUND EXTRACTED FROM... (2*)**
- Su2006. . . MEGACYSTIS MICROCOLON INTESTINAL HYPOPERISTALSIS SYNDROME: A... (5*)**
- Su2007. . . APRAGLUTIDE, A NOVEL LONG-ACTING GLUCAGON-LIKE PEPTIDE-2... (3*)**(Trial sponsored by VectivBio AG.)
- Su2008. . . A PHASE III STUDY OF TEDUGLUTIDE... (3*)**(Funding: Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies)
- Su2009. . . AN ANALYSIS OF THE BURDEN OF... (5*)**
- Su2010. . . SEX DIFFERENCES IN THE ASSOCIATION BETWEEN... (5*)**
- Su2011. . . THE EFFECT OF DIET COMPOSITION ON... (4*)**
- Su2012. . . OBESITY AND COLORECTAL NEOPLASM: IDENTIFYING OBESITY-ASSOCIATED... (5*)**
- Su2013. . . EFFECTIVENESS OF ONE-STOP COLORECTAL AND BREAST... (6*)**
- Su2014. . . THE ASSOCIATION OF SELF-REPORTED METABOLIC RISK... (2*)**
- Su2015. . . THE ASSOCIATION BETWEEN NONALCOHOLIC FATTY LIVER... (5*)**
- Su2016. . . COMBINATION TARGETING OF SQUALENE MONOOXYGENASE AND... (2*)**
- Su2017. . . GLYCINE PROTECTS FROM TLR4 AND NLRP3... (2*)**
- Su2018. . . ANTIOXIDANT CAPACITY RESPONSE DURING IBD EXACERBATION... (2*)**(European Union Funds, Innovative Economy Programme)
- Su2019. . . ADJUNCTIVE SUPPLEMENTATION WITH AN ORAL HEME... (5*)**
- Su2020. . . ENDOSCOPIC SLEEVE GASTROPLASTY AND POST-PROCEDURAL NUTRITIONAL... (5*)**
- Su2021. . . THE ROLE OF MALNUTRITION IN THE... (2*)**(European Union Funds, Innovative Economy Programme)
- Su2022. . . PROGNOSTIC ROLE OF ZINC DEFICIENCY ASSOCIATED... (5*)**
- Su2023. . . NUTRITIONAL IMPLICATIONS RELATED TO FOLLOWING A... (2*)**
- Mo1000. . . ETIOLOGY AND OUTCOMES OF GASTROINTESTINAL BLEEDING... (5*)**
- Mo1001. . . CAUSES OF UPPER GASTROINTESTINAL BLEEDING IN... (5*)**
- Mo1002. . . CAUSES OF LOWER GASTROINTESTINAL BLEEDING IN... (5*)**
- Mo1003. . . HOSPITAL PERFORMANCE FOR GASTROINTESTINAL BLEEDING MORTALITY,... (2*)**
- Mo1004. . . INCREASING UTILIZATION OF ANGIOGRAPHY FOR LOWER... (5*)**
- Mo1005. . . EARLY ENDOSCOPY IN CRITICALLY ILL PATIENTS... (5*)**
- Mo1006. . . QUALITATIVE ANALYSIS OF BARRIERS TO THE... (2*)**
- Mo1007. . . THE IMPACT OF NIGHT-TIME EMERGENCY DEPARTMENT... (5*)**
- Mo1008. . . OBSERVED REDUCTION IN EXCESS DAYS FOR... (5*)**
- Mo1009. . . COST-CONSCIOUSNESS AWARENESS TO PROMOTE HIGH VALUE-CARE... (5*)**
- Mo1010. . . SOMATOSTATIN AND ANALOGUES FOR ACUTE NON-VARICEAL... (5*)**
- Mo1011. . . THALIDOMIDE AND BEVACIZUMAB FOR THE TREATMENT... (5*)**
- Mo1012. . . HEMOGLOBIN MONITORING IN ACUTE GASTROINTESTINAL BLEEDING:... (5*)**
- Mo1013. . . INCREASING INCIDENCE OF ESOPHAGEAL ADENOCARCINOMA OCCURS... (4*)**
- Mo1014. . . RISK STRATIFICATION OF GASTRIC CANCER AFTER... (4*)**(This

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

study was supported by the Minister of Science and Technology, R.O.C. (105-2314-B-002-069-MY3), Taipei Institute of Pathology (TIP-106-005), and Japan Agency for Medical Research and Development (AMED) (JP19ck0106267).)

Mo1015. . . GLOBAL INCIDENCE AND MORTALITY OF ESOPHAGEAL... (5*)

Mo1016. . . EPIDEMIOLOGY OF CARCINOID TUMORS OF THE... (5*)

Mo1017. . . THE ASSOCIATION OF MODIFIABLE RISK FACTORS... (2*)

Mo1018. . . TUMOR LOCATION IS AN INDEPENDENT PREDICTOR... (5*)

Mo1019. . . DOES LIVING REMOTELY IMPACT ACCESS TO... (5*)

Mo1020. . . THE GLOBAL REALITY OF GASTRIC CANCER... (2*)

Mo1021. . . TRENDS IN MORTALITY FROM YOUNG-ONSET GASTRIC... (4*)

Mo1022. . . PANCREATIC CANCER IN HISPANIC PATIENTS: A... (5*)

Mo1023. . . DOES LIVING REMOTELY IMPACT STAGE OF... (5*)

Mo1024. . . LOWER INCOME LEVEL IS ASSOCIATED WITH... (5*)

Mo1025. . . TRENDS IN ACCESS TO TESTING/TREATMENT FOR... (5*)

Mo1026. . . YIELD OF OUTPATIENT ENDOSCOPY FOR DYSPEPSIA... (5*)

Mo1027. . . GLOBAL INCIDENCE, MORTALITY AND TEMPORAL TREND... (5*)

Mo1028. . . HPV16 LINEAGE B IS ASSOCIATED WITH... (2*)

Mo1029. . . NEW NASH BASED SCREENING CRITERIA ENHANCES... (5*)

Mo1030. . . COMPLICATIONS OF METABOLIC SYNDROME MAY DISTINGUISH... (5*)

Mo1031. . . PROTECTIVE ROLE OF THE PRO-RESOLVING LIPID... (4*)

Mo1032. . . THE CDC42/RAC NUCLEOTIDE EXCHANGE FACTOR, β PAK-INTERACTING... (2*)

Mo1033. . . EFFECT AND MECHANISMS OF CONSTITUTIVE TL1A... (4*)

Mo1034. . . INTESTINAL PROTECTION INDUCED BY TREATMENT WITH... (4*)

Mo1035. . . EFFECTS OF ASIV ON INTESTINAL EPITHELIAL... (1*)

Mo1036. . . SUB-MUCOSAL COLLAGEN DEPOSITION IS ASSOCIATED WITH... (5*)

Mo1037. . . PDGFC SIGNALING IS A POTENTIAL THERAPEUTIC... (2*)

Mo1038. . . ACTL6A DRIVES GASTRIC CANCER PROGRESSION THROUGH... (2*)

Mo1039. . . EARLY DETECTION OF ESOPHAGEAL ADENOCARCINOMA PROGRESSION... (4*)

Mo1040. . . THE ROLE OF MKP-5-P38/MAPK PATHWAY IN... (2*)[(National Natural Science Foundation of China NO.81600415)

Mo1041. . . PROBIOTIC-DERIVED FERRICHROME INHIBITS THE GROWTH OF... (4*)

Mo1042. . . COLORECTAL CANCER ASSOCIATED-E. COLI INDUCE THE... (2*)[(4)

Mo1043. . . PORPHYRIN COMBINED USE ACCELERATES CHEMOTHERAPEUTIC EFFECTS... (5*)

Mo1044. . . VERTEPORFIN INHIBITS THE GROWTH OF BOTH... (4*)

Mo1045. . . EFFECTS OF 17 β -ESTRADIOL ON COLORECTAL CANCER... (2*)

Mo1047. . . PLATELET-DERIVED GROWTH FACTOR(PDGF) REGULATES MESENCHYMAL STEM... (4*)

Mo1048. . . EXOSOME-DELIVERED CIRC RNA_1400 REGULATES MICRORNA-637 /EPHB3 AXIS... (2*)

Mo1049. . . CXCL1 AND MASPIN EXPRESSION IN INCOMPLETE... (4*)

Mo1050. . . CABOZANTINIB TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA... (4*)

Mo1051. . . CD44 VARIANT ISOFORM 9 AND ITS... (4*)

Mo1052. . . FUSOBACTERIUM CONTRIBUTES TO COLORECTAL CANCER METASTASIS... (2*)

Mo1053. . . REDUCED ANGIOTENSIN II TYPE 2 RECEPTOR... (2*)

Mo1054. . . TGR5 IS INVOLVED IN BILE ACIDS... (2*)

Mo1055. . . EXTREMELY SENSITIVE NEXT GENERATION SEQUENCING MUTATION... (4*)[(MLDS grant)

Mo1056. . . PRIMARY SCLEROSING CHOLANGITIS-RELATED CHOLANGIOCARCINOMA PROLIFERATES FASTER... (5*)

Mo1058. . . GENETIC CHARACTERIZATION OF MOLECULAR TARGETS IN... (4*)[(The authors wish to acknowledge the financial support of the Catholic Medical Center Research Foundation made in the program year of 2018. This work was supported by The Catholic University of Korea Daejeon St. Mary's Hospital, Clinical research institute)

Mo1059. . . NEW FECAL BACTERIAL SIGNATURE OF COLORECTAL... (2*)

Mo1060. . . THE GALNT14 GENOTYPE PREDICTS POSTOPERATIVE OUTCOME... (4*)[(2)

Mo1061. . . IDENTIFICATION OF A NOVEL EXTRACELLULAR MATRIX... (5*)

Mo1062. . . MATRIX GLA PROTEIN PROMOTES COLON CANCER... (4*)

Mo1063. . . GENOMEWIDE TRANSCRIPTOMIC PROFILING IDENTIFIES A NONINVASIVE... (5*)

Mo1064. . . ETV1 ASSESSMENT USING EUS-FNA SAMPLE IS... (5*)

Mo1065. . . CLINICOPATHOLOGICAL SIGNIFICANCE OF CD44, CD44 VARIANTS,... (5*)

Mo1066. . . GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) IS HIGHLY... (2*)

Mo1067. . . HSP70 AS A MOLECULAR MARKER FOR... (2*)

Mo1068. . . SCREENING BIOMARKERS ASSOCIATED WITH GASTRIC CANCER... (2*)

Mo1069. . . GASTRIC JUICE PIR-1245: A PROMISING PROGNOSTIC... (5*)

Mo1070. . . THE FIRSR EVIDENCE FOR SLFN11 EXPRESSION... (2*)

Mo1071. . . CANCER NUCLEAR FEATURES EXTRACTED FROM PATHOLOGY... (2*)

Mo1072. . . EARLY MONITORING OF PLASMA METHYLATED SEPTIN... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1073...** NOVEL FECAL PROTEIN BIOMARKER TEST FOR... (6*)(2)|(Sciences)
- Mo1074...** THE ROLE OF USTEKINUMAB IN COLORECTAL... (5*)
- Mo1075...** SYSTEMATIC CHARACTERIZATION OF PROGNOSTIC VALUES OF... (2*)
- Mo1076...** SPATIALLY RESOLVED ANALYSIS OF FAECAL METABOLITES... (2*)(3)|(Waters Corporation)
- Mo1077...** EPIGENETIC AGE ACCELERATION AND COLORECTAL SURGERY... (2*)
- Mo1078...** ARSENIC INDUCES DOWNREGULATION ON TUMOR SUPPRESSOR... (4*)
- Mo1081...** LYMPH NODE INVOLVEMENT IN GASTRIC ADENOCARCINOMA... (5*)
- Mo1082...** KCNQ10T1, THE LARGEST NON-CODING RNA OF... (4*)
- Mo1083...** MACHINE LEARNING-BASED PREDICTIVE MODELS ARE MORE... (5*)
- Mo1084...** GENOMIC PROFILING IDENTIFIES A NOVEL BIOMARKER... (5*)
- Mo1086...** MALIGNANT CONVERSION BASED ON NATURAL HISTORY... (5*)
- Mo1087...** THE EFFICACY OF PDT USING 5-AMINOLEVULINIC... (4*)
- Mo1088...** THE DIAGNOSTIC ROLE OF 18F-FLOURODEOXYGLUCOSE POSITRON... (5*)
- Mo1089...** HIGHER INCIDENCE OF ADVANCED GASTRIC NEOPLASMS... (5*)
- Mo1090...** TRENDS IN INCIDENCE AND STAGE AT... (2*)(This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81660404 and No. 81560398) and the Natural Science Foundation of Jiangxi Province (grant No. 20161ACG70014), Foundation of Jiangxi Educational Committee (g)
- Mo1091...** LOW GRADE GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE... (5*)
- Mo1092...** RISK PREDICTION MODEL FOR DETECTING GASTRIC... (2*)
- Mo1093...** ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST,... (3*)(Alpine Immune Sciences)
- Mo1094...** OPS-2071 HEALS T CELL MEDIATED COLITIS,... (5*)
- Mo1095...** ATRIAL NATRIURETIC PEPTIDE ATTENUATES INTESTINAL INFLAMMATION... (2*)
- Mo1096...** BTK DEFICIENCY LEADS TO NLRP3 INFLAMMASOME... (2*)
- Mo1098...** EFFECTS OF SHORT-CHAIN FATTY ACIDS SUPPLEMENTATION... (4*)
- Mo1099...** AN ESCHERICHIA COLI STRAIN WITH EXTRA... (2*)
- Mo1100...** ESCHERICHIA COLI NISSLE 1917 EXPRESSING ELAFIN... (2*)
- Mo1101...** PROPHYLACTIC ADMINISTRATION OF PHENOLIC COMPOUNDS EXTRACTED... (4*)
- Mo1103...** EFFECT OF WEICHANG'AN PILL ON TH17/TREG... (3*)
- Mo1104...** MONONUCLEAR MYELOID CELL TARGETED HISTONE DEACETYLASE... (4*)(3)|(GlaxoSmithKline - Stevenage - UK)
- Mo1105...** GB004, A NOVEL GUT-TARGETED PROLYL HYDROXYLASE... (3*)(Gossamer Bio, Inc.)
- Mo1106...** INFLAMMATION AND CHRONICITY - A NOVEL... (6*)
- Mo1107...** THE GEM PROJECT: CROHN'S DISEASE POLYGENIC... (6*)(2)
- Mo1108...** AN INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSIS... (5*)
- Mo1109...** DEVIATION FROM ADDITIVE MODEL IN GENETICS... (2*)(4)
- Mo1110...** INTEGRATING EQTL EVIDENCE AND GWAS SUMMARY... (2*)(4)
- Mo1111...** RNASET2 RISK VARIANT AS A NOVEL... (4*)
- Mo1112...** IDENTIFYING NOVEL HIGH-IMPACT RARE DISEASE-CAUSING MUTATIONS,... (2*)
- Mo1113...** GENOTYPING OF NUDT15 R139C PRIOR TO... (4*)
- Mo1114...** ACCURATE PREDICTION OF THERAPEUTIC RESPONSE TO... (6*)
- Mo1115...** WHOLE-BLOOD EXPRESSION PROFILES IN INFLAMMATORY BOWEL... (2*)
- Mo1116...** GENOME-WIDE DNA METHYLATION PROFILING IN DIFFERENTIATING... (2*)
- Mo1117...** INCREASED ABUNDANCE OF BACTERIAL BILE SALT... (2*)(7)
- Mo1118...** DEVELOPMENT OF AN EASY AND RAPID... (4*)
- Mo1119...** NOVEL GENETIC VARIANTS ASSOCIATED WITH RISK... (4*)
- Mo1120...** PHENOME WIDE ASSOCIATION STUDY USING INFLAMMATORY... (5*)
- Mo1121...** TARGETED MUCOSAL TRANSCRIPTOMICS ANALYSIS REVEALS DIFFERENTIAL... (2*)
- Mo1122...** INTEGRATED NETWORK ANALYSIS USING PATIENT-SPECIFIC SINGLE... (2*)
- Mo1123...** META-ANALYSIS OF GENE EXPRESSION DISEASE SIGNATURES... (5*)
- Mo1124...** RNA-SEQ GENE EXPRESSION PROFILE REVEALS THAT... (2*)(7)
- Mo1125...** GENETIC ANALYSIS OF ULCERATIVE COLITIS RESPONSE... (5*)
- Mo1126...** FAMILY-SPECIFIC HOST GENETIC AND GUT MICROBIAL... (2*)
- Mo1127...** REPERTOIRE ANALYSIS OF MEMORY T—CELL RECEPTORS... (1*)
- Mo1128...** INFLUENCE OF NUDT15 AND TPMT ON... (5*)
- Mo1129...** THE IMPACT OF A SNP-DOSE-RESPONSE-EFFECT ON... (2*)
- Mo1130...** SGK2 KNOCKDOWN BY GENE EDITING PROMOTES... (2*)
- Mo1131...** QUANTITATIVE PROTEOMIC ANALYSIS OF MACROPHAGES FROM... (5*)
- Mo1132...** TLR4 SIGNALING PROTECTS THE INTESTINAL EPITHELIUM... (2*)
- Mo1133...** ACTIVATION OF ARYL HYDROCARBON RECEPTOR ATTENUATES... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1134. . . . THE REGULATION OF ARYL HYDROCARBON RECEPTOR... (4*)**
- Mo1135. . . . ENDOPLASMIC RETICULUM STRESS ACTIVATES REGULATORY T... (4*)(2)**
- Mo1136. . . . INTESTINAL ALKALINE PHOSPHATASE EXERTS ANTI-INFLAMMATORY EFFECTS... (4*)**
- Mo1137. . . . HDAC3 MEDIATES THE INFLAMMATORY RESPONSE AND... (2*)**
- Mo1138. . . . STRESS-INDUCED VISCERAL PAIN: ROLE OF MICROGLIA... (4*)**
- Mo1139. . . . PHYSIOLOGIC IN VIVO HOMEOSTASIS OF INTESTINAL... (5*)**
- Mo1140. . . . SACRAL NERVE STIMULATION IMPROVES RECTAL DISTENTION-INDUCED... (2*)**
- Mo1141. . . . SQUALAMINE, AN AMINOSTEROL POTENTIALLY USEFUL IN... (2*)**
- Mo1142. . . . INTESTINAL ELECTRICAL STIMULATION ENHANCES RELEASE OF... (2*)**
- Mo1143. . . . ALTERATION OF ANTERIOR CINGULATE FUNCTIONAL CONNECTIVITY... (2*)**
- Mo1144. . . . EARLY ADVERSE LIFE EVENTS MODULATE FUNCTIONAL... (2*)**
- Mo1145. . . . THE STRUCTURE OF VAGAL NOCICEPTIVE AFFERENT... (2*)**
- Mo1146. . . . CHRONIC INTRA-COLONIC LINACLOTIDE ADMINISTRATION ALTERS GLIAL... (3*)(2)**[(Supported by Ironwood Pharmaceuticals Inc, Allergan and NHMRC Australia.)
- Mo1147. . . . INTESTINAL HYPERPERMEABILITY IN A DUAL EXPERIMENTAL... (5*)**
- Mo1148. . . . IMPACT OF ADVERSE CHILDHOOD EXPERIENCES ON... (2*)(4)**
- Mo1149. . . . A NOVEL R-SPONDIN 1/POMC NEUROCIRCUIT IN... (2*)**
- Mo1150. . . . CENTRAL MECHANISM OF INTESTINAL ELECTRICAL STIMULATION... (2*)**
- Mo1151. . . . ACCELERATED GASTRIC EMPTYING IN A SUBSET... (5*)**
- Mo1152. . . . SPECTRAL ANALYSIS OF FREQUENCY OF COLON... (2*)**
- Mo1153. . . . PREDICTING TREATMENT RESPONSE TO THE LOW... (5*)**
- Mo1154. . . . RQ-00433412, A NOVEL ORALLY ACTIVE GHRELIN... (3*)**[(RaQualia Pharma Inc.)
- Mo1155. . . . PERIPHERAL GHRELIN MEDIATES THE OREXIGENIC EFFECTS... (1*)**
- Mo1156. . . . LOW COMPLICATION RATES IN THE OUTPATIENT... (5*)**
- Mo1157. . . . DIFFERENCES IN BRAIN SIGNATURES IN ULCERATIVE... (2*)**
- Mo1158. . . . A MULTICENTER, PROSPECTIVE TRIAL EVALUATING THE... (3*)**[(Medtronics - research support)
- Mo1159. . . . BIOMARKERS OF EXTRACELLULAR MATRIX REMODELLING ARE... (5*)**
- Mo1160. . . . SEROLOGICAL BIOMARKERS OF INTERSTITIAL MATRIX AND... (5*)**
- Mo1161. . . . THE SIMPLIFIED MARIA SCORE IS STRONGLY... (4*)**
- Mo1162. . . . INITIAL CLINICAL EXPERIENCE OF USING TETHERED... (2*)**
- Mo1163. . . . ENDOSCOPY-DRIVEN ALGORITHM IDENTIFIES BARRETT NEOPLASIA WITH... (5*)**
- Mo1164. . . . VOLUMETRIC LASER ENDOMICROSCOPY FOR IDENTIFICATION OF... (2*)**
- Mo1165. . . . WIRELESS ELECTRODE PATCHES SHOW INTRAPATIENT REPRODUCIBILITY... (6*)**
- Mo1166. . . . THE NEW SIMPLIFIED MARIA SCORE APPLIES... (5*)**
- Mo1167. . . . DEVELOPMENT OF A SOFTWARE (ASSESS UC)... (5*)**
- Mo1168. . . . ACCURACY OF CLINICAL STAGING FOR T2N0... (4*)**
- Mo1169. . . . X-RAY PHASE CONTRAST IMAGING FOR STAGING... (4*)**
- Mo1170. . . . OPTIMIZING VOLUMETRIC LASER ENDOMICROSCOPY SCORING SYSTEMS... (5*)**
- Mo1171. . . . ARTIFICIAL INTELLIGENCE (AI) BASED ANALYSIS OF... (3*)**[(CDX Diagnostics)
- Mo1172. . . . A RADIOMICS MACHINE LEARNING PREDICTOR CAN... (2*)**
- Mo1173. . . . TRANSNASAL ENDOMICROSCOPY FOR UNSEDATED OCT IMAGING... (6*)**
- Mo1174. . . . DEVELOPMENT OF A SELF-GUIDED TRAINING MODULE... (5*)**
- Mo1175. . . . USE OF MACHINE LEARNING AND COMPUTER... (2*)**
- Mo1176. . . . DEVELOPMENT OF A MACHINE LEARNING (ML)... (7*)(4)**
- Mo1177. . . . RESPONSE AND PROGRESSION OF SMALL BOWEL... (3*)**
- Mo1179. . . . OUTCOMES OF THE SIX FOOD ELIMINATION... (5*)**
- Mo1180. . . . PATTERNS OF ALLERGIC SENSITIZATION BASED ON... (5*)**
- Mo1181. . . . G-EOE-RD: EXTENT OF EOSINOPHILIC ESOPHAGITIS PREDICTS... (5*)**
- Mo1182. . . . AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF... (3*)**[(Adare Pharmaceuticals)
- Mo1183. . . . PREDICTORS OF RESPONSE TO CORTICOSTEROID THERAPY... (3*)**[(This study was funded by Shire ViroPharma, Inc., a member of the Takeda group of companies. Medical writing support was provided by Luci Witcomb PhD, of PharmaGenesis London, London, UK, and funded by Shire Human Genetic Therapies Inc., a member of the Ta)
- Mo1184. . . . AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF... (3*)**[(Adare Pharmaceuticals Inc)
- Mo1185. . . . ENDOSCOPY DETECTS HISTOLOGIC REMISSION WITH VERY... (2*)**
- Mo1186. . . . STRONG ASSOCIATION BETWEEN DYSPHAGIA FREQUENCY WITH... (2*)**
- Mo1187. . . . DILATION REDUCES POSITIVE CORRELATION BETWEEN SYMPTOMS... (2*)**
- Mo1188. . . . DETERMINATION OF AN ENDOSCOPIC RESPONSE THRESHOLD... (2*)(3)**[(T32 DK007634, R01DK101856)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1189...** DYSPHAGIA IN EOSINOPHILIC ESOPHAGITIS IMPROVES WITH... (2*)|(R01DK101856, T32DK007634)
- Mo1190...** ESOPHAGEAL DISTENSION DYSFUNCTION DURING SWALLOW-INDUCED PERISTALSIS... (2*)
- Mo1191...** ANTI-TUMOR NECROSIS FACTOR THERAPY AND EOSINOPHILIC... (5*)
- Mo1192...** ACID SUPPRESSANT MEDICATIONS AND EOSINOPHILIC ESOPHAGITIS:... (5*)
- Mo1193...** PREDICTORS OF RESPONSE TO DIETARY THERAPY... (6*)|(The Belletete Foundation)
- Mo1194...** GENDER-STRATIFIED CLINICAL COURSE AND TREATMENT RESPONSE... (2*)|(4)
- Mo1195...** POOR ENVIRONMENTAL QUALITY OF LAND AND... (2*)
- Mo1196...** PREVALENCE AND COMORBID OCCURRENCE OF ESOPHAGEAL,... (5*)
- Mo1197...** THE COMORBID OCCURRENCE OF EOSINOPHILIC ESOPHAGITIS... (5*)
- Mo1198...** RETROSPECTIVE REVIEW OF MILD ESOPHAGEAL EOSINOPHILIA... (5*)
- Mo1199...** PERIPHERAL EOSINOPHILIA AND HYPOALBUMINEMIA ARE ASSOCIATED... (2*)
- Mo1200...** INDIVIDUALS WITH EOSINOPHILIC ESOPHAGITIS ARE AT ... (2*)
- Mo1202...** LONG-TERM TREATMENT WITH PROTON PUMP INHIBITORS... (5*)
- Mo1203...** EOSINOPHILIC ESOPHAGITIS – VISUAL SCORE: A... (5*)
- Mo1204...** EOSINOPHILIC ESOPHAGITIS QUALITY OF LIFE QUESTIONNAIRE... (5*)
- Mo1205...** INCIDENCE OF BIOPSY-VERIFIED EOSINOPHILIC ESOPHAGITIS: NATIONWIDE... (5*)
- Mo1206...** FACTORS RELATED TO SUBJECTIVE SYMPTOMS IN... (5*)
- Mo1207...** HIGH HEALTH CARE UTILIZATION OF ENDOSCOPY... (2*)
- Mo1208...** COMPOUNDED FLUTICASONE SLURRY IS AN EFFECTIVE... (5*)
- Mo1209...** TREATMENT OF LYMPHOCYTIC ESOPHAGITIS IN A... (5*)
- Mo1211...** CONTRIBUTING FACTORS TO DELAY IN DIAGNOSIS... (5*)
- Mo1212...** PATIENT CHARACTERISTICS AND DISEASE SEVERITY IN... (5*)
- Mo1213...** LAMINA PROPRIA YIELD USING PERPENDICULAR PLACEMENT... (4*)
- Mo1214...** PROVOCATIVE TESTS DURING HIGH-RESOLUTION MANOMETRY MAY... (5*)
- Mo1215...** LYMPHOCYTIC ESOPHAGITIS HAS BETTER OUTCOMES COMPARED... (5*)
- Mo1216...** PREVALENCE OF NONADHERENCE IN MAINTENANCE THERAPY... (5*)
- Mo1217...** QUALITATIVE PATIENT INTERVIEWS TO ASSESS CONTENT... (3*)|(Sanofi and Regeneron Pharmaceuticals, Inc.)
- Mo1218...** EFFICACY OF BENRALIZUMAB, A MONOCLONAL ANTIBODY... (5*)
- Mo1219...** IMPACT OF EOSINOPHILIC ESOPHAGITIS DISEASE ACTIVITY... (2*)
- Mo1220...** FREQUENCY AND PREDICTORS OF LOSS TO... (2*)
- Mo1221...** MORTALITY IN EOSINOPHILIC ESOPHAGITIS - NATIONWIDE,... (2*)
- Mo1222...** EOSINOPHILIC ESOPHAGITIS AND ASYMPTOMATIC ESOPHAGEAL EOSINOPHILIA... (5*)
- Mo1223...** DEMOGRAPHIC AND CLINICAL CORRELATES OF THE... (5*)
- Mo1224...** SEASONAL AND REGIONAL VARIATIONS OF HOSPITAL... (5*)
- Mo1225...** EPIDEMIOLOGY AND SEASONAL PATTERNS OF HOSPITALIZATIONS... (5*)
- Mo1226...** CORRELATION OF TREATMENT OPTIONS AND... (5*)
- Mo1227...** IN HUMAN ESOPHAGEAL SMOOTH MUSCLE CELLS,... (4*)
- Mo1228...** DUPILUMAB NORMALIZES THE EOSINOPHILIC ESOPHAGITIS DISEASE... (3*)|(Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.)
- Mo1229...** TH2-CYTOKINES SUPPRESS CD73-POSITIVE CELL-MEDIATED EPITHELIAL REGENERATION... (2*)
- Mo1230...** DIFFERENTIALLY CORRELATED GENE MODULES SUGGEST DIFFERENTIALLY... (5*)
- Mo1231...** RNA SEQUENCING REVEALS ALTERED SELENOPROTEIN EXPRESSION... (2*)|(4)
- Mo1232...** CHARACTERIZATION OF SALIVARY, GASTRIC AND ESOPHAGEAL... (5*)
- Mo1234...** UTILITY OF MAJOR BASIC PROTEIN, EOTAXIN-3,... (2*)
- Mo1235...** OESOPHAGEAL MUCOSA INNERVATION IN PAEDIATRIC EOSINIPHILIC... (4*)
- Mo1236...** MAST CELL LEVEL AND CLINICAL CORRELATES... (3*)|(Education grant from Allakos.)
- Mo1237...** ESTABLISHMENT OF NORMAL TISSUE MAST CELL... (4*)|(Educational Grant provided by Allakos.)
- Mo1238...** TIME DEPENDENT ESOPHAGEAL CLEARANCE OF GLIADIN... (4*)
- Mo1295...** SMOKING PROMOTES CHEMO-RESISTANCE THROUGH INDUCING WEE1... (2*)|(4)
- Mo1296...** QUANTIFICATION OF LYMPHOVASCULAR INVASION IS USEFUL... (5*)
- Mo1298...** GITR STIMULATION ENHANCES THE ANTI-TUMOR IMMUNE... (4*)
- Mo1299...** INDIVIDUAL RISK CALCULATOR TO PREDICT LYMPH... (5*)
- Mo1301...** IKK β REGULATES CXCL9 AND IMMUNE CELL... (2*)
- Mo1302...** THE ALCOHOL USE DISORDERS IDENTIFICATION TEST... (5*)
- Mo1303...** GLUTATHIONE S-TRANSFERASE OMEGA 2 (GSTO2)... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1304...** CLINICOPATHOLOGICAL CHARACTERISTICS AND LYMPH NODE METASTASIS... (4*)
- Mo1306...** HIGH GRADE DYSPLASIA (HGD) AND ESOPHAGEAL... (5*)
- Mo1307...** CLINICAL AND GENOMIC CHARACTERISTICS OF SUPERFICIAL... (2*)
- Mo1308...** CLINICAL SIGNIFICANCE OF EARLY EVALUATION DURING... (5*)
- Mo1309...** IS THERE A NON-BARRETT'S PATHWAY TO... (5*)
- Mo1310...** ESOPHAGEAL ADENOCARCINOMA AFTER BARIATRIC SURGERY: A... (5*)
- Mo1311...** DOES CONTROLLING ESOPHAGEAL PH > 4... (3*)|(Tsumura & Co.)
- Mo1312...** ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED HIGH-RISK... (5*)
- Mo1313...** STUDY ON EXPANSION OF INDICATION OF... (5*)
- Mo1314...** RISK OF GENERALIZATION IN PATIENTS WITH... (5*)
- Mo1315...** DIETARY TRIGGERS IN IRRITABLE BOWEL SYNDROME... (2*)|(3)| (Companies Winclove, Ingredia, Ingredion, Nexira, Naturex, Bioiberica, Wecare, Roquette and Darling Ingredients.)
- Mo1316...** FREQUENCY AND INTENSITY OF GASTROINTESTINAL SYMPTOMS... (5*)
- Mo1317...** ASSOCIATION BETWEEN INTESTINAL LACTASE AND SYMPTOMS... (5*)
- Mo1318...** PREVALENCE OF SELF-REPORTED FOOD INTOLERANCES AMONG... (5*)
- Mo1319...** USEFULNESS OF FECAL CALPROTECTIN IN PRIMARY... (5*)
- Mo1320...** IMPACT OF HUMAN MILK OLIGOSACCHARIDES ON... (3*)|(Glycom A/S sponsored the trial)
- Mo1321...** THE UTILITY OF GLUCOSE HYDROGEN BREATH... (4*)
- Mo1322...** HUMAN MILK OLIGOSACCHARIDES IMPROVE BOWEL HABITS... (3*)|(Glycom, Inc.)
- Mo1323...** SEX-BASED DIFFERENCES IN FECAL SHORT-CHAIN FATTY... (2*)
- Mo1324...** 36 MONTH SURVEILLANCE DATA CONFIRMS SAFETY... (3*)|(IM HealthScience, LLC)
- Mo1325...** INFLAMMATORY STATUS OF POST-INFECTIOUS IRRITABLE BOWEL... (2*)
- Mo1326...** IRRITABLE BOWEL SYNDROME (IBS) SYMPTOMS AND... (4*)
- Mo1327...** ANALYSIS OF A RANGE OF ABDOMINAL... (3*)|(This study was funded by Allergan plc. Writing assistance by Complete HealthVizion, funded by Allergan plc.)
- Mo1328...** EPIDEMIOLOGY OF PSYCHIATRIC DISORDERS IN IRRITABLE... (5*)
- Mo1329...** RIFAXIMIN IS EFFICACIOUS FOR THE TREATMENT... (3*)|(Salix Pharmaceuticals)
- Mo1330...** EFFECT OF MOXIBUSTION ON SYMPTOMS AND... (2*)
- Mo1331...** LONG-TERM NATURAL HISTORY OF SYMPTOMS AND... (5*)
- Mo1332...** ASSOCIATIONS OF FOOD INTOLERANCES WITH IRRITABLE... (5*)
- Mo1333...** PHASE 1 RESULTS OF ORP-101, A... (4*)|(The studies discussed in this abstract were funded by OrphoMed, Inc.)
- Mo1334...** SEXUAL DYSFUNCTION (SXD) WORSENS QUALITY OF... (5*)
- Mo1335...** HUMAN MILK OLIGOSACCHARIDES IMPROVE SYMPTOMS OF... (3*)|(Glycom Inc)
- Mo1336...** HIGHLY SENSITIVE DIAGNOSIS OF IRRITABLE BOWEL... (6*)
- Mo1338...** A POOLED ANALYSIS OF TWO PHASE... (3*)|(Salix Pharmaceuticals)
- Mo1339...** RELATIVE ABUNDANCES OF MICROBIAL GENES INVOLVED... (2*)
- Mo1340...** MILD TRAUMATIC BRAIN INJURY CAUSED BY... (4*)
- Mo1341...** STRESS-INDUCED ACTIVATION OF CORTICOTROPIN-RELEASING HORMONE, VASOPRESSIN... (2*)
- Mo1342...** ROLE OF TOLL-LIKE RECEPTOR 5 IN... (4*)
- Mo1343...** TRANSCRIPTOMIC ANALYSIS OF LASER CAPTURE MICRODISSECTED... (4*)
- Mo1344...** DEVELOPMENT OF A NOVEL CIRCULAR RNA-BASED,... (5*)
- Mo1345...** DIABETES MELLITUS IS A RISK FACTOR... (5*)
- Mo1346...** GENETIC VARIANTS IN THE PLATELET-DERIVED GROWTH... (2*)|(As Duke Cancer Institute members, QW acknowledge support from the Duke Cancer Institute as part of the P30 Cancer Center Support Grant (Grant ID: NIH CA014236). QW was also supported by a start-up fund from Duke Cancer Institute, Duke University Medical C)
- Mo1347...** ROLE OF COMPUTED TOMOGRAPHY IN THE... (5*)
- Mo1348...** AN EARLY INSIGHT INTO GENOMIC STRUCTURAL... (4*)
- Mo1349...** 3-D MULTIPLEX HISTOLOGY OF HUMAN PANCREAS... (2*)
- Mo1350...** PREDICTORS OF FAMILY HISTORY OF PANCREATIC... (4*)
- Mo1351...** PANCREATIC STEATOSIS ON CT-IMAGING IN PATIENTS... (5*)
- Mo1352...** RECOMBINANT CO-CULTURE PANCREATIC DUCTAL ADENOCARCINOMA TUMORIDS... (5*)
- Mo1353...** RISK OF INCIDENT PANCREATIC CANCER IN... (5*)
- Mo1354...** A NOVEL E2F1-P300-VMP1 PATHWAY MEDIATES GEMCITABINE-INDUCED... (4*)
- Mo1355...** EXPERT REVIEW IDENTIFIES A HIGH PREVALENCE... (5*)
- Mo1356...** AN INSIGHT INTO FIBROGENIC STIMULANTS IN... (4*)
- Mo1357...** FEASIBILITY OF DIGITAL PCR-BASED QUANTIFICATION AND... (2*)
- Mo1358...** THE IMPACT OF SKELETAL MUSCLE MASS... (5*)
- Mo1359...** SURGICAL RESECTION IMPROVES GLUCOSE HOMEOSTASIS IN... (2*)
- Mo1360...** USAGE OF A PANEL OF BIOMARKERS... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1361... ANTI-TUMOR NECROSIS FACTOR THERAPY IS EQUIVALENT... (5*)

Mo1362... IDENTIFYING KEY FACTORS FOR THE EFFECTIVENESS... (5*)

Mo1363... BARIATRIC SURGERY DECREASES PREVALENCE OF PANCREATIC... (5*)

Mo1364... THE LONG-TERM RESEARCH OF THERAPEUTIC EFFECT... (5*)

Mo1365... RISE IN OBESITY PREVALENCE EXPLAINS THE... (5*)

Mo1366... EFFICACY OF GEMCITABINE/NAB-PACLITAXEL INDUCTION CHEMOTHERAPY FOLLOWED... (5*)

Mo1367... CLINICAL PROFILE AND OUTCOMES OF EARLY-ONSET... (5*)

Mo1368... TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY IN... (5*)

Mo1369... IDENTIFICATION OF LIPOCALIN-2 EXPRESSION BY DIGITAL... (4*)

Mo1370... PROPENSITY SCORE MATCHED ANALYSIS OF NEOADJUVANT... (5*)

Mo1371... INFLAMMATORY RESPONSE IN EXPERIMENTAL PANCREATITIS INDUCED... (2*)

Mo1372... LONG-TERM MANAGEMENT OF TYPE 1 AUTOIMMUNE... (4*)

Mo1373... HUMAN PANCREAS-ON-A-CHIP TO STUDY PRESSURE-INDUCED PANCREATITIS... (2*)

Mo1374... PIRFENIDONE IMPROVES SEQUELAE OF WELL-ESTABLISHED CHRONIC... (2*)

Mo1375... IMPAIRED LONG-CHAIN FATTY ACID METABOLISM IN... (2*)

Mo1376... ASSESSMENT OF GENE EXPRESSION PROFILE IN... (5*)

Mo1377... AMINO ACID DEPRIVATION ON PANCREATIC HEALTH:... (4*)

Mo1378... INHIBITION OF PROTEIN KINASE D ATTENUATES... (2*)

Mo1379... IMPORTANCE OF DRUGS TARGETING TO AUTOPHAGY... (5*)

Mo1380... PIRFENIDONE TREATMENT AMELIORATES THE SEVERITY OF... (2*)

Mo1381... ROLE OF IL-17A IN THE PATHOGENESIS... (2*)

Mo1382... MECHANISMS UNDERLYING THE PATHOGENESIS OF HYPOCALCEMIA... (2*)|(4)

Mo1383... IGG4-NEGATIVE SCLEROSING PANCREATITIS: A THIRD SUBTYPE... (5*)

Mo1384... PREVALENCE OF ACUTE AND CHRONIC PANCREATITIS... (5*)

Mo1385... SLC9A8 ATTENUATES ACUTE PANCREATITIS THROUGH INHIBITING... (5*)

Mo1386... IS HYPERTHYROIDISM ASSOCIATED WITH INCIDENCE OF... (5*)

Mo1387... TARGETING NUCLEAR RECEPTOR NR5A2 IMPROVES EXOCRINE,... (4*)

Mo1388... CLINICAL CHARACTERISTICS OF PATIENTS WITH ATEZOLIZUMAB... (5*)

Mo1389... ACUTE KIDNEY INJURY IS AN INDEPENDENT... (5*)

Mo1390... ELECTIVE ENDOTRACHEAL INTUBATION PRIOR TO EGD... (5*)

Mo1391... ROLE OF ENDOSCOPIC EVALUATION PRIOR TO... (5*)

Mo1427... NOVEL METABOLOMIC PREDICTORS OF INCIDENT SYMPTOMATIC... (2*)

Mo1428... THE NEUTROPHIL PROPORTION AMONG WHITE BLOOD... (5*)

Mo1429... CLINICAL EPIDEMIOLOGY OF CHOLEDOCOLITHIASIS: EXAMINING THE... (5*)

Mo1430... SINGLE AND REPETITIVE PERCUTANEOUS GALLBLADDER ASPIRATION... (5*)

Mo1431... URINASTATIN VERSUS NAFAMOSTAT MESYLATE IN THE... (5*)

Mo1432... PROTON PUMP INHIBITOR (PPI) USE IS... (5*)

Mo1433... IS REPEAT ERCP REQUIRED AFTER INITIAL... (5*)

Mo1434... WHICH IS THE DETERMINING FACTOR... (5*)

Mo1435... LITHOLYTIC AGENTS AS AN ALTERNATIVE TREATMENT... (5*)

Mo1436... GALLSTONE DISEASE IN PATIENTS WITH NON-ALCOHOLIC... (5*)

Mo1437... EFFECT OF BILE ACID COMPOSITION ON... (2*)|(This research is financially supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant no. NRF-2017R1D1A1B03034172))

Mo1438... URINE AND SERUM METABOLOMIC PROFILES DISCRIMINATE... (4*)

Mo1439... IMPAIRED BILE SECRETION PROMOTES SICKLE CELL... (6*)

Mo1440... ASSOCIATION BETWEEN ATAZANAVIR-INDUCED HYPERBILIRUBINEMIA AND CARDIOVASCULAR... (5*)

Mo1441... COMPARISON OF OUTCOMES OF TREATMENT WITH... (5*)

Mo1442... HEPATITIS C PREVALENCE IN CABELL COUNTY,... (5*)

Mo1443... MOBILE FOOD TRUCK LICENSES AS A... (5*)

Mo1444... CHARACTERIZATION OF PATIENTS WITH CHRONIC HEPATITIS... (5*)

Mo1519... PREVALENCE OF AND RISK FACTORS FOR... (5*)

Mo1521... DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS—CONSTIPATION:... (3*)|(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc. Editorial assistance by Complete HealthVizion, funded by Allergan plc and Ironwood Pharmaceuticals, Inc.)

Mo1522... THE EFFICACY OF ELOBIXIBAT AS AN... (5*)

Mo1523... PREDICTORS OF NAUSEA SEVERITY IN CHILDREN... (5*)

Mo1524... PAIN TREATMENT EFFICACY IN PATIENTS WITH... (5*)

Mo1525... LONG TERM FOLLOW UP OF CYCLIC... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1526. . . . PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE... (5*)**
- Mo1527. . . . ASSESSMENT OF RESPONSE TO THERAPY IN... (4*)**
- Mo1528. . . . HIGH RATE OF CONCORDANCE BETWEEN PHYSICIANS... (5*)**
- Mo1529. . . . MALABSORPTIVE BARIATRIC SURGERY AND IBS, LOW... (5*)**
- Mo1530. . . . GENDER DIFFERENCES IN PATIENTS WITH SYSTEMIC... (5*)**
- Mo1532. . . . FUNCTIONAL GASTROINTESTINAL SYMPTOMS COMMON AND FREQUENTLY ... (5*)**
- Mo1533. . . . VOLATOMICS IN INFLAMMATORY BOWEL DISEASE AND... (2*)|(4)**
- Mo1534. . . . PREVALENCE OF METHANE POSITIVE SMALL INTESTINAL... (5*)**
- Mo1535. . . . INTERNET SURVEY ON LAXATIVE USE BY... (3*)|(EA Pharma Co. Ltd)**
- Mo1536. . . . FUNCTIONAL DYSPEPSIA, PEPTIC ULCER AND HELICOBACTER... (2*)|(6)**
- Mo1537. . . . MULTICENTRIC OBSERVATIONAL STUDY TO DETERMINE DUODENAL... (4*)**
- Mo1538. . . . EQUATING SCORES OF THE FUNCTIONAL DIGESTIVE... (2*)**
- Mo1539. . . . THIRTY DAY UNPLANNED READMISSIONS FOR CYCLICAL... (5*)**
- Mo1540. . . . THE EFFICACY AND SAFETY OF GCWB104... (4*)**
- Mo1541. . . . INTEGRATING PSYCHOLOGICAL SCREENING INTO MEDICAL CARE... (5*)**
- Mo1542. . . . DUODENAL EOSINOPHILS ACTIVITY IN DYSPEPSIA: ONLY... (5*)**
- Mo1543. . . . A DOUBLE-EDGED SWORD? #NAME? PERIPHERAL MECHANISM... (5*)**
- Mo1544. . . . IS SMALL INTESTINAL DYSBIOSIS (SIBO) RELATED... (5*)**
- Mo1545. . . . DISTINCT TREATMENT CHOICES BETWEEN PRIMARY CARE... (3*)|(Xian Janssen Pharmaceutical Ltd)**
- Mo1546. . . . DYSPEPSIA SYMPTOMS IN FUNCTIONAL DYSPEPSIA (FD)... (4*)**
- Mo1547. . . . LHMBT POSITIVE IBS-D PATIENTS PRESENTED A... (2*)**
- Mo1548. . . . REEVALUATION OF THE CARDIOVASCULAR SAFETY PROFILE... (3*)|(Alfasigma USA)**
- Mo1549. . . . CHARACTERISTICS AND PREDICTIVE MODELING OF POST-INFECTION... (2*)|(Supported by NIH K23 DK 103911 and R03 120745.)**
- Mo1550. . . . A NOVEL SCORE TO EVALUATE ABDOMINAL... (3*)|(This study was funded by Allergan plc and Ironwood Pharmaceuticals, Inc.)**
- Mo1551. . . . PSYLLIUM REDUCES COLONIC HYDROGEN PRODUCTION FOLLOWING... (2*)**
- Mo1552. . . . AN ANALYSIS OF PLACEBO RATE AND... (6*)**
- Mo1553. . . . EVALUATION OF SENSORY SENSITIVITY AND SOMATIC... (5*)**
- Mo1555. . . . BILE ACID MALABSORPTION: AN OVERLOOKED DIAGNOSIS... (5*)**
- Mo1556. . . . PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY IN... (3*)|(Abbott Laboratories)**
- Mo1557. . . . FACTORS AFFECTING CENTRAL NEUROMODULATOR USE BY... (4*)**
- Mo1558. . . . PREVALENCE OF FIRST-EVER DIAGNOSIS OF IRRITABLE... (5*)**
- Mo1559. . . . QUANTITATIVE ASSESSMENT OF THE BIDIRECTIONAL RELATIONSHIP ... (5*)**
- Mo1560. . . . CANNABIS USE IS ASSOCIATED WITH REDUCED... (5*)**
- Mo1561. . . . THE EFFECT OF LONG-ACTING MESALAMINE OF... (3*)|(Supported in part by grants from Shire Pharmaceuticals and the Department of Defense)**
- Mo1562. . . . ECONOMIC AND SOCIAL BURDEN OF IRRITABLE... (5*)**
- Mo1563. . . . DISCRIMINATING BETWEEN PATIENTS WITH IRRITABLE BOWEL... (2*)|(4)**
- Mo1564. . . . THE CLINICAL OUTCOMES OF CLOSTRIDIUM DIFFICILE... (5*)**
- Mo1565. . . . MUCOSAL SEROTONIN REUPTAKE TRANSPORTER (SERT) EXPRESSION... (2*)**
- Mo1566. . . . ANTI-VINCULIN AND ANTI-CYTOLETHAL DISTENDING TOXIN B... (6*)**
- Mo1567. . . . DIFFERENCES IN BRAIN STRUCTURE PREDICT SYMPTOM... (2*)**
- Mo1569. . . . IDENTIFICATION OF COLONIC MUCOSAL MICRORNAS ALTERED... (4*)|(2)**
- Mo1570. . . . THE INTESTINAL MICROBIOTA FROM A PATIENT ... (4*)**
- Mo1571. . . . INTRARECTAL ADMINISTRATION OF A TRPV4 ANTAGONIST ... (4*)**
- Mo1572. . . . MUCOSA-ASSOCIATED INTESTINAL MICROBIOTA AND SERUM CYTOKINES... (2*)**
- Mo1573. . . . IRRITABLE BOWEL SYNDROME WITH DIARRHEA IS... (5*)**
- Mo1574. . . . DIFFERENTIAL MRNA EXPRESSION IN ILEAL MUCOSAL... (2*)**
- Mo1575. . . . RELATIONSHIPS OF SHORT CHAIN FATTY ACIDS... (2*)**
- Mo1576. . . . DETERMINANTS OF RENTENTION IN CARE AFTER... (5*)**
- Mo1577. . . . BRIEF BEHAVIORAL THERAPY FOR INSOMNIA IN... (6*)**
- Mo1578. . . . INDIVIDUALS WITH IBS REPORT HIGH RATES... (5*)**
- Mo1579. . . . I JUST FEEL LIKE AN OUTCAST: STIGMA EXPERIENCES OF PATIENTS LIVING... (4*)**
- Mo1580. . . . GASTROENTEROLOGISTS' PRESCRIBING PATTERNS AND COMFORT-LEVEL VARY ... (5*)**
- Mo1581. . . . CHARACTERIZATION OF COGNITIVE FLEXIBILITY IN ESOPHAGEAL... (2*)**
- Mo1582. . . . IS THERE AN ASSOCIATION BETWEEN IMPROVEMENT... (2*)**
- Mo1583. . . . HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: THE... (5*)**
- Mo1584. . . . DO I REALLY HAVE TO DO... (2*)**
- Mo1585. . . . FACTORS ASSOCIATED WITH EFFICACY OF COGNITIVE... (2*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1586... TREATMENT EXPECTANCY FOR GI SYMPTOM IMPROVEMENT... (2*)

Mo1587... PSYCHOPHYSIOLOGICAL CORRELATES OF ESOPHAGEAL HYPERVIGILANCE: BUILDING... (2*)

Mo1588... POST-TRAUMATIC STRESS DISORDER IS PREVALENT AND... (5*)

Mo1589... HYPERACTIVITY AND AGGRESSION ARE ASSOCIATED WITH... (2*)

Mo1590... TRANSIENT EXPOSURE TO ENVIRONMENTAL ENRICHMENT PRODUCES... (2*)

Mo1591... GUT-FOCUSED HYPNOTHERAPY FOR CHILDREN AND ADOLESCENTS... (5*)

Mo1592... GREATER RISK FOR ADVERSE HOSPITALIZATION OUTCOMES... (5*)

Mo1593... KNOWLEDGE AND ATTITUDES OF DISCONTINUING COLON... (4*)

Mo1594... WHICH GUIDELINE TO FOLLOW? A NATIONAL... (4*)

Mo1595... COLORECTAL CANCER SCREENING AMONG AMERICAN ADULTS... (5*)

Mo1596... BASELINE FECAL HEMOGLOBIN CONCENTRATION IS AN... (5*)

Mo1597... COLORECTAL CANCER SCREENING AND YIELD IN... (2*)

Mo1598... ESTIMATING THE IMPACT OF IMPERFECT ADHERENCE... (3*)|(2)|(Exact Sciences)

Mo1599... HIGH-RISK SERRATED LESION DETECTION AT CRC... (5*)

Mo1600... HOSPITAL LEVEL POLYPECTOMY RATE WITHIN THE... (2*)

Mo1601... TRENDS IN COLORECTAL CANCER SCREENING COMPLETION:... (3*)|(2)|(Exact Sciences Corporation, Madison, WI)

Mo1602... INTERNATIONAL SURVEY OF INTERVAL CANCER AUDIT... (5*)

Mo1603... ADENOMA AND ADVANCED ADENOMA DETECTION RATE... (2*)|(7)

Mo1604... COLONOSCOPY FINDINGS FOLLOWING A FECAL IMMUNOCHEMICAL... (5*)

Mo1605... OLDER ADULTS TOLERANCE OF COLONOSCOPY AND... (4*)

Mo1606... EXERCISE IS ASSOCIATED WITH LOWER RISK... (5*)

Mo1607... INFLUENCE OF MASCULINITY ON COLORECTAL CANCER... (4*)

Mo1608... PERCEPTIONS AND BARRIERS TO COLORECTAL CANCER... (4*)

Mo1609... HIV PATIENTS WITH LOW CD4 COUNTS... (5*)

Mo1610... THE ASSOCIATION OF PATIENTS' PERCEPTION OF... (5*)

Mo1611... PATIENT NAVIGATION AFTER POSITIVE FECAL IMMUNOCHEMICAL... (5*)

Mo1612... COLORECTAL CANCER SCREENING OUTREACH PROGRAMS USING... (2*)

Mo1613... IDENTIFYING BARRIERS TO ADHERENCE TO SURVEILLANCE... (5*)

Mo1614... POST-OPERATIVE HOSPITAL OUTCOMES OF ELECTIVE SURGERY... (5*)

Mo1615... POTENTIAL CLINICAL UTILITY OF SNP-BASED POLYGENIC... (5*)

Mo1616... OPTIMAL SMALL POLYP (6-9 MM) RESECTION... (5*)

Mo1617... WHERE ARE WE TODAY? EFFORTS TO... (5*)

Mo1618... THE USE OF A QUICK AND... (5*)

Mo1619... THE SAFETY AND POLYP DETECTION RATE... (5*)

Mo1620... AGE, NOT GENDER, AFFECTS PATIENT COMPLIANCE... (5*)

Mo1785... INCREASED FECAL BILE ACID EXCRETION IN... (2*)

Mo1786... ELEVATED BREATH METHANE ON LACTULOSE BREATH... (4*)

Mo1787... OUTCOMES OF LOWER DOSING OF BUDESONIDE... (5*)

Mo1788... THE DIAGNOSIS OF CARBOHYDRATE MALABSORPTION BY... (5*)

Mo1789... A COMPARISON OF LACTULOSE BREATH TESTS... (5*)

Mo1790... CLINICAL UTILITY AND DIAGNOSTIC YIELD OF... (5*)

Mo1791... APPLICATION OF NORTH AMERICAN CONSENSUS CRITERIA... (1*)

Mo1792... EFFECTS OF SHORT-TERM PPI INTAKE ON... (5*)

Mo1793... ROBUSTNESS OF IBD DISABILITY INDEX (IBDDI)... (5*)

Mo1794... FECAL MICROBIOTA TRANSPLANTATION FOR C. DIFFICILE... (5*)

Mo1795... FRAILITY IS ASSOCIATED WITH NATIONWIDE READMISSION... (5*)

Mo1796... TUMOR NECROSIS FACTOR ANTAGONISTS ARE SUPERIOR... (5*)

Mo1797... LOSS OF SATB2 EXPRESSION IN COLORECTAL... (4*)

Mo1798... ACTIVE INFLAMMATORY BOWEL DISEASE, PARTICULARLY FISTULIZING... (5*)

Mo1799... THE ROLE OF ACOUSTIC RADIATION FORCE... (5*)

Mo1800... INFLAMMATORY BOWEL DISEASE AND LUNG CANCER... (5*)

Mo1801... DISEASE BURDEN AND OUTCOMES OF INFLAMMATORY... (5*)

Mo1802... HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH... (5*)

Mo1803... CLOSTRIDIODES DIFFICILE INFECTION IS NOT ASSOCIATED... (5*)

Mo1804... PRE-ADMISSION CANNABIS USE IS POSITIVELY CORRELATED... (5*)

Mo1805... CROHN'S DISEASE PHENOTYPE AND ACTIVITY ARE... (5*)

Mo1806... CIRCULATING LEVELS OF VITAMIN D BINDING... (3*)|(Immunodiagnostik AG)

Mo1807... EVALUATION AND COMPARISON OF SAFETY CHARACTERISTICS... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Mo1808. . . . CHROMOENDOSCOPY AND HIGH DEFINITION WHITE LIGHT... (5*)

Mo1809. . . . RISK FACTORS AND TREATMENT OUTCOMES OF... (5*)

Mo1810. . . . EOSINOPHILIA ON PATHOLOGY PREDICTS LOWER INFLIXIMAB... (5*)

Mo1811. . . . REAL-WORLD CLINICAL OUTCOMES OF BIOLOGIC-NAÏVE NON-COMPLICATED... (3*)|(Takeda Pharmaceuticals Company Ltd.)

Mo1812. . . . THE BURDEN OF VACCINE-PREVENTABLE INFECTIONS IN... (5*)

Mo1813. . . . THROMBOEMBOLIC EVENTS IN HOSPITALIZED PATIENTS WITH... (5*)

Mo1814. . . . THROMBOEMBOLIC EVENTS IN HOSPITALIZED PATIENTS WITH... (5*)

Mo1815. . . . FECAL INCONTINENCE IS COMMON IN... (5*)

Mo1816. . . . NEOPLASTIC LESIONS OUTSIDE DISEASED AREA IN... (5*)

Mo1817. . . . PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE... (5*)

Mo1818. . . . COLORECTAL NEOPLASIA RISK IN PATIENTS WITH... (5*)

Mo1819. . . . USE OF ANTI-TNF AGENTS MAY REDUCE... (5*)

Mo1820. . . . CHARACTERIZATION OF SPERM IN PATIENTS WITH... (4*)

Mo1821. . . . OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL... (5*)

Mo1822. . . . INCREASING ANEMIA SEVERITY IN IBD PATIENTS... (5*)

Mo1823. . . . BURDEN OF NEPHROLITHIASIS IN INFLAMMATORY BOWEL... (2*)

Mo1824. . . . A STUDY ON THE ASSOCIATION BETWEEN... (5*)

Mo1825. . . . THE BURDEN OF ANEMIA REMAINS SIGNIFICANT... (4*)

Mo1826. . . . THE IMPACT OF TOTAL COLECTOMY ON... (2*)

Mo1827. . . . INCREASING FREQUENCY IN THE DIAGNOSIS AND... (5*)

Mo1828. . . . THE EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASES... (4*)

Mo1829. . . . HISTOLOGICAL REMISSION DOSE NOT OFFER ADDITIONAL... (5*)

Mo1830. . . . INCREASED PREVALENCE BUT NOT INCIDENCE OF... (5*)

Mo1831. . . . UCEIS IS ASSOCIATED WITH PRO2, PARTIAL... (5*)

Mo1832. . . . PATIENT REPORTED OUTCOMES, PARTIAL MAYO SCORE... (5*)

Mo1833. . . . HIGH BURDEN OF OBESITY AND RELATED... (5*)

Mo1834. . . . DERMATOLOGIC MANIFESTATIONS OF INFLAMMATORY BOWEL... (5*)

Mo1835. . . . PREVALENCE OF OCULAR DISEASES IN INFLAMMATORY... (5*)

Mo1836. . . . IMPACT OF THERAPEUTIC STRATEGIES ON INTESTINAL... (4*)

Mo1837. . . . LINK BETWEEN CELIAC DISEASE AND INFLAMMATORY... (5*)

Mo1838. . . . EPIDEMIOLOGY AND RISK OF INFLAMMATORY BOWEL... (5*)

Mo1839. . . . TRENDS AND OUTCOMES OF HIP FRACTURE... (5*)

Mo1840. . . . COMPUTED TOMOGRAPHY CONTINUES TO BE A... (5*)

Mo1841. . . . ONE-YEAR RISK OF OPIOID ADDICTION AFTER... (5*)

Mo1842. . . . IBD IS ASSOCIATED WITH INCREASED RISK... (5*)

Mo1843. . . . CREATION OF A NOVEL CASE-FINDING DEFINITION... (6*)

Mo1844. . . . TRENDS IN THE MEDICAL MANAGEMENT OF... (5*)

Mo1845. . . . ASSOCIATION OF COMPLICATED DIVERTICULITIS WITH SUBSEQUENT... (5*)

Mo1846. . . . NON-ALCOHOLIC FATTY LIVER DISEASE PREVALENCE AND... (5*)

Mo1847. . . . LONG-TERM PROGNOSIS OF CROHN'S DISEASE AND... (2*)|(3)|(This work was partially supported by a Korean Health Technology R&D Project grant from the Korea Health Industry Development Institute to Suk-Kyun Yang (A120176), funded by the Ministry of

Abstract Funding Source Key

* = Primary Source

Health & Welfare; and by a research grant from Janssen Korea.)

Mo1848. . . . CAPSAICIN CONTRIBUTES TO DISEASE RELAPSE IN... (2*)|(4)

Mo1849. . . . IMMUNE STATUS TO VIRAL INFECTIOUS DISEASES... (5*)

Mo1850. . . . HIGH PREVALENCE OF MALNUTRITION IN INDIAN... (5*)

Mo1851. . . . POPULATION-BASED ESTIMATES FOR INFLAMMATORY BOWEL DISEASE... (5*)

Mo1852. . . . DIFFERENCES IN CLINICAL CHARACTERISTICS AND OUTCOMES... (2*)

Mo1853. . . . RATES OF PERFORATION IN PATIENTS WITH... (5*)

Mo1854. . . . IMAGING UTILIZATION IN PEDIATRIC INFLAMMATORY BOWEL... (5*)

Mo1855. . . . SMOKING IN AFRICAN AMERICANS RESULTS IN... (2*)

Mo1856. . . . EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE... (5*)

Mo1857. . . . A PHASE II OPEN LABEL STUDY... (3*)|(AbGenomics International Inc.)

Mo1858. . . . ENDOSCOPIC AND HISTOLOGIC OUTCOME IN TOFACITINIB... (5*)

Mo1859. . . . CLINICAL, SEROLOGIC, AND GENOMIC PREDICTORS OF... (2*)|(4)

Mo1860. . . . REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN... (5*)

Mo1861. . . . TRANSMURAL HEALING IN PATIENTS WITH CROHN'S... (5*)

Mo1862. . . . HIGH RATE OF LOSS OF RESPONSE... (5*)

Mo1864. . . . ILEAL AND RECTAL ULCER SIZE IMPACTS... (5*)

Mo1865. . . . WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS... (5*)

Mo1866. . . . USING CLINICAL ROUTINE DATA TO PREDICT... (5*)

Mo1867. . . . ITALIAN REAL-LIFE STUDY EVALUATING THE LONG... (3*)|(Takeda)

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1868. . . . EFFICACY AND SAFETY OF SIMULTANEOUS TREATMENT... (5*)**
- Mo1869. . . . EFFICACY OF DOSE INTENSIFICATION OF USTEKINUMAB... (5*)**
- Mo1870. . . . ASSESSMENT OF BODY WEIGHT CHANGES IN... (4*)**
- Mo1871. . . . VEDOLIZUMAB TREATMENT IN PATIENTS WITH REFRACTORY... (5*)**
- Mo1872. . . . SAFETY AND CLINICAL EFFICACY OF DOUBLE... (5*)**
- Mo1873. . . . WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE... (5*)**
- Mo1874. . . . BLOOD T CELL FREQUENCIES PREDICT AND... (4*)**
- Mo1875. . . . EVALUATION OF BIOLOGIC TREATMENT PATTERNS AMONG... (3*)**(Janssen Scientific Affairs, LLC)
- Mo1876. . . . TREATMENT PERSISTENCE AND MAINTENANCE DOSING FOR... (3*)**(Study sponsored by: Janssen Scientific Affairs, LLC, Horsham, PA, USA)
- Mo1879. . . . DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE (IBD)... (5*)**
- Mo1880. . . . USTEKINUMAB DOSE ESCALATION EFFECTIVE IN REAL-WORLD... (5*)**
- Mo1881. . . . USTEKINUMAB TROUGH LEVEL PREDICTS REMISSION AND... (1*)**(6)
- Mo1882. . . . EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN... (5*)**
- Mo1883. . . . REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS... (3*)**(Takeda)
- Mo1884. . . . PREDICTORS OF VEDOLIZUMAB TREATMENT PERSISTENCE IN... (5*)**
- Mo1885. . . . VEDOLIZUMAB - PERIOPERATIVE INFECTION RATES IN... (5*)**
- Mo1886. . . . REAL-WORLD EFFECTIVENESS OF VEDOLIZUMAB IN CROHN'S... (3*)**(The study was financially supported by Takeda.)
- Mo1887. . . . IMPACT OF TUMOR NECROSIS FACTOR ALPHA... (2*)**(4)
- Mo1888. . . . DECODING DELAYS IN BIOLOGIC AND SMALL... (6*)**
- Mo1889. . . . CORRELATION OF EARLY INFLIXIMAB LEVELS WITH... (3*)**(Janssen Scientific Affairs, LLC)
- Mo1890. . . . VEDOLIZUMAB DOSE ESCALATION IMPROVES DISEASE ACTIVITY... (5*)**
- Mo1891. . . . QUALITY OF TRANSITION CARE IN PEDIATRIC... (5*)**
- Mo1892. . . . PREDICTING SUB-OPTIMAL TRANSITIONS IN ADOLESCENTS WITH... (5*)**
- Mo1893. . . . PHENOTYPE AND OUTCOME OF INFLAMMATORY BOWEL... (4*)**
- Mo1894. . . . APPROACH TO TRANSGENDER AND GENDER NON-CONFORMING... (5*)**
- Mo1895. . . . POPULATION PHARMACOKINETIC BAYESIAN ESTIMATES AND VEDOLIZUMAB... (2*)**(4)
- Mo1896. . . . INFLIXIMAB SERUM LEVELS DURING INDUCTION PREDICT... (3*)**(KvH has received a research grant from Mundipharma Comm. VA and Celltrion Healthcare Co.)
- Mo1897. . . . TOTAL ABDOMINAL COLECTOMIES WITH PROCTECTOMY ARE... (4*)**
- Mo1898. . . . LOW RISK OF LYMPHOMA IN PEDIATRIC... (2*)**
- Mo1899. . . . SEX DIFFERENCES IN STATURAL GROWTH IMPAIRMENT... (2*)**(6)
- Mo1900. . . . THE INCIDENCE AND CHARACTERISTICS OF VENOUS... (2*)**
- Mo1901. . . . CHILDREN WITH INFLAMMATORY BOWEL DISEASE EXPERIENCE... (4*)**
- Mo1902. . . . NON-MONOGENIC VERY EARLY ONSET INFLAMMATORY BOWEL... (5*)**
- Mo1903. . . . HIGH RATES OF SURGERY PERSIST FOR... (5*)**
- Mo1904. . . . INSURANCE TYPE INFLUENCES INFLIXIMAB INITIATION TIME... (5*)**
- Mo1905. . . . THE ASSOCIATION BETWEEN HIRSCHSPRUNG'S DISEASE AND... (5*)**
- Mo1906. . . . FEASIBILITY OF THE FIRST PAEDIATRIC RANDOMIZED... (4*)**(3)(Rebiotix Inc. supplied the fecal transplant product for this study.)
- Mo1907. . . . REAL WORLD EXPERIENCE WITH USTEKINUMAB IN... (5*)**
- Mo1908. . . . INFLIXIMAB TREATMENT FAILURE IN CHILDREN WITH... (5*)**
- Mo1909. . . . EVALUATION OF NON-ALCOHOLIC FATTY LIVER DISEASE... (5*)**
- Mo1910. . . . SAFETY AND EFFICACY OF SUPRATHERAPEUTIC SERUM... (5*)**
- Mo1911. . . . NORMALISATION OF STOOL CALPROTECTIN- IS IT... (5*)**
- Mo1912. . . . RISK OF CANCERS IN PEDIATRIC INFLAMMATORY... (5*)**
- Mo1913. . . . MICROBIOTA-MODIFYING DRUG CSA13-DEPENDENT FECAL METABOLITES EXERT... (2*)**(3)(Merck)
- Mo1914. . . . SUPERIOR EFFICACY OF HIGHER VOLUME FRESH... (5*)**
- Mo1915. . . . IT IS NOT COST EFFECTIVE TO... (5*)**
- Mo1916. . . . RISING TEMPORAL TRENDS IN THE PREVALENCE... (5*)**
- Mo1917. . . . CLINICAL BURDEN OF RECURRENT CLOSTRIDIODES DIFFICILE... (3*)**(Ferring Pharmaceuticals Inc.)
- Mo1918. . . . VALIDATION OF A PREDICTIVE SCORING TOOL... (5*)**
- Mo1919. . . . BOWEL ANASTOMOSIS IS ASSOCIATED WITH... (5*)**
- Mo1920. . . . EPIDEMIOLOGY AND TREND ANALYSIS OF CLOSTRIDIODES... (5*)**
- Mo1921. . . . COMPARATIVE RISK OF CLOSTRIDIUM DIFFICILE INFECTION... (5*)**
- Mo1922. . . . ROLE OF SERUM PROCALCITONIN IN PREDICTING... (5*)**
- Mo1923. . . . RELATIONSHIP BETWEEN ILEOCECAL RESECTION AND POSTOPERATIVE... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Mo1924. . . . DIFFERENCES IN THE FECAL MICROBIOME AND... (4*)**
- Mo1925. . . . THE IMPACT OF APPENDECTOMY IN... (5*)**
- Mo1926. . . . PROBIOTICS FOR THE PREVENTION OF CLOSTRIDIUM... (5*)**
- Mo1927. . . . CLOSTRIDIOIDES DIFFICILE RIBOTYPE AS A PREDICTOR... (5*)**
- Mo1928. . . . ARE PATIENTS WITH ALTERED BILE ACID... (5*)**
- Mo1929. . . . ORALLY ADMINISTERED LYOPHILIZED FECAL MICROBIOTA TRANSPLANTATION... (4*)**
- Mo1930. . . . THE DONOR DOES NOT MATTER IN... (3*)**[(This analysis was funded by Rebiotix Inc. (Roseville, MN, USA))]
- Mo1931. . . . FAILURE IS NOT FINAL: CLINICAL RESPONSE... (3*)**[(This analysis was funded by Rebiotix Inc. (Roseville, MN).)]
- Mo1932. . . . CRITICAL ROLE FOR TOXIN ACTIVATING CLOSTRIDIUM... (4*)**
- Mo1933. . . . USE OF PROTON PUMP INHIBITORS DOES... (5*)**
- Mo1934. . . . IS CELIAC DISEASE ASSOCIATED WITH WORSE... (5*)**
- Mo1935. . . . IDENTIFYING BARRIERS AMONG PRIMARY CARE PHYSICIANS... (5*)**
- Mo1936. . . . CLOSTRIDIOIDES DIFFICILE INFECTION IN PATIENTS WITH... (5*)**
- Mo1937. . . . ACID-SUPPRESIVE THERAPY AS A RISK FACTOR... (5*)**
- Mo1938. . . . SEQUENTIAL FECAL MICROBIOTA TRANSPLANTATION FOR FULMINANT... (5*)**
- Mo1939. . . . TEMPORAL MODULATION OF TCR REPERTOIRE FOLLOWING... (4*)**[(2)]
- Mo1940. . . . TRENDS IN CLOSTRIDIUM DIFFICILE INFECTION INCIDENCE... (5*)**
- Mo1941. . . . CLOSTRIDIUM DIFFICILE INFECTION AS A CAUSE... (5*)**
- Mo1942. . . . OUTCOMES OF CLOSTRIDIOIDES DIFFICILE INFECTION IN... (5*)**
- Mo1943. . . . SEQUENTIAL FECAL MICROBIOTA TRANSPLANT BY ENEMA... (2*)**[(4)](MERCK Pharmaceuticals provided the fidaxomicin for this research for free. No other contributions were made.)
- Mo1944. . . . COMPARING TREATMENT OUTCOMES BETWEEN OPENBIOME FROZEN... (4*)**
- Mo1945. . . . EFFICACY AND SAFETY OF FECAL MICROBIOTA... (5*)**
- Mo1946. . . . ASSOCIATION OF FECAL CALPROTECTIN AND RECURRENCE... (4*)**
- Mo1947. . . . DETECTION OF NON - TOXIGENIC CLOSTRIDIOIDES... (5*)**
- Mo1948. . . . OUTCOMES OF INPATIENT FECAL TRANSPLANT ADMINISTRATION... (2*)**
- Mo1949. . . . ONE AND DONE? EVALUATION OF EFFICACY... (3*)**[(Rebiotix Inc.)]
- Mo1950. . . . HETEROGENEITY OF RANDOMIZED CONTROLLED TRIALS OF... (3*)**[(Ferring Pharmaceuticals)]
- Mo1951. . . . REPORTING OF RANDOMIZED CONTROLLED TRIAL METHODOLOGICAL... (3*)**[(Ferring)]
- Mo1952. . . . PATIENT SEX DOES NOT IMPACT EFFICACY... (5*)**
- Mo1953. . . . METAGENOMIC ANALYSIS OF HUMAN FECAL VIROME... (2*)**
- Mo1954. . . . ANAEROBIC FECAL MICROBIOTA TRANSPLANTATION PREPARATIONS ARE... (5*)**
- Mo1955. . . . HIGH STRESS REACTIVITY IS ASSOCIATED WITH... (6*)**[(2)]
- Mo1956. . . . ASSOCIATION OF FECAL MICROBIOME WITH RESILIENCE... (2*)**
- Mo1957. . . . LACTOBACILLUS RHAMNOSUS GG COLONIZATION IN EARLY... (2*)**
- Mo1958. . . . UTILITY OF A CONSUMER-FRIENDLY PORTABLE HYDROGEN... (3*)**[(GOS-based prebiotic provided for free from manufacturer (FrieslandCampina).)]
- Mo1959. . . . COMPARISON OF TWO READY-TO-USESUPPLEMENTARY FOODS (RUSF)... (6*)**[(3)](Arla Foods and the Danish Dairy Research Foundation)
- Mo1960. . . . EFFECT OF FIBER, OSMOLARITY, AND PROTEIN... (2*)**
- Mo1961. . . . CLINICAL EXPERIENCE OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY... (5*)**
- Mo1962. . . . COMBINATION OF PUREED DIET CONTAINING GELLING... (5*)**
- Mo1964. . . . SEX DIFFERENCES IN DIETARY COPPER-FRUCTOSE INTERACTION-INDUCED... (2*)**
- Mo1965. . . . EFFECTS OF ESTROGEN ON THE EXPRESSION... (2*)**[(National Natural Science Foundation of China (NSFC))]
- Mo1966. . . . COMMD10 REGULATES ADIPOSE TISSUE MACROPHAGE CONTROL... (6*)**
- Mo1967. . . . CRANBERRY PROANTHOCYANIDINS ATTENUATE METABOLIC DISORDERS, INCLUDING... (2*)**[(4)]
- Mo1968. . . . MECHANISM UNDERLYING STIMULATION OF APICAL BOAT1... (2*)**
- Mo1969. . . . OBESITY-INDUCED STIMULATION OF INTESTINAL VILLUS CELL... (2*)**
- Mo1970. . . . UNIQUE MECHANISM OF STIMULATION OF GLUCOSE... (2*)**
- Mo1971. . . . PHARMACOTHERAPY FOR OBESITY – TRENDS USING... (5*)**
- Mo1972. . . . CLASS II+III OBESITY IS AN INDEPENDANT... (5*)**
- Mo1973. . . . ECTOPIC FAT ACCUMULATION IN THE LIVER... (2*)**
- Mo1974. . . . WEIGHT REGAIN FOLLOWING BARIATRIC SURGERY: A... (5*)**
- Mo1975. . . . IMPACT OF BARIATRIC SURGERY ON ESOPHAGEAL... (5*)**
- Mo1976. . . . UPPER GI SYMPTOMS IN PATIENTS POST-BARIATRIC... (5*)**
- Mo1977. . . . THE RELATIONSHIP BETWEEN VISUAL PROCESSING IMPAIRMENTS... (5*)**
- Mo1978. . . . EFFECT OF WEIGHT LOSS ON RETINOCHOROIDAL... (5*)**
- Tu1000. . . . APPROPRIATENESS OF PROTON PUMP INHIBITORS AFTER... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1001. . . OUTCOMES OF A PROTON PUMP INHIBITOR... (5*)

Tu1002. . . PROTON PUMP INHIBITOR (PPI) PRESCRIBING PATTERNS... (5*)

Tu1003. . . LONG TERM USE OF PPI'S DOES... (5*)

Tu1004. . . PROVINCIAL PRESCRIBING DATA OF PROTON PUMP... (2*)

Tu1005. . . USE OF PROTON-PUMP INHIBITORS DURING ANTI-COAGULATION... (3*)|(Daiichi Sankyo Co., Ltd.)

Tu1006. . . THE ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE... (5*)

Tu1007. . . WORLDWIDE INCIDENCE AND PREVALENCE OF METABOLIC... (4*)

Tu1008. . . A META-ANALYSIS OF THE VALUE OF... (5*)

Tu1009. . . CONTAMINATION RATE OF REUSABLE PATIENT-READY DUODENOSCOPES... (5*)

Tu1010. . . HIGHER ADULT-ATTAINED HEIGHT IS AN INDEPENDENT... (4*)

Tu1011. . . MYTHS ABOUT OBSTRUCTIVE SLEEP APNEA DEBUNKED:... (5*)

Tu1012. . . INSURANCE STATUS AND LEVEL OF EDUCATION... (5*)

Tu1013. . . YOUNGER PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA HAVE... (5*)

Tu1014. . . MODULATION OF THE POSITIVE ASSOCIATION BETWEEN... (4*)

Tu1015. . . GASTRIC ADENOMA INCREASES THE RISK FOR... (5*)

Tu1016. . . OCCURRENCE OF ESOPHAGEAL ADENOCARCINOMA IN THE... (3*)

Tu1017. . . RISK FACTORS IN THE DEVELOPMENT OF... (2*)

Tu1018. . . INCIDENCE AND MORTALITY RATES OF APPENDICEAL... (5*)

Tu1183. . . CHARACTERISTICS OF 30-DAY ALL CAUSE READMISSIONS... (5*)

Tu1184. . . GASTROENTEROLOGISTS AND INFECTIOUS DISEASE PHYSICIANS ARE... (5*)

Tu1185. . . OLDER AGE AND PRESENCE OF ADVANCED... (3*)|(Research grant from Gilead Sciences)

Tu1186. . . ECONOMIC BURDEN OF INPATIENT CARE IN... (5*)

Tu1187. . . IF YOU HAVE TO ASK, YOU... (5*)

Tu1188. . . MALE GENDER, INSURANCE STATUS, AND RACE/ETHNICITY... (5*)

Tu1189. . . GASTRIC ELECTRICAL STIMULATOR FOR GASTROPARESIS, A... (5*)

Tu1190. . . IMPAIRED ACTIVATION OF SYMPATHETIC NERVOUS SYSTEM... (3*)|(Tsumura & Co.)

Tu1191. . . DISTRIBUTION OF DUODENAL TUFT CELLS IS... (2*)

Tu1192. . . ACTIVATION OF AKT-PI3K SIGNALING AND MIRNA-MEDIATED... (2*)

Tu1193. . . COQ10 PROTECTS GASTRIC ENDOTHELIAL CELLS AGAINST... (2*)

Tu1194. . . DIFFERENT CLASSES OF NONPEPTIDE AGONISTS HAVE... (2*)

Tu1195. . . ELUCIDATION OF THE MECHANISMS BY WHICH... (2*)

Tu1196. . . EFFECT OF HELICOBACTER PYLORI ON THE... (2*)

Tu1197. . . EFFECT OF AMINO ACID-BASED ORAL REHYDRATION... (4*)|(3)|(Entrinsic Health Solutions Inc. (fund based on a research agreement with the University of Florida))

Tu1198. . . PROPRIETARY BLEND OF AMINO ACIDS DECREASED... (4*)

Tu1199. . . INTEGRATIVE ANALYSIS OF DIFFERENTIAL LNCRNA/MRNA EXPRESSION... (2*)

Tu1200. . . BILE REFLUX PROMOTES GASTRIC INTESTINAL METAPLASIA... (2*)|(4)

Tu1201. . . EPITHELIAL TO MESENCHYMAL TRANSITION IN RESPONSE... (2*)|(4)

Tu1202. . . MITOCHONDRIAL DYSFUNCTION ALTERS METABOLISM OF HEPATIC... (2*)|(4)

Tu1203. . . M6A MODIFICATION CONTROLS THE AUTOPHAGIC RESPONSE... (5*)

Tu1204. . . BETTER UNDERSTANDING OF MENETRIER'S DISEASE AND... (4*)|(7)

Tu1205. . . OBESITY-RELATED ENDOGENOUS MICROENVIRONMENT IMPACTS INSULIN SIGNALING... (2*)

Tu1206. . . EFFECT OF BACILLUS SUBTILIS AND ENTEROCOCCUS... (4*)

Tu1207. . . APPLICATION OF A WHOLE BLOOD PHARMACODYNAMIC... (3*)|(Gilead Sciences, Inc.)

Tu1208. . . NEUROPEPTIDE W ALLEVIATES HEPATORENAL OXIDATIVE DAMAGE... (4*)

Tu1209. . . CHIRALLY-MODIFIED LARAZOTIDE COMPOUND ANALOG #6 FACILITATES... (3*)|(Funding from Innovate Biopharmaceuticals, Inc. 8480 Honeycutt Rd #120, Raleigh, NC 27615)

Tu1210. . . GENOME-WIDE TRANSCRIPTIONAL RESPONSES TO ASPIRIN WITH... (2*)|(4)

Tu1211. . . AN ANTISENSE OLIGONUCLEOTIDE FOR MICRORNA-24-3P EXHIBITS... (2*)|(6)

Tu1212. . . RELEVANT HETEROGENEITY IN MISMATCH REPAIR DEFICIENT... (2*)|(6)

Tu1213. . . USE OF BIOLOGICS AND IMMUNOMODULATORS DO... (5*)

Tu1214. . . THE SAFETY, EFFICACY, AND OUTCOMES FOR... (5*)

Tu1215. . . WHETHER THE FIRST-DEGREE RELATIVES SUFFERING FROM... (1*)

Tu1216. . . CLINICAL, ENDOSCOPIC AND HISTOLOGICAL OUTCOMES AMONG... (5*)

Tu1217. . . THE EFFICACY OF LOWER ENDOSCOPIC SURVEILLANCE... (5*)

Tu1218. . . RELATIONSHIP BETWEEN GERMLINE MUTATION, PHENOTYPE AND... (2*)

Tu1219. . . THE EFFICACY OF UPPER ENDOSCOPIC SURVEILLANCE... (5*)

Tu1220. . . IMPLEMENTATION AND OUTCOMES OF A NURSE-ADMINISTERED... (4*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1221. . . CLINICOPATHOLOGICAL ANALYSIS OF SIX FAMILIES WITH... (5*)**
- Tu1222. . . MALIGNANCY RISK IN FAMILIAL ADENOMATOUS POLYPOSIS... (5*)**
- Tu1223. . . FACTORS THAT AFFECT PENETRANCE OF COLORECTAL... (5*)**
- Tu1224. . . ADVANCED COLORECTAL POLYPS AS A WAY... (5*)**
- Tu1225. . . MUTYH ASSOCIATED POLYPOSIS IN THE NON-JEWISH... (5*)**
- Tu1226. . . SMALL INTESTINAL INVOLVEMENT IN FAMILIAL ADENOMATOUS... (5*)**
- Tu1227. . . CCL11 EXACERBATES COLITIS VIA MODULATION OF... (2*)**
- Tu1228. . . INTERLEUKIN-38 IS ELEVATED IN INFLAMMATORY BOWEL... (2*)**
- Tu1229. . . AUTOTAXIN STIMULATES LPA2 RECEPTOR IN MACROPHAGES... (2*)**
- Tu1230. . . EXAMINATION OF NEW PREDICTIVE FACTORS USING... (1*)**
- Tu1232. . . NEW INSIGHTS INTO THE ROLE OF... (2*)**
- Tu1233. . . REPAIR RECEPTOR CD74 IS NECESSARY FOR... (2*)**
- Tu1234. . . SACRAL NERVE STIMULATION INHIBITS THE MAPK/NF- κ B... (2*)**
- Tu1235. . . TNF RECEPTOR 1 PROMOTES EARLY-LIFE IMMUNITY... (2*)**
- Tu1236. . . DANGEROUS LIAISONS: CO-HOUSING WITH MIF-/- MICE... (4*)**
- Tu1237. . . ADENOSINE A3 RECEPTOR REGULATES INTESTINAL EPITHELIAL... (2*)**[(Natural Science Foundation of Guangdong Province, China (no. 2018A030313772) and Science and Technology Innovation Commission of Shenzhen Municipality, China (no. JCYJ20170307171548519).)]
- Tu1238. . . SERUM PCSK9 AS NOVEL BIOMARKER FOR... (5*)**
- Tu1239. . . CIAP INHIBITION WITH SMAC MIMETICS IN... (2*)**[(4)]
- Tu1240. . . SALIDROSIDE AMELIORATES EXPERIMENTAL COLITIS BY ATTENUATING... (5*)**
- Tu1241. . . SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING... (5*)**
- Tu1242. . . INTERLEUKIN-34 DEFICIENCY EXACERBATED EXPERIMENTAL DSS-INDUCED COLITIS... (2*)**
- Tu1243. . . MATRIX METALLOPROTEINASE 8 (MMP-8) DEFICIENCY RENDERS... (4*)**
- Tu1244. . . PN-943, AN ORAL α 4 β 7 INTEGRIN ANTAGONIST,... (3*)**[(Protagonist Therapeutics)]
- Tu1245. . . TL1A EXCERBATED CHRONIC EXPERIMENTAL COLITIS THROUGH... (2*)**[(National Natural Science Foundation of China)]
- Tu1246. . . COLONIC MUCOSAL KINASE ACTIVITY, CYTOKINE AND... (3*)**[(The research presented in this abstract was funded by an unrestricted investigator initiated research grant of Pfizer (ASPIRE 2017). The funding party did not have any role in the design, conduct, analyses or reporting of the study.)]
- Tu1247. . . DELTA OPIOID RECEPTOR SIGNALING IN ENDOSOMES:... (6*)**
- Tu1248. . . THE ROLE OF PAI-1 IN THE... (2*)**[(European Union Funds, Innovative Economy Programme)]
- Tu1249. . . THE ROLE OF INFLAMMATION AND MALNUTRITION... (2*)**[(European Union Funds, Innovative Economy Programme)]
- Tu1250. . . INTESTINAL HELMINTHS PROMOTE ALLOTOLERANCE AND REGULATE... (2*)**
- Tu1251. . . MAST CELLS ARE SIGNIFICANTLY ACTIVATED IN... (3*)**[(Allakos, Inc.)]
- Tu1252. . . DAMP MOLECULES NMI AND IFP35 MAY... (2*)**
- Tu1253. . . RANDOMIZED CONTROLLED TRIAL OF COGNITIVE BEHAVIORAL... (6*)**
- Tu1254. . . GLYCANS ARE DUAL REGULATORY ELEMENTS IN... (2*)**[(4)]
- Tu1255. . . MICROBIOTA AND VIRUENCE FACTORS ASSOCIATED WITH... (6*)**
- Tu1256. . . CHROMOGRANIN-A REGULATES THE GUT MICROBIOTA COMPOSITION... (2*)**
- Tu1257. . . THE IMPACT OF FUT2 DEFICIENCY ON... (2*)**
- Tu1258. . . CIRCADIAN MISALIGNMENT IN INFLAMMATORY BOWEL DISEASE... (4*)**
- Tu1259. . . INDUCTION OF INNATE LYMPHOID CELL IL-22... (2*)**
- Tu1260. . . PSYLLIUM FIBER INDUCES UNIQUE CHANGES IN... (2*)**
- Tu1261. . . RESTRAINT STRESS INDUCES DEPRESSIVE-LIKE BEHAVIOR AND... (2*)**
- Tu1262. . . GUT MICROBIOME OF JAPANESE PATIENTS OF... (5*)**
- Tu1263. . . IMMUNOLOGICAL EVALUATION OF FECAL MICROBIOME TRANSPLANTED... (2*)**
- Tu1264. . . THE ROLE OF GASTROINTESTINAL PATHOGENS BY... (5*)**
- Tu1265. . . TRANSCRIPTOME ANALYSIS REVEALS THAT MICROBIOTA IN... (5*)**
- Tu1266. . . IMPAIRED VITAMIN D RECEPTOR EXPRESSION AND... (4*)**
- Tu1267. . . COLONIC ORGANIDS AS A MODEL TO... (4*)**
- Tu1268. . . THE INFLAMMATORY SIGNATURE OF HUMAN ENTEROIDS... (2*)**
- Tu1269. . . HIGHER ANTI-TNF α TROUGH LEVELS ARE ASSOCIATED... (5*)**
- Tu1270. . . IN VITRO HUMAN ORGANIDS COLITIS MODEL... (2*)**
- Tu1271. . . INTEGRATION OF MESENCHYMAL STEM CELLS AND... (5*)**[(Fistula plugs provided by COOK)]
- Tu1272. . . TARGETING METABOLISM AS AN EMERGING THERAPEUTIC... (4*)**
- Tu1273. . . PREEXISTING INTESTINAL STEM CELL VARIANTS... (2*)**
- Tu1274. . . A NOVEL MECHANISM OF SPHINGOSINE-1-PHOSPHATE RECEPTOR... (3*)**[(This project is funded by Celgene/Bristol-Myers Squibb.)]
- Tu1275. . . ANTI-TUBERCULAR THERAPY GIVEN TO DIFFERENTIATE CROHN'S... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1277... PERIPHERAL GASTROINTESTINAL CIRCADIAN DISRUPTION ASSOCIATED WITH... (3*)(Pfizer 2019 Inflammatory Bowel Disease Competitive Grant Program)

Tu1278... ENDOPLASMIC RETICULUM STRESS-MEDIATED MACROPHAGE-TO-MYOFIBROBLAST TRANSITION CONTRIBUTES... (6*)

Tu1279... FLAGELLIN-INDUCED CASPASE-1 ACTIVATION OF HUMAN INTESTINAL... (2*)

Tu1280... SUCCESSFUL ESTABLISHMENT OF DECELLULARIZED INTESTINAL EXTRACELLULAR... (2*)

Tu1281... PROTEINS CITRULLINATION AND CROHN'S DISEASE: PAD4... (5*)

Tu1283... PRECLINICAL CHARACTERIZATION OF AN ORAL SMALL... (3*)(Morphic Therapeutic)

Tu1284... PROTECTIVE EFFECT OF SAFFRON IN MOUSE... (2*)

Tu1285... CROHN'S DISEASE ILEAL B3 WITH STENOSIS... (7*)

Tu1286... HYDROGEN PEROXIDE-MEDIATED CROSSTALK OF EPITHELIAL DUOX2... (2*)(4)

Tu1287... MUCUS FROM HUMAN STEM CELL-DERIVED COLONIODS... (5*)

Tu1288... NEUTROPHILS REGULATE PROGRESSION OF COLON CANCER... (6*)(7)

Tu1289... MACROPHAGE CYSTATHIONINE GAMMA-LYASE CONTRIBUTES TO EXPERIMENTAL... (2*)(6)

Tu1290... PANETH CELL DEFECTS IN CROHN'S DISEASE... (2*)(6)

Tu1291... DYSBIOSIS AND GOBLET CELLS DEPLETION TRIGGERS... (2*)(4)

Tu1292... EFFICACY OF GRANULOCYTE AND MONOCYTE ADSORPTIVE... (4*)

Tu1293... EPITHELIAL LONG NON-CODING RNA REGULATE IN-CIS... (2*)

Tu1294... EXOGENOUS L-FUCOSE PROTECTS THE INTESTINAL MUCOSAL... (2*)

Tu1295... GRAPHENE OXIDE AGGRAVATED DEXTRAN SULFFATE SODIUM-INDUCED... (2*)

Tu1296... BILE ACIDS DELAY THE WOUND HEALING... (5*)

Tu1297... GUT MICROBIAL META-ANALYSIS OF INFLAMMATORY AND... (2*)

Tu1298... LOW ABUNDANCE OF LACTOCOCCUS LACTIS IN... (5*)

Tu1299... HELICOBACTER_BILIS MAY PLAY A ROLE IN... (5*)

Tu1300... SULFATE-REDUCING BACTERIA INCREASE EXPRESSION OF PRO-INFLAMMATORY... (4*)

Tu1301... ANTI-INFLAMMATORY EFFECT OF FAECALIBACTERIUM PRAUSNITZII IN... (2*)

Tu1302... INVESTIGATING THE ROLE OF BIOACTIVES PRODUCED... (4*)

Tu1303... INTESTINAL MICROBIOTA CHANGES ACCORDING TO DISEASE... (5*)

Tu1304... STREPTOCOCCUS MOBILIS-LIKE BACTERIAL GASTROPATHY: IS THE... (5*)

Tu1305... FECAL BACTERIOPHAGES INCREASED THE GROWTH OF... (6*)

Tu1306... CARBON MONOXIDE IS AN IMPORTANT FACTOR... (2*)

Tu1307... MICROBIOTA-TLR2 MEDIATED NESTIN-DERIVED ENTERIC NEUROGENESIS IN... (2*)

Tu1308... NEURAL NETWORK ENHANCEMENT AND GLIAL HYPERPLASIA... (5*)

Tu1310... ALTERATIONS IN EPIGENETIC MODIFIERS IN GASTRIC... (4*)(6)

Tu1311... THE EFFECT OF ACUTE STRESS DISORDER... (5*)

Tu1312... NERVE GROWTH FACTOR PRODUCED BY ENTERIC... (5*)

Tu1313... ESTIMATING THE GLOBAL PREVALENCE OF BARRETT'S... (5*)

Tu1314... REFLUX ESOPHAGITIS IS ASSOCIATED WITH WORSE... (5*)

Tu1315... ADHERENCE TO QUALITY INDICATORS IN THE... (5*)

Tu1316... ONLY 65% OF INDIVIDUALS MEETING THE... (2*)

Tu1317... HEALTHCARE UTILIZATION BURDEN FOR GASTROESOPHAGEAL REFLUX... (3*)(IBM Truven Commercial Claims & Encounter (patient de-identified) database access using Ethicon data license)

Tu1318... EFFICACY OF VONOPRAZAN IN PATIENTS WITH... (1*)

Tu1319... THE EPIDEMIOLOGY OF BARRETT'S ESOPHAGUS IN... (5*)

Tu1320... ASSOCIATION BETWEEN OBSTRUCTIVE SLEEP APNEA AND... (5*)

Tu1321... VONOPRAZAN 10 OR 20 MG DEMONSTRATED... (3*)(Funded by Takeda Development Center Asia Pte Ltd, Singapore.)

Tu1322... EFFICACY OF UPPER ESOPHAGEAL SPHINCTER ASSIST... (7*)

Tu1323... HIGH QUALITY OF LIFE IMPAIRMENT IN... (5*)

Tu1324... COMBINED HYPOPHARYNGEAL-ESOPHAGEAL IMPEDANCE-PH MONITORING: A PILOT... (5*)

Tu1325... ESOPHAGEAL FUNCTION AND REFLUX EVALUATIONS IN... (5*)

Tu1326... GASTROESOPHAGEAL REFLUX DISEASE AND RISK OF... (5*)

Tu1327... OBJECTIVE MEASURES OF GASTROESOPHAGEAL REFLUX ARE... (5*)

Tu1328... A SUBJECTIVE DIAGNOSIS OF GERD IS... (5*)

Tu1329... PRE-TRANSPLANT REFLUX TESTING DEMONSTRATES HIGH PREVALENCE... (5*)

Tu1330... THE PREDICTIVE VALUE OF FULL COLUMN... (5*)

Tu1331... PRE-TRANSPLANT GERD INCREASES POST-LUNG TRANSPLANT MORTALITY:... (5*)

Tu1332... EFFICACY OF A HIGH-DOSE PROTON PUMP... (5*)

Tu1333... CORRELATION OF GASTROESOPHAGEAL REFLUX DISEASE SYMPTOMS,... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1334. . . A STUDY ON THE EFFECT OF... (5*)**
- Tu1335. . . SLEEP DISORDERS ARE VERY COMMON IN... (5*)**
- Tu1336. . . REFLUX MONITORING WITH IMPEDANCE-PHMETRY: NEW SET... (4*)**
- Tu1337. . . ESOPHAGEAL CONTRACTILE SEGMENT IMPEDANCE (CSI) FROM... (5*)**
- Tu1338. . . NOVEL ESOPHAGEAL BASELINE IMPEDANCE METRICS CORRELATE... (5*)**
- Tu1339. . . PATIENTS WITH BORDERLINE ACID EXPOSURE TIME... (5*)**
- Tu1340. . . MUCOSAL INTEGRITY TESTING OR PH MONITORING:... (5*)**
- Tu1341. . . SALIVARY PEPSIN AS A BIOMARKER OF... (5*)**
- Tu1342. . . ABNORMAL BOLUS REFLUX WITH NORMAL ACID... (5*)**
- Tu1343. . . REFLUX PROFILES IN POST-BARIATRIC SURGERY PATIENTS... (5*)**
- Tu1345. . . THE DIAGNOSTIC USEFULNESS OF E-CADHERIN AND... (1*)**
- Tu1346. . . DISTAL MEAN NOCTURNAL BASAL IMPEDANCE AS... (5*)**
- Tu1347. . . ESTABLISHING AN OPTIMAL CUT-OFF FOR DISTAL... (5*)**
- Tu1348. . . PEPSIN AND BILE ACIDS DETECTION IN... (5*)**
- Tu1349. . . CLINICAL UTILITY OF BASELINE IMPEDANCE MEASURED... (5*)**
- Tu1350. . . USEFULNESS OF MEAN NOCTURNAL BASELINE IMPEDANCE... (5*)**
- Tu1351. . . DIAGNOSTIC ACCURACY OF THE ESOPHAGOGASTRIC JUNCTION... (5*)**
- Tu1352. . . MUCOSAL IMPEDANCE ENABLES ACCURATE DETECTION OF... (7*)|(3)|(Diversatek Healthcare, Inc. provided mucosal impedance balloons and Sandhill Scientific Insight Ultima System with Mucosal Impedance Software at no charge to perform this study., Diversatek Healthcare, Inc.**
- Tu1353. . . DIETARY EVALUATION BEFORE AND DURING IMPEDANCE-PH... (5*)**
- Tu1355. . . ANALYSIS OF SYMPTOMS AND REFLUX PARAMETERS... (5*)**
- Tu1356. . . IS HIGH-RESOLUTION MANOMETRY USEFUL FOR... (5*)**
- Tu1358. . . A PHASE 3, NON-INFERIORITY RANDOMIZED CONTROLLED... (3*)|(Daewoong Pharmaceutical)**
- Tu1359. . . IN VITRO TOPICAL PROTECTION OF ESOPHAGEAL... (2*)**
- Tu1360. . . RISK OF CANCER WITH USE OF... (5*)**
- Tu1361. . . NOVEL PHYSIOLOGICAL NOMOGRAM PREDICTS SYMPTOM OUTCOME... (5*)**
- Tu1362. . . 2-YEAR INTERIM ANALYSIS RESULTS OF VISION... (3*)**
- Tu1363. . . SAFETY AND EFFICACY OF AN IMPLANTABLE... (4*)|(3)|(Torax Medical)**
- Tu1364. . . VONOPRAZAN MAINTENANCE THERAPY IS MORE EFFECTIVE... (5*)**
- Tu1365. . . ACUTE EFFECT OF CURCUMINOID ON ESOPHAGEAL... (2*)**
- Tu1366. . . OESOPHAGEAL ADHESIVE PROPERTIES OF SODIUM ALGINATES... (3*)|(4)|(Reckitt Benckiser, UK)**
- Tu1367. . . THE EFFECTS OF CONTINUOUS POSITIVE AIRWAY... (5*)**
- Tu1369. . . CURRENT ESTIMATE OF PREVALENCE, CLINICAL CHARACTERISTICS... (3*)|(Ironwood Pharmaceuticals)**
- Tu1370. . . EFFICACY OF DA-5204 FOR GASTROESOPAGEAL REFLUX... (5*)**
- Tu1371. . . PPI DE-ESCALATION: DO SPECIALTY CLINICS PERFORM... (5*)**
- Tu1372. . . INFULUENCE OF DAILY OR ALTERNATE-DAY DOSING... (5*)**
- Tu1373. . . WHAT IS THE NEXT TREATMENT OPTION... (5*)**
- Tu1374. . . DOES GENDER PLAY A ROLE IN... (5*)**
- Tu1375. . . IS IT POSSIBLE TO WITHDRAW PPI... (5*)**
- Tu1376. . . UPPER ESOPHAGEAL SPHINCTER DYSFUNCTION ON FUNCTIONAL... (5*)**
- Tu1377. . . ESOPHAGEAL REMODELING MIGHT AFFECT THE PROGNOSIS... (5*)**
- Tu1378. . . EFFECTIVENESS OF N-ACETYLCYSTEINE ON THE TREATMENT... (5*)**
- Tu1379. . . FUNCTIONAL LUMEN IMAGING PROBE TOPOGRAPHY DETECTS... (5*)**
- Tu1380. . . ESOPHAGEAL PROVOCATIVE MANUEVERS ARE ASSOCIATED WITH... (4*)**
- Tu1381. . . GLOBAL CHANGES IN THE CORRELATION STRUCTURE... (2*)**
- Tu1382. . . IS IT REALLY LARYNGOPHARYNGEAL REFLUX? LARYNGEAL... (5*)**
- Tu1383. . . EFFECT OF SWALLOW STRENGTH TRAINING ON... (2*)**
- Tu1384. . . RISK FACTORS FOR GASTROESOPHAGEAL REFLUX DISEASE... (5*)**
- Tu1385. . . ESOPHAGO-GASTRIC JUNCTION CONTRACTILE INTEGRAL (EGJ-CI) MAY... (4*)**
- Tu1386. . . USEFULNESS OF BARIUM ESOPHAGRAM WITH NEWLY ... (5*)**
- Tu1387. . . ACUTE OPIOID ADMINISTRATION IS NOT ASSOCIATED... (5*)**
- Tu1388. . . PARTIAL OPIOID AGONIST ARE NOT ASSOCIATED... (5*)**
- Tu1389. . . THE CHALLENGES OF EGJOO, IS IT... (5*)**
- Tu1390. . . PREDICTORS OF FUNCTIONAL LUMINAL IMPEDANCE PLANIMETRY... (4*)**
- Tu1391. . . PREVALENCE OF ESOPHAGEAL DYSMOTILITY AND GASTROESOPHAGEAL... (5*)**
- Tu1392. . . PREVALANCE OF DYSPHAGIA FOLLOWING ROUX-EN-Y AND... (5*)**
- Tu1393. . . A REFLUX PHENOTYPE EXISTS IN PATIENTS... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1394. . . LOWER ESOPHAGEAL SPHINCTER AND PERISTALTIC PRESSURES... (5*)**
- Tu1395. . . COEXISTING ABNORMAL ESOPHAGEAL BODY MOTILITY PREDICTS... (5*)**
- Tu1396. . . BOLUS TRANSIT IN ESOPHAGOGASTRIC JUNCTION OUTFLOW... (5*)**
- Tu1397. . . CLINICAL, PSYCHOLOGICAL AND MANOMETRIC CHARACTERISTICS OF... (5*)**
- Tu1398. . . DELAYED ESOPHAGOGASTRIC JUNCTION RELAXATION AND ELEVATED... (5*)**
- Tu1399. . . HIGH PROPORTIONS OF OBSTRUCTIVE PHENOTYPES WITHIN... (5*)**
- Tu1400. . . ABSENCE OF CONTRACTION RESERVE IN SEVERE... (5*)**
- Tu1401. . . EFFECT OF PERORAL ENDOSCOPIC MYOTOMY FOR... (5*)**
- Tu1402. . . UNINTENDED MYOTOMY OF THE CRURAL DIAPHRAGM... (5*)**
- Tu1403. . . ACHALASIA, HYPERCONTRACTILE AND SPASTIC ESOPHAGEAL MOTILITY... (1*)**
- Tu1404. . . CIRCADIAN ALTERATIONS OF ESOPHAGEAL CONTRACTILITY IN... (1*)**
- Tu1405. . . ESOPHAGEAL AND GASTRIC MOTILITY ARE RELATED... (1*)**
- Tu1406. . . VISCOUS BOLUS AND TRENDELENBURG POSITION ALLOW... (2*)**
- Tu1407. . . EFFECTS OF EXTERNAL NEURAL STIMULATION ON... (2*)**
- Tu1408. . . IMPEDANCE SIGNALS RECORDED DURING ESOPHAGEAL MANOMETRY... (2*)**
- Tu1409. . . IDENTIFYING CLINICAL PHENOTYPES OF HYPERCONTRACTILE ESOPHAGEAL... (2*)**
- Tu1410. . . INFLUENCE OF PRUCALOPRIDE ON SILDENAFIL-INDUCED INHIBITION... (4*)|(Ministry of Science and Technology, Taipei, Taiwan.)**
- Tu1411. . . LEG ELEVATION MANEUVER IMPROVES MEASURING CONTRACTILE... (4*)|(Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.)**
- Tu1412. . . IMPACT OF INEFFECTIVE ESOPHAGEAL MOTILITY ON... (4*)|(Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan)**
- Tu1413. . . ESOPHAGEAL ACID REFLUX BURDEN IN GERD... (4*)|(Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan)**
- Tu1414. . . ARRHYTHMIC ESOPHAGEAL DEGLUTITION: OVEREXPRESSION AND... (2*)**
- Tu1415. . . STRENGTH TRAINING USING TECHNIQUE OF SWALLOWING... (2*)**
- Tu1416. . . STRENGTH TRAINING USING TECHNIQUE OF SWALLOWING... (2*)**
- Tu1418. . . ESOPHAGOGASTRIC JUNCTION-CONTRACTILE INTEGRAL FOR CLINICAL ASSESSMENT... (2*)**
- Tu1419. . . THE INFLUENCE OF CRURAL DIAPHRAGM ON... (5*)**
- Tu1420. . . UTILITY OF A NEW AUTOMATED ANALYSIS... (5*)**
- Tu1421. . . ESOPHAGOGASTRIC JUNCTION MORPHOLOGY AND CONTRACTILE INTEGRAL... (5*)**
- Tu1422. . . INCREASED INCIDENCE OF ALTERED COUPLING OF... (2*)**
- Tu1423. . . ABNORMALITIES OF DEGLUTITIVE PHARYNGEAL BIOMECHANICS NEGATIVELY... (2*)**
- Tu1424. . . EVALUATION OF DYSPHAGIA SYMPTOM ASSOCIATION WITH... (2*)**
- Tu1425. . . HIGH-RESOLUTION IMPEDANCE MANOMETRY PARAMETERS MAY IMPROVE... (2*)**
- Tu1426. . . HIGH RESOLUTION MANOMETRY IN UPRIGHT POSITION... (5*)**
- Tu1427. . . CHARACTERIZING THE PROXIMAL ESOPHAGEAL SEGMENT IN... (5*)**
- Tu1428. . . ACHALASIA PHENOTYPE IS ASSOCIATED WITH PREDICTABLE... (5*)**
- Tu1429. . . A CONVOLUTIONAL NEURAL NETWORK ACCURATELY IDENTIFIES... (5*)**
- Tu1430. . . ESOPHAGEAL OUTFLOW RESISTANCE IN PARKINSON'S DISEASE... (5*)**
- Tu1431. . . RAPID DRINKING CHALLENGE EVALUATED BY HIGH-RESOLUTION... (5*)**
- Tu1432. . . THE VALUE OF REPEAT MANOMETRIC TESTING... (5*)**
- Tu1433. . . REGIONAL PHARYNGEAL CONTRACTILE INTEGRALS (PHCI)... (5*)**
- Tu1435. . . SUPRAGASTRIC BELCHING INDUCE RE-REFLUX DURING REFLUX... (4*)**
- Tu1436. . . IMPLEMENTATION AND ANALYSIS OF A 2-YEAR... (5*)**
- Tu1437. . . PERISTALTIC FUNCTION BUT NOT INTEGRATED SPHINCTER... (5*)**
- Tu1438. . . DEMOGRAPHIC AND GASTROINTESTINAL SYMPTOM CHARACTERISTICS OF... (4*)**
- Tu1439. . . ESOPHAGEAL DYSFUNCTION IS PREVALENT FOLLOWING LUNG... (5*)**
- Tu1440. . . EVALUATING THE IMPACT OF POSITION, VOLUME... (4*)**
- Tu1441. . . THE CLINICAL SYMPTOMS AND MANOMETRIC CHARACTERISTICS... (1*)**
- Tu1442. . . PREVALENCE AND CLINICAL SIGNIFICANCE OF ESOPHAGOGASTRIC... (5*)**
- Tu1443. . . THE EFFECTS OF A NOVEL VISCOUS... (6*)|(This work was supported by a grant to Guofeng Xie from the Castell Foundation (Grant No. 10015806).)**
- Tu1444. . . FACTORS ASSOCIATED WITH HIATAL HERNIA IN... (5*)**
- Tu1445. . . THE ROLE OF ABDOMINAL CT SCAN... (5*)**
- Tu1446. . . ROLE OF BROAD-SPECTRUM ANTIBIOTICS IN THE... (5*)**
- Tu1448. . . CHARACTERIZATION OF PATIENTS WHO SHOULD RECEIVE... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1449. . . . GASTROINTESTINAL INFECTIONS IN CANCER PATIENTS WITH... (5*)**
- Tu1450. . . . COMBINATION IMMUNOSUPPRESSIVE THERAPY POST-SOLID ORGAN TRANSPLANTATION... (5*)**
- Tu1451. . . . THE DIAGNOSTIC VALUE OF FECAL CALPROTECTIN... (4*)**
- Tu1452. . . . ATYPICAL ENTEROPATHOGENIC E. COLI (EPEC) ISOLATES... (2*)**
- Tu1453. . . . COMPARISON OF ENDOSCOPIC FEATURES, CLINICAL OUTCOME,... (5*)**
- Tu1454. . . . MULTIPLEX GASTROINTESTINAL PATHOGEN PANELS ARE ASSOCIATED... (5*)**
- Tu1455. . . . WHEAT AMYLASE TRYPSIN INHIBITORS (ATIS): ANALYSES... (4*)**
- Tu1456. . . . MAST CELL-NERVE INTERACTIONS CORRELATE WITH BLOATING... (4*)**
- Tu1457. . . . POTENTIAL ROLE OF TCR γ δ + INTRAEPITHELIAL LYMPHOCYTES... (4*)(6)**
- Tu1458. . . . IMPACT OF GERMINATION ON GLUTEN, AMYLASE... (4*)**
- Tu1459. . . . SYMPTOMATIC AND ASYMPTOMATIC CELIAC DISEASE PATIENTS... (5*)**
- Tu1460. . . . BIFIDOBACTERIUM INFANTIS NLS-SS SHIFTS FECAL MICROBIOTA... (5*)**
- Tu1461. . . . INCREASED ERYTHROCYTE-BOUND IMMUNOGLOBULIN COMPLEXES IN CELIAC... (4*)**
- Tu1462. . . . INTERLEUKIN(IL) 1-IL-6, TUMOR NECROSIS FACTOR #NAME?... (4*)**
- Tu1463. . . . IN-VIVO ASSESSMENT OF CELIAC CLINICAL FORMULATION... (3*)(Innovate Biopharmaceuticals)**
- Tu1464. . . . NEO-EPI TOPE TISSUE TRANSGLUTAMINASE IS THE BEST ... (3*)**
- Tu1465. . . . SEROREACTIVITY TO FIRMICUTES FLAGELLIN PRECEDES THE... (4*)**
- Tu1466. . . . PREVALENCE OF INADEQUATE SEROLOGICAL CELIAC DISEASE... (5*)**
- Tu1467. . . . INCREASED ENERGY EXPENDITURE AND REDUCED EXERCISE... (5*)**
- Tu1468. . . . EXOCRINE PANCREATIC INSUFFICIENCY IS COMMON IN... (5*)**
- Tu1469. . . . CHARACTERISTICS AND MATERNAL-FETAL OUTCOMES OF PREGNANT... (5*)**
- Tu1470. . . . INCREASED RISK OF CELIAC DISEASE IN... (5*)**
- Tu1471. . . . CELIAC-ASSOCIATED LIVER DYSFUNCTIONS: PREVALENCE AND CLINICOPATHOLOGIC... (5*)**
- Tu1472. . . . FACING THE UNKNOWN: NAVIGATING CELIAC DISEASE... (5*)**
- Tu1473. . . . NON-CELIAC GLUTEN SENSITIVITY CAN BE DIFFERENTIATED... (4*)**
- Tu1474. . . . CAN HUMAN LEUKOCYTE ANTIGEN TYPING DIFFERENTIATE... (5*)**
- Tu1475. . . . SMALL BOWEL MUCOSA ATROPHY IN A... (4*)**
- Tu1476. . . . THE SIGNIFICANCE AND CLINICAL OUTCOME OF... (5*)**
- Tu1477. . . . LOW QUALITY DIET AND FOOD PATTERNS... (4*)(2)**
- Tu1579. . . . THIRTY-DAY READMISSION AMONG PATIENTS WITH ALCOHOLIC... (5*)**
- Tu1580. . . . ACUTE PANCREATITIS IN HISPANICS: SEVERITY, LENGTH... (5*)**
- Tu1581. . . . BEYOND THE INDEX HOSPITALIZATION: CAN THE... (4*)**
- Tu1582. . . . ACUTE PANCREATITIS IN PATIENTS WITH END... (5*)**
- Tu1583. . . . EPIDEMIOLOGY AND RISK OF PANCREATITIS IN... (5*)**
- Tu1584. . . . OUTCOMES OF OPEN VS. LAPAROSCOPIC VS.... (5*)**
- Tu1585. . . . NATIONWIDE TRENDS, PREVALENCE, DISPARITIES, AND OUTCOMES... (5*)**
- Tu1586. . . . PROPHYLACTIC CYSTGASTROSTOMY PREVENTS LATE PERIPANCREATIC FLUID... (5*)**
- Tu1587. . . . CELIAC DISEASE ASSOCIATED WITH HIGHER RISK... (5*)**
- Tu1588. . . . PROSPECTIVE STUDY OF RENAL ULTRASOUND AND... (4*)**
- Tu1589. . . . PREDICTIVE FACTORS OF INTRA ABDOMINAL HYPERTENSION... (5*)**
- Tu1590. . . . TRENDS IN THE MANAGEMENT OF ACUTE... (5*)**
- Tu1591. . . . RED CELL DISTRIBUTION WIDTH (RDW) TO... (5*)**
- Tu1592. . . . OBESITY AND NECROTIZING PANCREATITIS : INCIDENCE... (5*)**
- Tu1593. . . . TRANSGASTRIC DEBRIDEMENT IN NECROTIZING PANCREATITIS: ENDOSCOPIC... (5*)**
- Tu1594. . . . OVER 50% OF PATIENTS WITH ABDOMINAL... (5*)**
- Tu1595. . . . THE PANCREATITIS ACTIVITY SCORING SYSTEM PREDICTS... (5*)**
- Tu1596. . . . PRESENCE OF NECROSIS INCREASES THE ODDS... (5*)**
- Tu1597. . . . PRIOR NSAID USE IS ASSOCIATED WITH... (5*)**
- Tu1598. . . . INCIDENCE AND PREVALENCE OF ACUTE AND... (5*)**
- Tu1599. . . . NATIONWIDE TRENDS IN CHOLECYSTECTOMY RATES AMONG... (5*)**
- Tu1600. . . . QUALITY GAPS IN MANAGEMENT OF ACUTE... (5*)**
- Tu1601. . . . OUTCOMES OF 126 HYPERTRIGLYCERIDEMIA-INDUCED ACUTE PANCREATITIS... (5*)**
- Tu1602. . . . ACUTE PANCREATITIS WITH COMORBID ANXIETY AND... (5*)**
- Tu1603. . . . ASSOCIATION BETWEEN FASTING BREATH HYDROGEN LEVELS... (5*)**
- Tu1604. . . . DEVELOPMENT OF AN EUS CONVOLUTIONAL NEURAL... (5*)**
- Tu1605. . . . ROLE OF ENDOSCOPY IN PATIENTS WITH... (5*)**
- Tu1606. . . . QUANTITATIVE EVALUATION OF TREATMENT EFFECT USING... (5*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1607... CLINICAL USEFULNESS OF FDG-PET/CT FOR DIFFERENTIATION... (5*)

Tu1608... THE COMBINATION OF INTRAVENOUS FLUID AND... (5*)

Tu1609... METHODOLOGY OF PANCREATIC JUICE COLLECTION FROM... (5*)

Tu1610... ENDOSCOPIC ULTRASOUND (EUS)-GUIDED DRAINAGE OF PANCREATIC... (5*)

Tu1611... PREVALENCE TREND, HOSPITAL UTILIZATION, AND PREDICTORS... (5*)

Tu1612... FOXA2 EXPRESSION IS SIGNIFICANTLY ASSOCIATED WITH... (4*)

Tu1613... GERMLINE RET AND MAPT (TAU) MUTATIONS... (5*)

Tu1614... GENE CO-EXPRESSION NETWORK ANALYSIS OF PRECURSOR... (4*)(6)

Tu1615... RISK FACTORS ASSOCIATED WITH FATTY PANCREAS... (5*)

Tu1616... FAMILIAL PANCREATIC NEUROENDOCRINE TUMORS – ROLE... (5*)

Tu1617... RNASEQ ANALYSIS OF SEVENTEEN PANCREATITIS TPIAT... (2*)

Tu1618... VITAMIN D/VITAMIN D RECEPTOR AXIS DYSFUNCTION... (2*)

Tu1619... WATER AVOIDANCE STRESS PROMOTES MOUSE PANCREATIC... (4*)

Tu1621... ALTERD COMPOSITION OF GUT MICROBIOTA IN... (2*)(4)

Tu1634... THE COMPLICATION RATE AND DOWNSTREAM PROCEDURE... (5*)(3 of the authors are Medtronic employees. This was a Medicare database analysis. Medtronic employees assisted in converting clinical procedures instructed by physicians to the appropriate CPT and ICD-10 codes and in completing the SAS programming to extra)

Tu1635... YIELD OF RADIOLOGIST RECOMMENDATION FOR HEPATOLOGY... (5*)

Tu1636... HYPOXIC HEPATITIS IS UNDERRECOGNIZED AND UNDERDIAGNOSED... (5*)

Tu1637... LONGITUDINAL HCV CARE OF PREGNANT PATIENTS... (5*)

Tu1638... USEFULNESS OF ANTI-LKM-1 ANTIBODY TESTING IN... (5*)

Tu1639... EPIDEMIOLOGY AND RISK FACTORS OF CHOLANGIOCARCINOMA... (5*)

Tu1640... OVEREXPRESSION OF FOXM1 PREDICTS POORER SORAFENIB... (4*)(2)(Ministry of Science and Technology, Taiwan Kaohsiung Medical University, Taiwan)

Tu1641... OUTCOMES OF PATIENTS WITH HILAR CHOLANGIOCARCINOMA... (5*)

Tu1642... QUANTITATIVE HEPATIC FUNCTION PREDICTS TIME TO... (5*)

Tu1643... SEX, RACIAL AND ETHNIC DISPARITIES IN... (5*)

Tu1644... REVEALING THE MOLECULAR DRIVERS OF HEPATOBLASTOMA... (2*)

Tu1645... MIR-125B-5P CONFERS RESISTANCE TO SORAFENIB BY... (5*)

Tu1646... INCIDENCE AND MORTALITY TRENDS OF INTRAHEPATIC... (5*)

Tu1647... LONG TERM OUTCOMES OF SELF-EXPANDABLE METAL... (5*)

Tu1648... PROGNOSTIC IMPACT OF TYROSINE KINASE INHIBITOR... (1*)

Tu1649... MECHANISTIC STUDY OF COPPER-STIMULATED PROGRESSION OF... (5*)

Tu1650... EPIDEMIOLOGY AND PREVALENCE OF GALLBLADDER CANCER... (5*)

Tu1651... OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CARCINOMA... (5*)

Tu1652... PREVALENCE AND MANAGEMENT OF GALLBLADDER CANCER... (5*)

Tu1653... THERAPEUTIC EFFICACY AND SAFETY OF LENVATINIB... (1*)

Tu1751... ANALGESIC EFFECTS OF VAGAL NERVE STIMULATION... (5*)

Tu1752... EFFECT OF LIQUID AND SOLID TEST... (2*)

Tu1753... ASSOCIATIONS BETWEEN MOOD DISORDERS AND GASTRIC... (5*)

Tu1754... IMPAIRED DUODENAL MUCOSAL BARRIER FUNCTION CAUSES... (5*)

Tu1755... NATIONAL TRENDS IN READMISSION FOR CANNABINOID... (5*)

Tu1756... SMALL BOWEL TRANSIT ABNORMALITIES IN PATIENTS... (5*)

Tu1757... EFFECTS OF 4-WEEK CURCUMINOID ON CLINICAL... (2*)

Tu1758... EFFICACY OF TOPIRAMATE AS PROPHYLAXIS IN... (5*)

Tu1759... EFFECT OF PROTON PUMP INHIBITOR ON... (5*)

Tu1760... DUODENAL BILE SALTS AND MUCOSAL CHANGES... (4*)

Tu1761... DEVELOPMENT OF A MOTILITY FRAILTY INDEX... (5*)

Tu1762... IMPACT OF SLEEP IMPROVEMENT ON GASTROINTESTINAL... (5*)

Tu1763... A RECURRING COST OF CARE: EMERGENCY... (5*)

Tu1764... NATIONAL ESTIMATES OF 30-DAY READMISSIONS AMONG... (5*)

Tu1765... FUNCTIONAL DYSPEPSIA AND NON-CELIAC WHEAT SENSITIVITY... (4*)(2)

Tu1766... DISCRIMINATION OF PATIENTS WITH CHRONIC NAUSEA... (5*)

Tu1768... EFFICACY OF SUMATRIPTAN AS ABORTIVE TREATMENT... (5*)

Tu1769... HALOPERIDOL USE IN THE EMERGENCY DEPARTMENT... (5*)

Tu1770... RUMINATION SYNDROME: ASSESSMENT OF VAGAL TONE... (4*)

Tu1771... FACTORS IN ESTABLISHMENT OF ENTERAL AUTONOMY... (5*)

Tu1772... NAUSEA AND VOMITING SEVERITY IS ASSOCIATED... (5*)

Tu1773... ANTRAL EXPRESSION OF PROSTAGLANDIN E SYNTHASE... (1*)

Tu1774... EVALUATION OF GASTRIC MOTOR FUNCTION IN... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1775. . . SLEEP PARASOMNIAS ARE ASSOCIATED WITH AUTONOMIC... (2*)

Tu1776. . . MAGNETIC RESONANCE DEFECOGRAPHY IN CHILDREN AND... (5*)

Tu1777. . . PROSPECTIVE EVALUATION OF ANAL SPHINCTER BOTULINUM... (5*)

Tu1778. . . ROLE OF GLUCOSE BREATH TEST FOR... (5*)

Tu1779. . . IMPROVED FUNCTIONING PRECEDES IMPROVEMENT OF ABDOMINAL... (5*)

Tu1780. . . VASOACTIVE INTESTINAL PEPTIDE PLASMA CONCENTRATIONS IN... (5*)

Tu1781. . . AKKERMANSIA MUCINIPHILA AND BIFIDOBACTERIUM BIFIDUM G9-1:... (5*)

Tu1782. . . YIELD AND PREDICTORS OF POSITIVE COLONIC... (5*)

Tu1783. . . EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE... (5*)(Tsumura & Co.)

Tu1784. . . TYROSINE KINASE INHIBITORS THAT TARGET ERBBS... (2*)

Tu1785. . . EOSINOPHILIC COLITIS IN CANCER PATIENTS ... (5*)

Tu1786. . . IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED DIARRHEA AND COLITIS:... (5*)

Tu1787. . . THE STATUS AND RELATED FACTORS OF... (1*)(4)

Tu1788. . . CLINICAL CHARACTERISTICS AND TREATMENT DIFFERENCES BETWEEN... (5*)

Tu1789. . . INTESTINAL PERMEABILITY IN PATIENTS WITH FUNCTIONAL... (4*)

Tu1790. . . BIFIDOBACTERIUM LONGUM RELIEVES VISCERAL HYPERSENSITIVITY AND... (2*)

Tu1791. . . BIOMARKERS OF ELASTIN DEGRADATION DIFFERENTIATE BETWEEN... (5*)

Tu1792. . . BIOMARKERS OF ELASTIN DEGRADATION IS ASSOCIATED... (5*)

Tu1793. . . BILE ACID MALABSORPTION AND OUTCOMES AFTER... (4*)

Tu1794. . . DIARRHEA IN THE LUNG TRANSPLANT RECIPIENT:... (5*)

Tu1795. . . A CLINIC-PATHOLOGICAL COMPARISON BETWEEN CROHNS' DISEASE... (4*)

Tu1796. . . ALTERNATION OF GUT MICROBIOTA IN PATIENT... (5*)

Tu1797. . . MANAGEMENT OF PATIENTS WITH HISTOLOGICALLY PROVEN... (5*)

Tu1798. . . EARLY-ONSET COLORECTAL ADENOCARCINOMA INCIDENCE RATES ARE... (5*)

Tu1799. . . RISK FACTORS FOR EARLY ONSET SPORADIC... (2*)

Tu1800. . . RISK FACTORS FOR EARLY ONSET SPORADIC... (2*)

Tu1801. . . METABOLIC SYNDROME: ARE CURRENT COLON CANCER... (2*)

Tu1802. . . VARIATION IN ESTIMATED COLORECTAL CANCER RISK... (5*)

Tu1803. . . PREVALENCE OF COLORECTAL NEOPLASIA IN PATIENTS... (5*)

Tu1804. . . THE MEAN AGE AT COLORECTAL CANCER... (5*)

Tu1805. . . THE RISK OF SECOND PRIMARY MALIGNANCY... (5*)

Tu1806. . . YOUNG ONSET COLORECTAL CANCER RISK AMONG... (2*)

Tu1807. . . THE RISK OF EARLY-ONSET COLORECTAL CANCER... (5*)

Tu1808. . . EFFECT OF COMORBIDITIES ON RISK OF... (5*)

Tu1809. . . IS ORAL ANTICOAGULATION ASSOCIATED WITH IMPROVED... (5*)

Tu1810. . . COLORECTAL CANCER INCIDENCE AND MORTALITY... (2*)(4)

Tu1811. . . DOES PROXIMITY TO TERTIARY REFERRAL CENTER... (5*)

Tu1812. . . DEVELOPMENT AND VALIDATION OF RISK PREDICTION... (2*)(7)

Tu1813. . . LONG-TERM INCIDENCE AND MORTALITY OF COLORECTAL... (2*)(7)

Tu1814. . . MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR... (2*)(6)

Tu1815. . . THE IMPACT OF DIVERTICULAR DISEASE ON... (5*)

Tu1816. . . THE IMPACT OF INFLAMMATORY BOWEL DISEASE... (5*)

Tu1817. . . THE LONG-TERM RISKS OF LOW-RISK ADENOMA,... (2*)

Tu1818. . . CAREFUL SELECTION OF BOTH POSITIVITY THRESHOLD... (3*)(4)(Eiken Chemical Company.)

Tu1819. . . COMPLEMENTARY HYPERMETHYLATED CTDNA BIOMARKERS FOR EARLY... (2*)(3)(Clinical Genomics Pty Ltd)

Tu1820. . . PATIENT CHARACTERISTICS AND MORTALITY ASSOCIATED WITH... (5*)

Tu1821. . . COLORECTAL CANCER (CRC) IN THE YOUNG:... (5*)

Tu1822. . . HIGHER IMPACT ON CLINICAL OUTCOMES FROM... (3*)(Exact Sciences)

Tu1823. . . MOBILE MESSENGERS-INITIATED REMINDERS IMPROVES COMPLIANCE IN... (6*)

Tu1825. . . MEDIA COVERAGE OF THE AMERICAN CANCER... (5*)

Tu1826. . . EVALUATION OF EFFECTIVENESS AND COST-EFFECTIVENESS OF... (4*)

Tu1827. . . THE ASSOCIATION OF PATIENTS' PERCEPTION OF... (5*)

Tu1828. . . OFFERING A BLOOD TEST INCREASES COLORECTAL... (3*)(7)(Epigenomics)

Tu1829. . . EFFECT OF ANTITHROMBOTIC THERAPY ON DIAGNOSIS... (5*)

Tu1830. . . IS THE COLORECTAL CANCER SCREENING GUIDELINE... (5*)

Tu1831. . . BARRIERS TO COLONOSCOPIC FOLLOW UP AFTER... (4*)

Tu1832. . . GROWING SURVIVAL DISPARITIES AMONGST ASIAN ETHNICITIES... (5*)

Tu1833. . . CDH1 GENE MUTATIONS PREDISPOSE PATIENTS TO... (2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFa, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1834. . . . INCIDENCE AND ANATOMICAL DISTRIBUTION OF COLORECTAL... (5*)

Tu1835. . . . UTILITY OF FECAL IMMUNOCHEMICAL TEST (FIT)... (5*)

Tu1836. . . . TUMOR AREA AND MICROSCOPIC EXTENT OF... (3*)|(GRAIL Inc)

Tu1837. . . . HIGH SEDATION REQUIREMENTS FOR PATIENTS AGES... (5*)

Tu1838. . . . COLORECTAL CANCER SCREENING: ADDING RISK PROFILING... (5*)|(NIL)

Tu1839. . . . CLINICOPATHOLOGICAL CHARACTERIZATION AND SURVIVAL OUTCOME OF... (5*)

Tu1840. . . . THE EFFECT OF DIRECT-ACTING ORAL ANTICOAGULANTS... (5*)

Tu1841. . . . FREQUENCY OF SIGNS AND SYMPTOMS PRECEDING... (5*)

Tu1842. . . . GEOGRAPHIC DISPARITIES OF YOUNG ONSET COLORECTAL... (5*)

Tu1843. . . . INCREASED RISK OF ADVANCED COLONIC ADENOMAS... (5*)

Tu1844. . . . CHANGING EPIDEMIOLOGY OF COLORECTAL CANCER RELATED... (5*)

Tu1845. . . . COMPARATIVE EFFECTIVENESS OF SURVEILLANCE COLONOSCOPY TIMING... (2*)

Tu1846. . . . PHASE 2A PROOF OF CONCEPT PLACEBO... (3*)|(ABIVAX)

Tu1847. . . . THE IMPACT OF COGNITIVE BEHAVIORAL MINDFULNESS... (6*)

Tu1848. . . . EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS... (3*)|(This study was funded by Janssen Research & Development, LLC.)

Tu1849. . . . HISTOLOGIC REMISSION AND MUCOSAL HEALING IN... (3*)|(The study was funded by Eli Lilly and Company.)

Tu1850. . . . DOSE ESCALATION OF UPADACITINIB IN CROHN'S... (3*)|(AbbVie, Inc.)

Tu1851. . . . CORTICOSTEROID SPARING EFFECTS OF USTEKINUMAB THERAPY... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1852. . . . PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A... (3*)|(Oppilan Pharma)

Tu1853. . . . SUSTAINED REDUCTION OF IL-23 RELATED CYTOKINES... (3*)|(The study was funded by Eli Lilly and Company.)

Tu1854. . . . MIRIKIZUMAB REGULATES GENES INVOLVED IN ANTI-TNF... (3*)|(The study was funded by Eli Lilly and Company)

Tu1855. . . . EFFICACY AND SAFETY OF ESCALATION TO... (3*)|(Pfizer Inc)

Tu1856. . . . THE EFFECT OF TOFACITINIB ON SERUM... (3*)|(Pfizer Inc)

Tu1857. . . . TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS... (3*)|(Pfizer Inc)

Tu1858. . . . ASSESSMENT OF AGE AS A RISK... (3*)|(Pfizer Inc)

Tu1859. . . . CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1860. . . . ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING AFTER... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1861. . . . A RANDOMIZED, OBSERVER-BLINDED PHASE IB MULTIPLE,... (3*)|(Sponsored by Genentech, Inc.)

Tu1862. . . . BI 695501 DEMONSTRATES SIMILAR EFFICACY AND... (3*)|(Boehringer Ingelheim)

Tu1863. . . . TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE... (3*)|(Pfizer Inc)

Tu1864. . . . ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB... (3*)|(This study was supported by Janssen)

Tu1865. . . . VEDOLIZUMAB TREATMENT PERSISTENCE AND SAFETY IN... (3*)|Takeda)

Tu1866. . . . EFFICACY AND SAFETY OF AN ADDITIONAL... (3*)|(Pfizer Inc)

Tu1867. . . . EFFICACY OF TOFACITINIB DOSE ESCALATION TO... (3*)|(Pfizer Inc)

Tu1868. . . . THE EFFECT OF TOFACITINIB ON EXTRAINTestinal... (3*)|(Pfizer Inc)

Tu1869. . . . TIME TO LOSS OF EFFICACY AMONG... (3*)|Pfizer Inc)

Tu1870. . . . C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO... (3*)|(Pfizer Inc)

Tu1871. . . . THE CONCORDANCE OF SHORT FORM-36 HEALTH... (3*)|(Pfizer Inc)

Tu1872. . . . IDENTIFICATION OF BIOMARKERS AND MECHANISTIC INSIGHT... (3*)|(AbbVie, Inc.)

Tu1873. . . . LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB... (3*)|(AbbVie Inc.)

Tu1874. . . . MAINTENANCE OF REMISSION WITH TOFACITINIB IN... (3*)|(Pfizer Inc)

Tu1875. . . . IMPACT OF DISEASE DURATION ON TOFACITINIB... (3*)|(Pfizer Inc)

Tu1876. . . . A PILOT DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL... (2*)|(6)|(|Supported by grants from the CIHR Institute of Nutrition, Metabolism and Diabetes (INMD), the Canadian Association of Gastroenterology (CAG), AbbVie Canada and Crohn's and Colitis Canada (CCC). Vitamin D was provided in kind by Euro-Pharm International)

Tu1877. . . . EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL... (3*)|(Celltrion, Inc.)

Tu1878. . . . FILGOTINIB DECREASES MOLECULAR MARKERS OF JAK1... (3*)|(Gilead Sciences, Inc.)

Tu1879. . . . EFFICACY AND SAFETY OF LONG-TERM TREATMENT... (3*)|(This study was funded by Janssen Research & Development, LLC)

Tu1880. . . . EFFECTS OF THE JANUS KINASE (JAK1)-SELECTIVE... (3*)|(Sponsored by Gilead Sciences, Inc.)

Tu1881. . . . SAFETY, PHARMACOKINETICS AND IMMUNE MODULATORY PROPERTIES... (3*)

Tu1882. . . . GB004, A NOVEL PROLYL HYDROXYLASE... (3*)|(Gossamer Bio, Inc)

Tu1883. . . . HIGHER TROUGH GOLIMUMAB LEVELS ARE ASSOCIATED... (3*)|(GOAL-ARC is

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

supported as an investigator initiated study by MSD and Thermo Fisher Scientific)

Tu1884. . . . DIAGNOSTIC ACCURACY OF RECTAL BLEEDING AND... (3*)|(Pfizer Inc)

Tu1885. . . . EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS... (3*)|(This study was funded by Janssen Research & Development, LLC.)

Tu1886. . . . DOSE ADJUSTMENT IN PATIENTS WITH MODERATE... (3*)|(This study was funded by Janssen Research & Development, LLC.)

Tu1887. . . . IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED... (3*)|(This study has been funded by Eli Lilly and Company.)

Tu1888. . . . EARLY AND SUSTAINED IMPROVEMENT IN STOOL... (3*)|(The study was funded by Eli Lilly and Company.)

Tu1889. . . . UPADACITINIB WAS NOT ASSOCIATED WITH ANAEMIA... (3*)|(AbbVie, Inc.)

Tu1890. . . . THE EFFICACY AND SAFETY OF ADALIMUMAB... (3*)|(AbbVie)

Tu1891. . . . RISK OF LATE POST-OPERATIVE RECURRENCE OF... (5*)

Tu1892. . . . TOFACITINIB FOR ULCERATIVE COLITIS: RESULTS OF... (1*)

Tu1893. . . . REAL WORLD EFFECTIVENESS OF TOFACITINIB FOR... (5*)

Tu1894. . . . IMPACT OF DISCONTINUING THIOPURINES AT ANTI-TNF... (4*)|(2)

Tu1895. . . . TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION... (5*)

Tu1896. . . . TOFACITINIB IS SAFE AND EFFECTIVE AS... (5*)

Tu1897. . . . PORTAL VEIN THROMBOSIS IS A RISK... (5*)

Tu1898. . . . EXCLUSIVE ENTERAL NUTRITION WITH A POLYMERIC... (5*)

Tu1899. . . . REAL-WORLD EFFECTIVENESS AND SAFETY OF TOFACITINIB... (4*)|(7)

Tu1900. . . . A PHARMACOKINETIC (PK) AND SAFETY STUDY... (3*)|(Enterome)

Tu1901. . . . NON-ADHERENCE TO MAINTENANCE MEDICATIONS IN PREGNANT... (2*)

Tu1902. . . . COMPREHENSIVE REGISTERED DIETICIAN ASSESSMENT IN THE... (4*)

Tu1903. . . . EVALUATION OF POTENTIAL MECHANISMS UNDERLYING THE... (3*)|(Gilead Sciences, Inc.)

Tu1904. . . . USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY... (5*)

Tu1905. . . . CANNABIS EFFECT ON INPATIENT DISEASE OUTCOMES... (4*)

Tu1906. . . . PREVALENCE AND ASSOCIATION OF CANNABIS USE... (5*)

Tu1907. . . . EFFICACY INCLUDING RAPID RESPONSE AND... (4*)

Tu1908. . . . EFFECT OF FIBER-BASED ENTERAL FEEDS ON... (2*)|(4)

Tu1909. . . . IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON... (3*)|(4)|(This study was primarily funded as an investigator initiated study by Finch Therapeutics)

Tu1910. . . . SUBJECTS ON A GLUTEN-FREE DIET HAVE... (6*)

Tu1911. . . . THE EFFECT OF A PLANT-BASED DIET... (2*)

Tu1912. . . . NUTRIENT-DEPENDENT PHYSIOLOGICAL AND PROTEOMIC ANALYSIS OF... (2*)

Tu1913. . . . ROLE OF DIETARY AND NON-DIGESTIBLE CARBOHYDRATES... (2*)

Tu1914. . . . THE SMALL INTESTINAL MICROBIOME IN OBESITY... (6*)

Tu1915. . . . MICROBIOTA-MEDIATED EFFECTS OF DIETARY FIBER ON... (2*)|(4)

Tu1916. . . . CURDLAN FEEDING IN MICE IMPROVES DSS... (2*)

Tu1917. . . . PRANDIAL DIETARY ZINC INTAKE AFFECT DEVELOPMENT... (2*)

Tu1918. . . . THE INFLUENCE OF WALNUT CONSUMPTION ON... (6*)

Tu1919. . . . A NOVEL INTEGRATED IN VIVO/ EX... (2*)|(3)|((Lantmännen Research Foundation)

Tu1920. . . . ASSOCIATION BETWEEN DIETARY FAT INTAKE AND... (6*)|(2)

Tu1921. . . . THE INTERPLAY BETWEEN GUT MICROBIOTA AND... (5*)

Tu1922. . . . DIET SIGNIFICANTLY ALTERS ENTEROHEPATIC RECIRCULATION OF... (4*)|(2)

Tu1923. . . . SPIRULINA PLATENSIS ALLEVIATE CHRONIC LOW-GRADE INFLAMMATORY... (5*)

Tu1924. . . . CHANGES IN THE GUT MICROBIOTA AND... (4*)

Tu1925. . . . SEX- AND COLORECTAL CANCER-ASSOCIATED CHANGES IN... (4*)

Tu1926. . . . MICROBIAL DIGESTION OF XANTHAN GUM IN... (2*)

Tu1927. . . . THE EFFECTS OF CAROTENOID INGESTION ON... (2*)

Tu1928. . . . STREPTOCOCCUS SP. VT_162 MRNAS TARGETS CONTRIBUTES... (2*)

Tu1929. . . . ANTIMICROBIAL RESISTANCE GENE BURDEN DECREASES OVER... (2*)

Tu1930. . . . FECAL LIPIDOMICS ANALYSIS OF THE NEONATAL... (2*)

Tu1931. . . . LACTOBACILLUS-CONTAINING PROBIOTICS ARE ASSOCIATED WITH CHANGES... (6*)

Tu1932. . . . THE DOSE-RESPONSE RELATION BETWEEN A FIBER... (5*)|(Tsumura & Co.)

Tu1933. . . . THE CHALLENGES IN DEVELOPING A FAECAL... (4*)

Tu1934. . . . SALIVARY AND STOOL MICROBIOTA DIFFERENCES ARE... (2*)

Tu1935. . . . DOES THE USE OF ANGIOTENSIN RECEPTOR... (5*)

Tu1936. . . . PATIENT PERSPECTIVES ON THE LONG-TERM MANAGEMENT... (2*)

Tu1937. . . . PATIENT WILLINGNESS TO PARTICIPATE IN CELIAC... (5*)

Tu1938. . . . PROBIOTICS FOR CELIAC DISEASE: A SYSTEMATIC... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

- Tu1939. . . IS A MULTIVITAMIN SUFFICIENT TO MEET... (5*)**
- Tu1940. . . PREVALENCE OF OBESITY IN PATIENTS WITH... (5*)**
- Tu1941. . . SELF-REPORTED NON-CELIAC GLUTEN SENSITIVITY IN KOREAN... (5*)**
- Tu1942. . . COMPARISON OF PARENTAL GLUTEN-FREE DIET KNOWLEDGE... (6*)**
- Tu1943. . . REFERRAL FOR DIETARY INTERVENTION FOR CELIAC... (5*)**
- Tu1944. . . A GASTROENTEROLOGIST SUPERVISED BEHAVIORAL WEIGHT MANAGEMENT... (5*)**
- Tu1945. . . FREQUENCY OF OBESITY COUNSELING BY PHYSICIANS... (5*)**
- Tu1946. . . USE OF A NOVEL VIRTUAL HEALTH... (5*)**
- Tu1947. . . IMPACT OF A CHILDCARE CENTER-BASED OBESITY... (2*)**
- Tu1948. . . TRENDS IN OBESITY SELF-AWARENESS AMONG OBESE... (5*)**
- Tu1949. . . GLOBAL, REGIONAL AND TIME-TREND PREVALENCE OF... (4*)**
- Tu1950. . . OBESE MINORITIES HAVE HIGHER HOSPITALIZATION RATES... (5*)**
- Tu1951. . . AUTOPHAGY DYSFUNCTION THROUGH HEPATIC BCL-2 OVEREXPRESSION... (3*)|(Tsumura & Co.)**
- Tu1952. . . DEFINING THE ROLE OF INTESTINE-SPECIFIC FFA2... (4*)**
- Tu1954. . . IMMEDIATE POSTOPERATIVE COMPLICATION REASON FOR READMISSION... (5*)**
- Tu1955. . . CALCIUM-SENSING RECEPTOR REGULATES INTESTINAL DIPEPTIDE ABSORPTION... (2*)|(National Natural Science Foundation of China (NSFC))**
- Tu1957. . . ANOREXIA NERVOSA CARE PATHWAY. THE ROAD... (5*)**
- Tu1958. . . CONTINUOUS DECREASE OF THE MYOBLAST DETERMINATION... (3*)**
- Tu1959. . . INTESTINAL ELECTRICAL STIMULATION FOR TREATING DIABETES:... (2*)**
- Tu1960. . . COST EFFECTIVENESS OF OFFERING UNSEDATED COLONOSCOPY... (5*)**
- Tu1961. . . WHEN TO FORGO ENDOSCOPY IN FAVOR... (5*)**
- Tu1962. . . VISITATION WITH A GASTROENTEROLOGIST AND PATIENT... (4*)**
- Tu1963. . . SINGLE-USE DUODENOSCOPES FOR ERCP: A COST-EFFECTIVE... (5*)|(Boston Scientific reimbursed funds to purchase a 1-year license for the Treeage Decision analysis software used to build and analyze the economic model. The presenting author, Ananya Das, MD is a teaching and research consultant with Boston Scientific.)**
- Tu1964. . . USABILITY OF A NOVEL DISPOSABLE ENDOSCOPE... (2*)**
- Tu1965. . . GASTROINTESTINAL ENDOSCOPY CAPACITY IN EAST AFRICA:... (5*)**
- Tu1966. . . ANAESTHETIC SUPPORT TO PERFORM COLONOSCOPY:WHEN IS... (5*)**
- Tu1967. . . RATE OF GASTROINTESTINAL ENDOSCOPY USE AND... (2*)**
- Tu1968. . . TO SCOPE OR NOT TO SCOPE?... (4*)**
- Tu1969. . . IMPROVING QUALITY OF UPPER ENDOSCOPY AMONG... (4*)**
- Tu1970. . . MACHINE LEARNING CAN IMPROVE ESTIMATION OF... (5*)**
- Tu1971. . . A NOVEL AND EFFICIENT METHOD USING... (5*)**
- Tu1972. . . POSITIVE MULTI-TARGET STOOL DNA TEST AND... (5*)**
- Tu1973. . . AUTOMATED DIGITAL PATIENT NAVIGATION PROGRAM IMPROVES... (5*)**
- Tu1974. . . EVALUATING THE NUMBER NEEDED TO SCREEN... (3*)|(Guardant Health)**
- Tu1975. . . INCIDENCE OF INADEQUATE ENDOSCOPIC ASSESSMENT AND... (5*)**
- Tu1976. . . MISINFORMING THE PUBLIC: PREDICTORS OF FACTUAL... (5*)**
- Tu1977. . . CHARACTERIZATION OF UNPLANNED HOSPITAL VISITS AFTER... (5*)**
- Tu1978. . . WHERE DO WE GO FROM HERE?... (5*)**
- Tu1979. . . FACTORS ASSOCIATED WITH DELAYS IN INPATIENT... (5*)**
- Tu1980. . . SHORT TERM CARDIOVASCULAR COMPLICATIONS RELATED TO... (5*)**
- Tu1981. . . ASSOCIATION MODELING BETWEEN PATIENTS' AGE AND... (5*)**
- Tu1982. . . COMPARISON BETWEEN SPLIT-DOSE AND SINGLE-DOSE POLYETHYLENE... (5*)**
- Tu1983. . . COMPARING THE IMPACT OF MORTALITY DATA... (5*)**
- Tu1984. . . COMPARING THE REAL-WORLD EFFECTIVENESS OF 4L... (1*)**
- Tu1985. . . A PATIENT-DRIVEN APPROACH TO IMPROVING THE... (4*)**
- Tu1986. . . OPEN ACCESS COLONOSCOPY: AN UNDERUTILIZED PROGRAM... (5*)**
- Tu1987. . . THE IMPACT OF A 2 LITER... (5*)**
- Tu1988. . . TELEPHONE TRIAGE TO 'STRAIGHT TO TEST'(TSTT)... (5*)**
- Tu1989. . . PRE-COLONOSCOPY BOSTON BOWEL PREPARATION SCORE ASSESSMENT... (5*)**
- Tu1990. . . MACHINE LEARNING MODELS FOR PREDICTING NAFLD... (5*)**
- Tu1991. . . ANALYSIS OF ERCP IMAGE USING ARTIFICIAL-INTELLIGENCE... (5*)**
- Tu1992. . . NEEDLE-BASED CONFOCAL LASER ENDOMICROSCOPY (NCLE) FOR... (5*)**
- Tu1993. . . PERCUTANEOUS TRANSHEPATIC GALLBLADDER DRAINAGE FACILITATES TRANSPAPILLARY... (5*)**
- Tu1994. . . FACTORS RELATED TO THE IMAGE CLEANLINESS... (1*)**
- Tu1995. . . PILOT STUDY TO IDENTIFY PREDICTORS OF... (1*)**
- Tu1996. . . NON-INVASIVE BREATH TEST SCREENING TO ASSESS... (2*)**

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1997. . . . UPPER GI TRACT BIOPSY USING AN... (6*)

Tu1998. . . . PREDICTORS OF LOCATION, SIZE AND NUMBER... (5*)

Tu1999. . . . WIZARDY OF CHROMATIC HANDS- SAVING THE... (5*)

Tu2000. . . . RISK OF METACHRONOUS ADVANCED NEOPLASTIC LESIONS... (5*)

Tu2001. . . . A NOVEL PANEL OF 92 BLOOD-BASED... (4*)|(6)

Tu2002. . . . DOES THE 330° VIEWING ANGLE COLONOSCOPE... (5*)

Tu2003. . . . ESTABLISHING NEED FOR SERRATED POLYP DETECTION... (0*)

Tu2004. . . . APPLICATION OF COMPUTATIONAL FLUID DYNAMICS TO... (4*)

Tu2005. . . . DUODENAL UNDERWATER ENDOSCOPIC MUCOSAL RESECTION IS... (5*)

Tu2006. . . . EVALUATION OF PERFORMANCE IN COLON CAPSULE... (5*)

Tu2007. . . . OUTCOMES OF PHARMACOLOGIC VENOUS THROMBOEMBOLISM PROPHYLAXIS... (5*)

Tu2008. . . . SYSTEMATIC REVIEW AND META-ANALYSIS OF DECOMPRESSION... (5*)

Tu2009. . . . IMMUNOHISTOCHEMISTRY EXPRESSION OF CYTOKINES FOR DIAGNOSING... (4*)

Tu2010. . . . HEALTH RELATED QUALITY OF LIFE AND... (5*)

Tu2011. . . . GASTRIC VERSUS ESOPHAGEAL BUTTON BATTERY INGESTIONS... (4*)

Tu2012. . . . CAREGIVERS KNOWLEDGE ATTITUDE AND PRACTICES ON... (5*)

Tu2013. . . . EOSINOPHILIC ESOPHAGITIS IN NON-CAUCASIANS: A UNIQUE... (5*)

Tu2014. . . . LYMPHANGIOGRAPHY AS A DIAGNOSTIC AND THERAPEUTIC... (5*)

Tu2015. . . . GASTROINTESTINAL AND HEPATIC MANIFESTATIONS OF PTEN... (5*)

Tu2016. . . . HIRSCHSPRUNG'S DISEASE IN PATIENTS WITH CONGENITAL... (5*)

Tu2060. . . . LONG-TERM SAFETY OF THE SEQUENTIAL USE... (5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)